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Abstract 
It is well established that ingested protein has a greater satiating effect than other macronutrients. 
The mechanisms behind this effect are unknown, although it is believed that protein induces a 
greater increase in levels of anorectic gut hormones than carbohydrate or fat. Recent identification 
of a family of promiscuous L-amino acid receptors has provided a potential mechanism for the 
effects of protein on appetite. These amino acid receptors - the G-protein coupled receptor family C 
group 6 member A (GPRC6A), the Taste receptor type 1 member 1/Taste receptor type 1 member 3 
(T1R1/T1R3) dimer and the calcium-sensing receptor (CaR) - are non-specific in their ligand binding 
but show preference for different families of amino acids.  
I assessed the effects of peripheral administration of a wide range of amino acids on food intake in 
rodents. My results demonstrate that the specific amino acids L-arginine, L-cysteine and L-lysine 
acutely reduce food intake following peripheral administration. The 0-1 hour food intake following 
both intraperitoneal (i.p.) and oral administration of amino acids in rats negatively correlated with 
the stimulatory efficacy of amino acids at the T1R1/T1R3. I subsequently investigated the 
mechanisms by which L-arginine, L-cysteine and L-lysine inhibit food intake. Oral administration, of 
L-arginine and L-lysine tended to increase levels of the anorectic hormones glucagon-like peptide 1 
(GLP-1) and peptide YY (PYY). Intraperitoneal administration of L-cysteine reduced levels of 
circulating total and acyl-ghrelin.  
Conditioned taste aversion studies suggested that the anorectic effect of these amino acids is not 
secondary to visceral illness. Chronic administration of L-cysteine significantly reduces cumulative 
food intake. My studies suggest that specific amino acids can influence food intake, perhaps by 
altering circulating levels of gastrointestinal hormones. Altering dietary amino acid content may be 
helpful to prevent or treat obesity. 
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1.1 The obesity epidemic 
Obesity is increasing within the United Kingdom and throughout the world. Once thought to be a 
health problem only in affluent countries with an abundant food supply, obesity is becoming 
increasingly prevalent in low- and middle- income countries (WHO, 2011). Body Mass Index (BMI) is 
commonly used as an indicator of a person’s proportion of body fat. It is calculated as a person’s 
height in metres divided by their weight in kilograms squared. Persons with a BMI of greater than 
twenty-five are considered overweight and those with a BMI greater than thirty are considered 
obese. It was estimated that in 2008, more than one and a half billion adults worldwide were 
overweight and, of these, around five hundred million were obese (WHO, 2011) and these levels are 
increasing. On a national economic level, obesity and overweight are estimated to cost over four 
billion pounds each year. On an individual level, people with a raised BMI face a series of health 
problems as a result of their habitus, as well as social stigma. Raised BMI is a major risk factor for 
cardiovascular disease, obstructive pulmonary disease, musculoskeletal disorders and some cancers 
(Conway and Rene, 2004). However, the foremost concern regarding obesity is its association with 
insulin resistance, type 2 diabetes and the constellation of other metabolic disorders known as the 
metabolic syndrome (Moller and Kaufman, 2005). 
Increases in the prevalence of overweight and obese individuals can be attributed to the global shift 
towards increased energy-dense diets and decreased physical activity levels. However, there is still 
much debate over the relative contributions of this obesogenic environment and of genetic factors 
to the current prevalence of obesity. The increasing rates of obesity and the associated morbidity 
and mortality have resulted in great research interest in the physiological systems that regulate body 
weight, which may identify possible treatments for obesity. 
1.2. Energy homeostasis 
Food intake and energy expenditure are regulated to promote stable levels of energy storage in 
organs such as adipose tissue and the liver. Energy homeostasis is a process resulting from the 
integration of diverse neural signals from the central nervous system (CNS) and neural and hormonal 
signals from the periphery. A coordinated response to these signals allows the body to regulate food 
intake and defend a relatively constant weight. Following a period of fasting, food intake is 
increased, body weight recovers and food intake returns to baseline levels (Harris et al., 1986). 
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1.3. Central regulation of food intake 
The major CNS region regulating energy homeostasis is the hypothalamus. The hypothalamus is 
located at the base of the brain below the thalamus and above the optic chiasm. It is intimately 
associated with basic functions such as thirst, reproduction, body temperature, hormonal balances 
and biological rhythms (Meister, 2007). Its importance regarding energy homeostasis was first 
investigated when it was observed that damage to the hypothalamus can result in obesity (Brobeck, 
1949). The hypothalamus is made up of discrete nuclei, as shown in Figure 1.1. A number of 
individual hypothalamic nuclei have been shown to play a role in the regulation of energy 
homeostasis. It was shown in the 1940s that lesions to the ventromedial hypothalamus (VMH) 
caused obesity (Hetherington and Ranson, 1940) and, a decade later, that lesions of the lateral 
hypothalamus (LH) caused weight loss (Anand and Brobeck, 1951). These observations gave rise to 
the dual centre hypothesis, which proposed that the VMH acted as a satiety centre and the LH as a 
feeding centre. This model has since been superseded by the more complex concept of a network of 
neural circuits which signal within the hypothalamus and to other parts of the brain. Evidence from 
human studies has confirmed the importance of the hypothalamus to food intake in humans. 
Trauma to, or lesions of, the hypothalamus can also cause hyperphagia and obesity in humans (Bray 
and Gallagher, 1975). 
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Figure 1.1. Schematic diagrams showing the relative location of the hypothalamic nuclei involved in appetite regulation as seen in (a) a coronal section 
and (b) a sagittal section of the rat hypothalamus (not to scale). 
PVN, Paraventricular nucleus; LH, Lateral hypothalamus; DMN, Dorsomedial nucleus; VMN, Ventromedial nucleus; ARC, Arcuate nucleus; SCN, 
Suprachiasmatic nucleus; SON, Supraoptic nucleus; 3V, third cerebral ventricle ((a) redrawn from (Arora and Anubhuti, 2006), (b) adapted from (Druce and 
Bloom, 2006)). 
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1.3.1. The Arcuate nucleus (ARC) 
The ARC encloses the base of the third ventricle (Figure 1.1) and is situated directly above the 
median eminence. It is regarded as critical to the hypothalamic regulation of energy balance. The 
proximity of the ARC to the median eminence, which is a circumventricular organ with an 
incomplete blood brain barrier, places the ARC in a unique position amongst the other hypothalamic 
nuclei, able to sample the hormonal and nutritional milieu of the peripheral circulation. Within the 
ARC there are two neuronal populations that play well characterised roles in the regulation of 
appetite: the medially located neuropeptide Y (NPY)/agouti-related peptide (AgRP) neurones and 
the laterally located pro-opiomelanocortin (POMC)/cocaine- and amphetamine-regulated transcript 
(CART) neurones (see Figure 1.2). The medially located population of ARC neurones show almost 
complete detectable co-expression of NPY and AgRP at both mRNA and protein levels (Broberger et 
al., 1998, Hahn et al., 1998). Both NPY and AgRP have been shown to increase appetite (Clark et al., 
1984, Levine and Morley, 1984, Rossi et al., 1998). The laterally located population of ARC neurones 
have high co-expression of POMC and CART mRNA (Elias et al., 1998). These neurones were thought 
of as purely anorexigenic (Kristensen et al., 1998, Lambert et al., 1998), although there is evidence 
that CART peptide can also increase food intake in specific circumstances (Abbott et al., 2001). 
These ARC orexigenic and anorexigenic neuronal populations project to other nuclei within the 
hypothalamus, including the paraventricular nucleus (PVN), ventromedial nucleus (VMN), 
dorsomedial nucleus (DMN) and lateral hypothalamus (LH). These nuclei process the information 
they receive regarding energy and metabolic status and both project to, and receive projections 
from, the dorsal vagal complex (DVC)  of the brainstem (in particular, the nucleus tractus solitarius 
(NTS) and the dorsal motor nucleus of the vagus (DMV)), allowing the integration of meal related 
satiety signals. The NPY/AgRP and POMC/CART neurones of the ARC project extensively to second 
order corticotrophin-releasing hormone and thyrotrophin-releasing hormone neurones in the PVN 
(Bai et al., 1985, Schwartz et al., 2000). Injection of NPY directly into the PVN increases food intake 
(Stanley and Leibowitz, 1984) whilst injection of α-MSH, a neuropeptide product of POMC, reduces 
food intake (Kim et al., 2000). 
ARC neurones project intranuclearly as well as to other nuclei, creating local regulatory circuits. 
Short NPY projections exist within the ARC providing a pathway by which NPY may be locally 
released. ARC NPY neurones regulate ARC POMC neurones. A subpopulation of ARC NPY neurones 
also synthesise the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) (Horvath et al., 
1997). Electron microscopy has shown that NPY and GABA are colocalised in synaptic terminals 
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engaging with POMC neurones, and NPY reduces the frequency of GABA-mediated inhibitory post-
synaptic potentials in ARC POMC neurones (Cowley et al., 2001). This is suggestive of a GABAergic 
inhibitory tone on POMC neurones from NPY/AgRP neurones. ARC NPY neurones express the 
inhibitory Y2 receptor (Broberger et al., 1997) and locally released NPY may inhibit its own release 
via this receptor, attenuating GABA release and thus activating the POMC neurones. A short 
inhibitory feedback loop may also exist between POMC neurones and NPY/GABA neurones since 
both NPY and POMC neurones express the MC3R, and a selective MC3R agonist has been shown to 
increase the firing rate of GABA mediated inhibitory post-synaptic potentials in POMC neurones 
(Cowley et al., 2001). NPY may also directly regulate the activity of POMC neurones via the 
postsynaptic Y1 receptor (Broberger et al., 1997). These intranuclear interactions are illustrated in 
Figure 1.2. 
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Figure 1.2. Schematic representation of the interactions between the two primary arcuate nucleus 
neuronal populations involved in energy homeostasis – the Neuropeptide Y/Agouti-Related 
Peptide (NPY/AgRP) neurones and the pro-opiomelanocortin/cocaine- and amphetamine-
regulated transcript (POMC/CART) neurones. 
NPY acts through the Y1 and Y5 receptors as well as the autoinhibitory Y2 receptor. The POMC 
product alpha-melanocyte-stimulating hormone (α-MSH) acts through the melanocortin 3 and 
melanocortin 4 receptors (MC3R and MC4R). AgRP is the endogenous antagonist for MC3R and 
MC4R. NPY/AgRP neurones also influence POMC/CART neurones via local release of gamma-
aminobutyric acid. Adapted from (Schwartz and Morton, 2002). 
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1.3.2. The Central Melanocortin System 
The hypothalamic melanocortin system is composed of the neural populations encoding AgRP and 
POMC. Melanocortins are peptides produced from the gene encoding pro-opiomelanocortin 
(POMC). Cleavage of POMC also produces β-endorphins. Melanocortins and β-endorphins are 
generated in a tissue-specific manner due to the requirements for specific enzymatic cleavage of the 
POMC precursor molecule. The POMC gene and its melanocortin products are illustrated in Figure 
1.3. Melanocortins act both peripherally and centrally, and mediate their effects via five G-protein 
coupled melanocortin receptors (MC1R - MC5R) (Cone et al., 1996). Peripherally, the melanocortins 
regulate adrenal glucocorticoid production via the MC2R and pigment in hair and skin via MC1R. The 
MC3R and MC4R are predominantly expressed in the brain (Mountjoy et al., 1994), and it is through 
these receptors that the melanocortins, in particular alpha melanocyte-stimulating hormone (α-
MSH), mediate their central effects on energy homeostasis. There is also some evidence to suggest 
that β-MSH plays a role in MC4R signalling in humans (Lee et al., 2006). In situ hybridisation has 
localised both receptors to nuclei involved in the control of food intake which receive innervations 
from POMC neurones (Gantz et al., 1993a, Gantz et al., 1993b, Mountjoy et al., 1994). The MC3R is 
found in hypothalamic and brainstem nuclei but the MC4R is more widely expressed, and in addition 
to these areas can be detected in the cortex, hippocampus, thalamus, and spinal cord (Mountjoy et 
al., 1994).  
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Figure 1.3. Schematic diagram showing pro-opiomelanocortin (POMC) and its products. 
Cleavage of POMC into the products shown is achieved enzymatically in a tissue specific manner. 
SP, signalling peptide; JP, joining peptide; MSH, melanocyte stimulating hormone; ACTH, 
adrenocorticotropic hormone; CLIP, corticotrophin-like intermediate peptide. 
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The central melanocortin system is the best characterised CNS system involved in the regulation of 
energy homeostasis. It is comprised of neurones originating in the ARC that express AgRP or POMC, 
POMC-containing neurones originating in the commissural nucleus of the solitary tract (NTS) of the 
brainstem, and the MC3R- and MC4R-expressing neurones that are the downstream targets of these 
populations (Cone, 2005). The central melanocortin system is distinctive in that many of these 
downstream targets not only receive projections from these POMC-expressing, and therefore 
agonist-producing, neurones, but also from neurones which release AgRP, a high affinity 
endogenous antagonist of the MC3R and MC4R (Cone, 2005). 
Pharmacological studies have demonstrated the importance of the MC3R and MC4R in the 
regulation of appetite. Intracerebroventricular (ICV) administration of α-MSH potently inhibits food 
intake in rats (Tsujii and Bray, 1989). In addition, ICV administration of the synthetic MC3R and 
MC4R agonist melanotan II (MTII) inhibits feeding in several models of hyperphagia including fasted 
mice, yellow agouti (Ay/a) mice, ob/ob mice and NPY treated mice (Fan et al., 1997). Co-
administration of MTII with SHU-9119, an MC3R and MC4R antagonist, completely prevents this 
inhibition (Fan et al., 1997). 
Mouse models have verified the physiological importance of the melanocortin system in the 
maintenance of body weight. Deletion of the MC4R results in a hyperphagic obese phenotype 
(Huszar et al., 1997, Schwartz et al., 2000). The yellow agouti (Ay/a) mouse, in which there is ectopic 
expression of the MCR antagonist agouti in the brain, displays a similar phenotype due to 
antagonism of the MC3R and MC4R. This suggests there is a physiological anorectic tone at the 
MC4R which restrains food intake and body fat mass. The role of the MC3R in energy homeostasis is 
less well characterised and the specific role of this receptor is yet to be defined. MC3R deletion, 
unlike the MC4R knockout, does not result in obesity, but does result in increased adipose mass and 
decreased lean mass associated with an increase in feed efficiency (defined as the ratio of weight 
gain to food intake) (Butler et al., 2000, Chen et al., 2000). A mouse lacking the POMC gene has also 
been created and has an obese phenotype similar to the MC4R knockout mouse (Yaswen et al., 
1999). Replacement of melanocortin signalling in this model by injection of a stable agonist of α-
MSH reduces body weight (Yaswen et al., 1999).  
The importance of the melanocortin system has also been demonstrated in humans. Null mutations 
in POMC result in a syndrome displaying symptoms of disruption of peripheral and central POMC 
actions, including adrenocorticotropic hormone insufficiency, red hair and obesity (Krude et al., 
1998). Heterozygous mutations of the MC4R gene were the first recognised dominantly inherited 
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cause of morbid obesity in humans (Vaisse et al., 1998, Yeo et al., 1998). Haploinsufficiency of the 
MC4R gene was subsequently shown to be the most common known monogenic cause of severe 
human obesity (Farooqi et al., 2000, Vaisse et al., 2000). No dominant MC3R mutations have yet 
been identified as causes of obesity in humans, but it has been postulated that MC3R gene 
polymorphisms may act as a predisposing factor to the development of childhood obesity (Lee et al., 
2007b). 
1.3.2.1. Alpha-melanocyte-stimulating hormone (α-MSH) 
Alpha-MSH is a 13 amino acid peptide product of the POMC precursor molecule. Acting in functional 
opposition to ARC NPY/AgRP neurones, ARC POMC neurones decrease appetite, and this effect is 
thought to be largely mediated by α-MSH. Alpha-MSH is thought to tonically reduce food intake by 
activating the MC3R and MC4R. POMC mRNA levels are decreased in food deprived rats and ICV 
administration of α-MSH reduces food intake in rats (Brady et al., 1990, Brown et al., 1998, Poggioli 
et al., 1986). Deletion of the POMC gene, and the consequent α-MSH deficiency, results in obesity 
(Yaswen et al., 1999).  
1.3.2.2. Agouti-related protein (AgRP) 
AgRP is a 132 amino acid long protein. It has a 40 amino acid cysteine-rich carboxyl terminus which is 
homologous to the agouti protein, a protein found in the periphery which regulates hair 
pigmentation by antagonising the MC1R (Ollmann et al., 1997). AgRP is expressed almost exclusively 
in the ARC and exerts its orexigenic effects by competitively antagonising α-MSH at the MC3R and 
MC4R (Fong et al., 1997, Hagan et al., 2000, Ollmann et al., 1997, Rossi et al., 1998). ARC AgRP 
mRNA levels are increased in acutely food deprived rats, and decreased in rats with diet induced 
obesity (Bi et al., 2003, Hahn et al., 1998, Harrold et al., 1999). In addition, transgenic ubiquitous 
overexpression of AgRP results in obesity (Ollmann et al., 1997). Thus, during negative energy 
balance, anorectic melanocortinergic tone is down-regulated by an increase in AgRP synthesis and 
release, and there is a converse reduction in AgRP during periods of positive energy balance. ICV 
administration of the C-terminal fragment of AgRP increases food intake in rats. This hyperphagia 
can be sustained for up to a week following a single injection (Rossi et al., 1998). This long-term 
orexigenic effect is mediated by an as yet unknown mechanism, which may operate downstream 
from, or independent of, MCR antagonism (Hagan et al., 2000). 
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1.3.3. Other ARC neuropeptides 
1.3.3.1. Neuropeptide Y (NPY) 
NPY is a 36 amino acid orexigenic peptide with a high degree of homology to peptide YY (PYY) and 
pancreatic polypeptide (PP), gut hormones with a role in satiety signalling. NPY is co-expressed with 
the orexigenic peptide AgRP in the ARC. ICV administration of NPY potently increases food intake in 
satiated rats (Clark et al., 1984, Levine and Morley, 1984) and chronic central administration of NPY 
induces obesity (Zarjevski et al., 1993). In food restricted and food deprived rats, ARC NPY mRNA 
levels are increased (Brady et al., 1990). NPY is thought to mediate its orexigenic effects via the Y1 
and Y5 receptors (Gerald et al., 1996, Hu et al., 1996, Kask et al., 1998). However, single or double 
embryonic knockouts of NPY/AgRP do not have significantly altered energy homeostasis (Erickson et 
al., 1996, Qian et al., 2002). Postnatal toxin-mediated ablation of the NPY/AgRP neurone results in a 
hypophagic phenotype suggesting a crucial role for these neurones in the regulation of feeding 
(Bewick et al., 2005, Gropp et al., 2005, Luquet et al., 2005). These results suggest that either 
developmental changes in other orexigenic neural circuits (Ste Marie et al., 2005), or other as yet 
unknown factors released from these neurones can compensate for the lack of NPY or AgRP. 
NPY/AgRP neurones are GABAergic and account for a large part of the GABAergic innervation of 
POMC neurones (Cowley et al., 2001). AgRP neurone-specific deletion of the vesicular GABA 
transporter results in a lean phenotype, consistent with an important role for GABA signalling in the 
ARC in mediating food intake (Tong et al., 2008). NPY is expressed in other hypothalamic nuclei 
(Akabayashi et al., 1994) particularly the DMN (Kalra et al., 1999), but its role in these regions is less 
well characterised. 
1.3.3.2. Cocaine- and amphetamine- regulated transcript (CART) 
CART codes for a putative neuropeptide, and is present in several hypothalamic nuclei important in 
feeding, including the ARC, PVN, supraoptic nucleus (SON) and rostral VMN (Kalra et al., 1999). In the 
ARC, CART is strongly colocalised with POMC (Elias et al., 1998). ARC CART mRNA levels are 
decreased in food deprived rats, and ICV administration of the putative bioactive CART peptide, 
CART55-102, decreases food intake in mice and rats (Kristensen et al., 1998, Lambert et al., 1998). In 
addition, blocking hypothalamic CART signalling by the ICV administration of CART antiserum 
increased night time feeding, suggesting that CART may be a physiological anorectic neuropeptide 
(Kristensen et al., 1998, Lambert et al., 1998). However, intranuclear ARC and VMN injections of 
CART increase food intake in rats (Abbott et al., 2001), suggesting that CART peptide can also play an 
orexigenic role. The role of CART in appetite regulation is therefore unclear at present. 
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1.3.4. The role of the brainstem 
The hypothalamus is well established as a key CNS area controlling appetite regulation. However, 
the brainstem is also considered important. The brainstem is comprised of three distinct anatomical 
structures: moving rostro-caudally the midbrain, the pons and the medulla. There are specific 
regions of the brainstem that are particularly important in appetite regulation: the area postrema 
(AP), the dorsal motor nucleus of the vagus (DMV) and the nucleus tractus solitarius (NTS). Together, 
these constitute the dorsal vagal complex (DVC) which is the major integrative centre for the 
autonomic nervous system. These structures are shown in Figure 1.4. The AP is a circumventricular 
organ, i.e. it lies outside the protection of the blood brain barrier. It lies in the brainstem directly 
above the NTS. Like the ARC, it can therefore be directly targeted by factors in the circulation. The 
NTS receives meal-related visceral signals from the alimentary tract (Schwartz, 2006). These are 
transmitted by the afferent vagus nerve, which terminates in the NTS. Vagal fibre signalling is also 
stimulated by factors such as gut distension, pH and osmolarity (Schwartz, 2006). The DMV arises 
from the floor of the fourth ventricle and is the area where efferent parasympathetic nerve fibres 
that innervate the gastrointestinal (GI) tract originate. 
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Figure 1.4. Schematic illustrating a coronal section of the brainstem, highlighting the major areas 
involved in appetite regulation 
Hormones and toxins circulating in the blood are sensed by the area postrema (AP) whilst neural 
signals are received by the nucleus tractus solitarius (NTS). 
AP, area postrema; NTS, nucleus tractus solitarius; DMV, dorsal motor nucleus of the vagus. 
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Extensive reciprocal neuronal connections exist between the AP, NTS and DMV and hypothalamic 
nuclei, including the PVN and the ARC. This means that peripheral factors can signal to the 
hypothalamic feeding centres directly via the ARC or indirectly via the brainstem. The importance of 
the brainstem in energy homeostasis is illustrated by the fact that lesioning of the brainstem results 
in hypophagia and reduced body weight (Hyde and Miselis, 1983). However, these effects are not as 
substantial as those observed following lesioning of specific hypothalamic nuclei. The importance of 
the connections between the hypothalamus and the brainstem in regulating feeding was first shown 
by Grill and Norgren (Grill and Norgren, 1978) who developed a lesion model of decerebration, in 
which the forebrain (which includes the hypothalamus) was disconnected from the hindbrain (which 
contains the brainstem). They showed that decerebrated rats were able to terminate, but not 
initiate, feeding and were unable to sense the caloric value of the solutions they were fed. The 
brainstem has been shown to be important in mediating the action of many gut hormones on 
appetite. This evidence will be further discussed in section 1.4.3. 
1.4. Peripheral factors regulating energy homeostasis 
The ARC, situated at the base of the hypothalamus, and the AP of the brainstem, both have an 
incomplete blood brain barrier, and thus are well positioned to detect signalling factors in the 
circulation. These CNS sites and the peripheral factors that signal to them are integrated with other 
CNS neural circuits to coordinate the regulation of energy homeostasis. 
1.4.1. Leptin 
In 1953, Kennedy suggested that an unknown circulating factor was released from adipose tissue to 
regulate appetite via the hypothalamus and defend a stable body weight. This concept was known as 
the adipostat model (Kennedy, 1953). The existence of a circulating satiety factor was further 
supported by parabiosis experiments 15-20 years later which used ob/ob, db/db and wild type mice 
(Coleman and Hummel, 1969, Coleman, 1973). The ob/ob and db/db mice are profoundly 
hyperphagic and obese. These experiments suggested that the ob/ob mouse lacked the postulated 
adipostat, whilst the db/db mouse was resistant to its satiating effects. It was another 20 years 
before positional cloning of the ob gene identified that it coded for the 16kD protein leptin (Zhang et 
al., 1994). It is now known that ob/ob mice lack functional leptin (Zhang et al., 1994) and that db/db 
mice have an inactivating mutation in the leptin receptor (i.e. leptin resistance) (Tartaglia et al., 
1995). Peripheral administration of leptin reduces food intake and body weight in ob/ob mice or wild 
type mice, but has no effects on db/db mice (Pelleymounter et al., 1995, Halaas et al., 1995). Leptin 
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is secreted from adipocytes and circulates at levels proportional to adipose tissue mass (Badman and 
Flier, 2007, Considine et al., 1996). Thus, obese humans and rodents have elevated plasma leptin 
levels (Maffei et al., 1995). Leptin is transported across the blood-brain barrier via a saturable 
transport system (Banks et al., 1996) and, in lean individuals, enters the CNS at levels proportional to 
circulating levels. In obese subjects, however, leptin transport across the blood brain barrier appears 
to be lower (Considine et al., 1996). Peripheral or central administration of leptin to rodents reduces 
food intake and body weight, and increases energy expenditure (Halaas et al., 1995, Schwartz et al., 
1996, Friedman and Halaas, 1998).  
The leptin receptor, Ob-R exists in six known isoforms: Ob-Ra, Ob-Rb, Ob-Rc, Ob-Rd, Ob-Re and Ob-
Rf. These isoforms result from alternative splicing and post-translational processing events 
(Tartaglia, 1997). Ob-Ra, Ob-Rb, Ob-Rc, Ob-Rd and Ob-Rf have common extracellular and 
transmembrane domains, but have intracellular domains of various lengths. The intense expression 
of Ob-Ra isoforms in cerebral capillaries and choroid plexus suggests that these receptors may play a 
role in leptin transport to the CNS (Ziylan et al., 2009). Ob-Re is a ‘soluble receptor,’ consisting only 
of the extracellular domain, and acts as a leptin binding protein in the circulation (Tartaglia, 1997, Li 
et al., 1998). Leptin exerts its effects on energy homeostasis via the Ob-Rb, the so-called ‘long 
receptor.’ This is the only receptor which has the intracellular domains necessary to activate the JAK-
STAT signal transduction pathway, by which leptin is believed to exert many of its effects on energy 
homeostasis (Baumann et al., 1996, Ghilardi et al., 1996). In the hypothalamus, Ob-Rb is primarily 
expressed in the ARC (Banks et al., 1996), but is also expressed in the VMN, PVN and DMN (Elmquist 
et al., 1998). 
Within the ARC, Ob-Rb mRNA is expressed on NPY- (Baskin et al., 1999), AgRP- (Wilson et al., 1999), 
POMC- (Cheung et al., 1997) and CART- (Kristensen et al., 1998) expressing neurones. Leptin 
differentially regulates ARC NPY/AgRP and POMC/CART neurones (Cowley et al., 2001). Leptin 
inhibits the activity of the NPY/AgRP neurones whilst increasing that of the POMC/CART neurones. 
Lesioning of the ARC, VMN or PVN reduced sensitivity to centrally administered leptin, suggesting 
that leptin signalling in these nuclei is critical to its anorectic action (Choi et al., 1999). However, 
lesioning of the DMN increases sensitivity to centrally administered leptin (Choi et al., 1999). This is 
probably a result of blockade of orexigenic signals from other nuclei. 
Mice or humans lacking leptin or the leptin receptor are hugely hyperphagic and obese (Zhang et al., 
1994, Chen et al., 1996, Clement et al., 1998, Lee et al., 1996, Montague et al., 1997). Treating leptin 
deficient individuals with recombinant leptin reduces their hyperphagia and body fat (Farooqi et al., 
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2002, Pelleymounter et al., 1995, Farooqi et al., 1999). However, most obese humans have normal 
ob gene expression and high levels of leptin, reflecting their high body fat mass. Leptin treatment is 
of little benefit to this group, who are believed to be leptin resistant (Mantzoros and Flier, 2000). 
The anorexigenic potency of leptin is also reduced in obese animals (Cusin et al., 1996) as leptin 
resistance develops (Halaas et al., 1997). The mechanisms underlying this leptin resistance are 
largely unknown (Badman and Flier, 2007, Wynne et al., 2005b). Leptin has been described as a 
hormone of absence; very low or absent leptin levels have profound effects as the body tries to 
compensate for apparent starvation, whilst high leptin levels are much less physiologically significant 
(Wynne et al., 2005b). 
1.4.2. Insulin 
Insulin is a 5.8k-Da hormone which is critical in the regulation of carbohydrate and fat metabolism. It 
is synthesised and secreted primarily by pancreatic β-cells, rather than adipocytes. Nonetheless, 
circulating levels are proportional to adiposity (Polonsky et al., 1988), and thus, like leptin, insulin 
may act as a signal of adiposity. However, unlike leptin, insulin secretion increases rapidly post-
prandially (Polonsky et al., 1988). Increased adiposity is associated with reduced sensitivity to insulin 
and so, in the obese population, insulin levels are higher both basally and post-prandially (Polonsky 
et al., 1988). Peripheral insulin enters the CNS in proportion to its circulating level (Baura et al., 
1993), crossing the blood-brain barrier via a saturable receptor mediated mechanism (Baura et al., 
1993). Little or no insulin is produced in the CNS (Banks, 2004) but peripheral insulin is thought to 
act as an anorexigenic signal in the brain. CNS administration of insulin reduces food intake in a 
dose-dependent manner (Woods et al., 1979, Air et al., 2002), while CNS administration of anti-
insulin antibodies increases food intake and body weight (McGowan et al., 1992). 
The insulin receptor (IR) is widely distributed throughout the brain but the highest concentrations 
are found in the olfactory bulb and hypothalamus (Marks et al., 1990). Within the hypothalamus, 
insulin binding sites are present in the ARC, DMH, PVN and the suprachiasmatic and periventricular 
regions (Corp et al., 1986), consistent with the notion of insulin acting to regulate energy 
homeostasis. Disruption of IR signalling is associated with altered energy homeostasis (Farooqi et al., 
2007). Loss of function of the tub gene, which is an intracellular signalling protein phosphorylated in 
response to IR activation, results in an obese phenotype (Kapeller et al., 1999). Mice with neuron-
specific disruption of the IR are mildly obese, with increased fat mass and plasma leptin levels 
(Bruning et al., 2000). 
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The role of insulin in the acute regulation of energy homeostasis remains unclear. It may act, at least 
in part, by modulating NPY and melanocortin signalling. ICV insulin administration prevents the 
fasting-induced increases in NPY peptide in the PVN and preproNPY gene expression in the ARC of 
fasted rats (Schwartz et al., 1992). IR expression has been detected on POMC neurones in the ARC 
and ICV insulin administration to fasted rats increases hypothalamic POMC expression (Benoit et al., 
2002). In addition, the anorectic effect of ICV insulin is blocked by pre-treatment with a 
melanocortin receptor antagonist (Benoit et al., 2002). 
With regards long term signals of energy balance, insulin, along with leptin, is a circulating signal of 
body adiposity. However, leptin is considered the more important adiposity signal, as leptin deficient 
ob/ob mice are hyperphagic despite being hyperinsulinaemic (Zhang et al., 1994). In addition, leptin 
replacement in leptin-deficient mice with insulin-deficient diabetes prevents diabetic hyperphagia 
(Sindelar et al., 1999). 
1.4.3. Humoral gut peptides 
Several peripheral peptides secreted from the GI tract and circulating in the plasma have been 
shown to act as appetite signals. These peptides are thought to act via the hypothalamus and the 
brainstem, which both express the relevant receptors, as illustrated in Figure 1.5. 
1.4.3.1. Ghrelin 
Ghrelin is a 28 amino acid orexigenic peptide synthesised in the stomach and is the only 
gastrointestinal hormone known to stimulate appetite. It was first discovered as the endogenous 
ligand for the growth hormone secretagogue receptor (GHS-R) (Kojima et al., 1999). Ghrelin is also 
expressed in the ARC and hypothalamic periventricular areas (Kojima et al., 1999, Cowley et al., 
2003). The GHS-R is expressed in many tissues throughout the body, including the gut, hypothalamus 
and pituitary (Hosoda et al., 2006). Ghrelin levels rise before meals and fall post-prandially 
(Cummings et al., 2002). Acutely, central or peripheral administration of ghrelin potently stimulates 
feeding in rodents (Wren et al., 2000), and chronically, induces weight gain (Tschop et al., 2000). 
Intravenous ghrelin infusion increases energy consumption during a buffet meal in humans (Wren et 
al., 2001a). 
The orexigenic effects of circulating ghrelin are thought to be mediated by the ARC. Injections of 
ghrelin into various hypothalamic nuclei determined that ghrelin had most potent effect when 
injected into the ARC (Wren et al., 2001b). In addition, specific ablation of the ARC prevents ghrelin-
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induced hyperphagia (Tamura et al., 2002). It is thought that the ARC NPY/AgRP population is 
responsible for mediating ghrelin’s orexigenic effects; peripheral administration of ghrelin increases 
ARC expression of NPY and also induces c-fos expression in NPY/AgRP neurones (Nakazato et al., 
2001, Wang et al., 2002). In addition, ghrelin has no effect on mice which lack both NPY and AgRP 
(Chen et al., 2004). 
The ghrelin receptor is also expressed in the brainstem (Zigman et al., 2006), and peripheral ghrelin 
administration induces c-fos expression in the NTS and AP (Nakazato et al., 2001). These actions may 
be partially mediated by the vagus nerve, as ghrelin has no effect in humans or rodents after 
vagotomy (le Roux et al., 2005, Williams et al., 2003). Ghrelin is also thought to target the 
mesolimbic dopamine system. Injection of ghrelin into the ventral tegmental area (VTA) stimulates 
feeding whilst injection of a ghrelin receptor antagonist into the VTA blocks feeding induced by 
ghrelin and by fasting (Naleid et al., 2005, Abizaid et al., 2006). In addition, ghrelin has been shown 
to increase the firing rate of VTA dopamine neurones (Abizaid et al., 2006). It is therefore possible 
that ghrelin may play a role in enhancing reward systems. 
1.4.3.2. Cholecystokinin (CCK) 
CCK was originally known for its role in the exocrine pancreas and gallbladder. In the early seventies 
it became the first gut hormone demonstrated to influence food intake. CCK is secreted by 
specialised neurones in the myenteric plexus and brain, as well as post-prandially by L-cells located 
in the mucosa of the duodenum, jejunum and proximal ileum (Chandra and Liddle, 2007). CCK-8 is 
thought to be the predominant form of CCK in the brain, whilst CCK-58 is the most predominant 
circulating form in humans and rats (Eberlein et al., 1987, Reeve et al., 2003). ICV or peripheral 
administration of CCK-8 reduces food intake in rats (Lorenz and Goldman, 1982, Schick et al., 1986). 
Peripheral CCK is thought to signal via the vagus nerve to the brainstem; vagotomised rats do not 
reduce their food intake in response to peripheral CCK administration (Lorenz and Goldman, 1982). 
This effect is mediated via the cholecystokinin 1 (CCK1) receptors on the vagal nerve. Lesioning the 
ascending afferents of the NTS prevents the anorexigenic effects of CCK (Crawley et al., 1984). CCK1 
receptor antagonists have been reported to increase food intake in rodents and humans, suggesting 
that CCK plays a physiological role in reducing food intake. In addition, the Otsuka Long-Evans 
Tokushima Fatty rat, which lacks the CCK1 receptor and is unresponsive to CCK, is hyperphagic and 
obese (Moran and Bi, 2006). However, mice lacking CCK1 which are unresponsive to exogenous CCK 
do not show an altered energy homeostasis phenotype (Kopin et al., 1999). 
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Figure 1.5. Schematic illustrating the gut hormones which signal to the hypothalamus and/or 
brainstem to influence appetite. 
Orexigenic and anorexigenic signals from the gut signal to the hypothalamus as well as directly or 
indirectly via the vagus nerve to the brainstem to indicate feelings of hunger and satiety. Adapted 
from (Stanley et al., 2005). 
PYY, peptide YY; OXM, oxyntomodulin; PP, pancreatic polypeptide; GLP-1, glucagon-like peptide-1; 
CCK, cholecystokinin. 
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1.4.3.3. Members of the PP fold family 
1.4.3.3.1. Peptide YY (PYY) 
PYY is a 36 amino acid peptide hormone related to NPY and PP. All these peptides possess the PP 
fold structural motif, and all three bind to the Y family of receptors. PYY was first isolated from 
colonic extracts in 1980 (Tatemoto and Mutt 1980) and was named peptide ‘YY’ due to the C- and N- 
terminal tyrosine (Y) residues. PYY exists in two forms. The amino terminal of the full length peptide 
PYY1-36 is cleaved by the enzyme dipeptidyl peptidase IV (DPP-IV) to form the amino-terminally 
truncated PYY3-36. PYY3-36 comprises the majority of PYY circulating immunoreactivity (Grandt et al., 
1994, Medeiros and Turner, 1994). PYY1-36 binds with relatively high affinity to all 5 Y receptors (Y1R-
Y5R), whereas PYY3-36 is a selective Y2R agonist (Abbott et al., 2005b). 
PYY is expressed in enteroendocrine L-cells throughout the length of the gastrointestinal tract. 
Concentrations of PYY immunoreactivity are higher in more distal sections of the gut, with highest 
tissue content in the terminal ileum, colon and rectum (Adrian et al., 1985, Ekblad and Sundler, 
2002). PYY is released into the circulation following a meal at levels proportional to calories 
consumed (Adrian et al., 1985), and circulating levels are reduced by fasting. Peripheral 
administration of PYY3-36 reduces food intake in rodents and humans (Batterham et al., 2002, 
Batterham et al., 2003a). PYY-knockout mice are hyperinsulinaemic and obese, suggesting that PYY 
signalling has a physiological role in the regulation of energy homeostasis (Batterham et al., 2006, 
Boey et al., 2006). Interestingly, post-prandial increases in PYY are rapid and occur before nutrients 
reach the L-cells in the distal intestine. These early increases might be due to neural reflexes, 
whereas later increases may result from direct contact of gut contents with the L-cells (Fu-Cheng et 
al., 1997). 
The anorectic effects of PYY3-36 are thought to be mediated by Y2R, as they are attenuated by Y2R 
antagonists (Abbott et al., 2005b) and abolished in Y2R-knockout mice (Batterham et al., 2002). It is 
thought that PYY3-36 acts on the Y2R in the hypothalamus (Figure 1.5.), which acts as a presynaptic 
inhibitory receptor on ARC NPY neurones (Broberger et al., 1997, Batterham et al., 2002). Peripheral 
injection of PYY3-36 activates ARC neurones and decreases hypothalamic NPY mRNA expression, and 
injection of PYY3-36 directly into the ARC suppresses food intake in rats (Batterham et al., 2002). 
Electrophysiological studies have shown that PYY3-36 inhibits NPY neurones (Batterham et al., 2002). 
In contrast to these data, ICV administration of PYY or PYY3-36 increases food intake (Clark et al., 
1987, Corp et al., 2001). This action is likely to be due to pharmacological activation of the Y1R 
47 
 
and/or Y5R in the PVN by high concentrations. It is also thought that PYY may act on the vagus 
nerve, as vagotomy results in a loss of the anorexigenic effects of PYY3-36 (Koda et al., 2005). 
Some studies report that fasting and post-prandial levels of circulating PYY are lower in obese 
individuals (Batterham et al., 2003a, Korner et al., 2005, le Roux et al., 2006), but others have found 
no significant differences between levels in the lean and obese (Kim et al., 2005, Stock et al., 2005). 
A reduction in PYY release therefore seems unlikely to be involved in the aetiology of obesity. 
Indeed, investigation of PYY levels following weight loss in children indicates that reduced PYY-like 
immunoreactivity levels are a consequence rather than a cause of obesity (Roth et al., 2005). 
However, PYY3-36 may have utility in the treatment of obesity. Circulating levels of PYY are not raised 
in the obese, in contrast to leptin levels (Batterham et al., 2003a), and obese humans show normal 
sensitivity to the anorectic effects of PYY3-36. 
1.4.3.3.2. Pancreatic Polypeptide (PP) 
PP is also a member of the PP fold family.  It is synthesised and released post-prandially from the 
endocrine pancreas in proportion to the calorie content of a meal. PP suppresses pancreatic 
exocrine secretion and gall bladder contraction, and modulates gastric acid secretion and 
gastrointestinal motility. PP is also postulated to act as a satiety signal via activation of the Y4 
receptor. Peripheral administration of PP to both rodents and humans reduces food intake. This 
effect occurs at doses which do not influence gastric emptying, suggesting it is not secondary to 
effects on the stomach (Asakawa et al., 2003, Batterham et al., 2003b). Peripheral administration of 
PP activates neurones in the area postrema of the brainstem, an area where the Y4R is highly 
expressed (Whitcomb et al., 1997). The AP is thus thought to be the principal site of action of PP. 
However, the reduction in food intake by peripheral administration of PP is abolished in 
vagotomised rodents (Asakawa et al., 2003), suggesting that PP may also work indirectly via the 
vagus to influence the brainstem (Figure 1.5.). The Y4R is also expressed in several hypothalamic 
nuclei involved in appetite regulation (Parker and Herzog, 1999), including the ARC and PVN. In 
addition, peripheral administration of PP to mice reduces hypothalamic NPY expression, though it is 
unclear whether this represents a pharmacological activation of other orexigenic Y receptors, or 
whether the Y4R is involved in orexigenic pathways in the hypothalamus. As with PYY, ICV 
administration of PP to rats increases food intake (Clark et al., 1984, Asakawa et al., 1999). 
Chronic peripheral administration of PP reduces body weight in obese ob/ob mice (Asakawa et al., 
2003). Patients with Prader-Willi Syndrome have significantly blunted post-prandial release of PP 
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compared to BMI-matched controls, potentially contributing to the obesity observed in this 
condition (Zipf et al., 1981, Zipf et al., 1983). 
1.4.3.4. Pre-proglucagon products 
An incretin is a gut-derived factor that stimulates insulin release. Selective post-translational 
proteolysis of pre-proglucagon generates two incretins: glucagon-like peptide-1 (GLP-1) and 
oxyntomodulin (OXM). Pre-proglucagon is expressed in a number of tissues and is cleaved by 
prohormone convertases 1 and 2 into various peptide hormones in a tissue-specific manner. In 
addition to GLP-1 and OXM, products of pre-proglucagon include glucagon-like peptide-2 (GLP-2), 
glucagon and glicentin (Figure 1.6.). 
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Figure 1.6. Schematic representation of pre-pro-glucagon processing in neuroendocrine cells. 
The diagram illustrates peptide products of differential processing in the gut, brain and pancreas. 
The incretin factors discussed are shown in blue (GLP-1) and purple (oxyntomodulin). Numbers 
indicate amino acid positions. 
GRPP, glicentin-related propeptide; SP, spacer peptide; GLP-1, glucagon-like peptide-1; GLP-2, 
glucagon-like peptide-2; MPGF, major pro-glucagon fragment.  
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1.4.3.4.1. Glucagon-like Peptide-1 (GLP-1) 
GLP-1 is released from enteroendocrine L-cells in the gastrointestinal tract, as are PYY and 
oxyntomodulin (OXM). There are two bioactive forms of GLP-1: GLP-17-36 amide and GLP-17-37, both of 
which are found in the gut, however GLP-17-36 amide is thought to be the most important biologically 
active form. GLP-17-36 amide peptide has also been detected within the AP and NTS of the brainstem in 
neurones projecting to the PVN and DMN (Larsen et al., 1997). Circulating levels of immunoreactive 
GLP-1 are increased post-prandially (Herrmann et al., 1995), and stimulates the synthesis and 
secretion of insulin at physiological concentrations (Gutniak et al., 1992). Central or peripheral 
administration of GLP-17-36 amide reduces food intake in rodents (Turton et al., 1996, Ruttimann et al., 
2009). In humans, peripheral administration of GLP-17-36 amide reduces food intake, and circulating 
GLP-17-36 amide levels are reported to be inversely correlated with body mass (Verdich et al., 2001). 
The effects of GLP-1 on food intake and insulin release are mediated by the GLP-1 receptor (GLP-1R); 
both bioactive forms of GLP-1 are equally potent at the GLP-1R. ICV co-administration to rats of the 
GLP-1R antagonist, exendin9-39, abolishes the anorexigenic effects of GLP-17-36 amide (Turton et al., 
1996). ICV exendin9-39 alone doubles food intake in satiated rats, suggesting that GLP-1 has a 
physiological role in the regulation of food intake. Chronic central administration of GLP-17-36 amide 
induces significant weight loss in rats (Meeran et al., 1999). 
The GLP-1R is highly expressed in several hypothalamic nuclei important in appetite regulation, 
including the ARC and PVN (Shughrue et al., 1996), and in the brainstem. Peripheral or ICV 
administration of GLP-17-36 amide induces expression of c-fos, a marker of neuronal activation, in the 
PVN, but only peripheral administration induces expression in the brainstem (Turton et al., 1996, 
Baggio et al., 2004b). The role of the brainstem in GLP-1 signalling is further demonstrated by the 
fact that vagotomy or lesioning of the brainstem-hypothalamic connections ameliorates the appetite 
suppression induced by peripheral GLP-17-36 amide administration (Abbott et al., 2005a). In addition, 
peripheral administration of GLP-17-36 amide increases neuronal activity in the brainstem of mice 
(Parkinson et al., 2009). These data suggest that peripheral GLP-1 may act directly or via vagal 
afferents on the brainstem which subsequently relays signals to the hypothalamus (Figure 1.5.). 
Mice with targeted deletion of GLP-1R have normal body weight and food intake, but are glucose 
intolerant (Gallwitz and Schmidt, 1997). This finding implies that GLP-1 is more important in glucose 
homeostasis than in energy homeostasis, but may reflect compensatory changes in other appetite-
regulating systems. 
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1.4.3.4.2. Oxyntomodulin (OXM) 
OXM is a 37 amino acid peptide originally isolated from porcine jejeno-ileal cells. It contains the 
entire sequence of glucagon with the addition of an octapeptide C-terminal extension called spacer 
peptide-1 (SP-1) (Kieffer and Habener, 1999). It is released from L-cells in the distal GI tract, together 
with GLP-1 and PYY. OXM is also an incretin (Schjoldager et al., 1988, Maida et al., 2008). OXM is 
released into the circulation post-prandially, at plasma levels proportional to caloric content of the 
meal (Le Quellec et al., 1992). Central or peripheral administration of OXM reduces food intake in 
rodents with a potency similar to that of GLP-17-36 amide (Dakin et al., 2001, Dakin et al., 2004). 
Repeated intraperitoneal (i.p.) administration of OXM for seven days reduces weight gain and fat 
mass in rats (Dakin et al., 2002). OXM-treated animals gained weight at a slower rate than saline-
treated pair-fed controls, implying that OXM may reduce body weight in part by increasing energy 
expenditure. There is also evidence that it may act centrally to suppress peripheral ghrelin release 
(Patterson et al., 2009). Acute peripheral administration of OXM to humans reduces food intake, and 
chronic peripheral administration reduces food intake and body weight and may influence energy 
expenditure (Cohen et al., 2003, Wynne et al., 2005a, Wynne et al., 2006). The only known receptor 
for OXM is the GLP-1R (Fehmann et al., 1994). It has been hypothesised that another, as yet 
unidentified receptor mediates the anorexigenic effects of OXM. However, the GLP-1R antagonist 
exendin9-39 prevents the anorexigenic effects of ICV OXM (Dakin et al., 2004) and mice with targeted 
disruption of GLP-1R are insensitive to the anorexigenic effects of OXM (Baggio et al., 2004a). The 
appetite-suppressing effects of GLP-1 and OXM are comparable, but OXM has a much lower binding 
affinity for the GLP-1R than GLP-17-36 amide (Fehmann et al., 1994). It is possible that the GLP-1R could 
alter ligand specificity in the presence of other proteins. Receptor activity-modifying proteins 
(RAMPs) have been identified and tissue specific isoforms of these proteins may alter ligand 
selectivity and affinity of various receptors as has been shown for the Calcitonin Gene-Related 
Peptide Receptor (CGRP-R) (McLatchie et al., 1998). This receptor binds CGRP in the presence of 
RAMP-1 and adrenomedullin in the presence of RAMP-2 (McLatchie et al., 1998). It is possible that 
such a mechanism might mediate the ligand interactions of the GLP-1R. 
1.5. Nutrient sensing 
Ingested and circulating nutrients are sensed both centrally and peripherally, with the system acting 
as a rheostat of acute nutrient availability (Blouet and Schwartz, 2010). The hypothalamus has a high 
concentration of nutrient-sensing elements and is a major centre for integration of various nutrient-
related signals. Within specific hypothalamic nuclei, subsets of neurones are receptive to glucose, 
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fatty acids, amino acids and other fuel-related stimuli. Within these neuronal populations, nutrients 
can act as signalling molecules which engage several neurochemical responses to influence energy 
intake and nutrient utilisation (Blouet and Schwartz, 2010). In addition, peripheral sensory systems 
may signal from the gut, liver or portal circulation to the brain via neural signals and/or the release 
of gastrointestinal hormones. 
1.5.1. Carbohydrate sensing 
The hypothalamus is highly sensitive to changes in blood glucose. The ARC and VMN, in particular, 
are known to contain large populations of glucose-sensing neurones. Blood glucose can originate 
from ingested glucose, from the breakdown of other ingested carbohydrates, from the breakdown 
of glycogen and, from gluconeogenesis, the synthesis of glucose from sources such as amino acids 
and fatty acids. The existence of glucose-sensing neurones was first demonstrated when it was 
shown that specific hypothalamic neurones were able to modulate their firing activity in response to 
changes in extracellular glucose concentrations (Oomura et al., 1969, Anand et al., 1964). Two major 
types of glucose-sensing neurones are known to exist: glucose-excited (GE) neurones, which increase 
their firing rate in response to increases in extracellular glucose concentrations, and glucose-
inhibited (GI) neurones, which are activated in response to a reduction in extracellular glucose 
concentrations (Oomura and Yoshimatsu, 1984). Although both neuronal types are expressed 
throughout the brain, GE neurones are found at highest concentrations in the VMN, ARC and PVN, 
whilst GI neurones are most abundant in the LH, the median ARC and the PVN (Silver and Erecinska, 
1998). Within the ARC, it has been shown that increasing extracellular glucose concentrations inhibit 
NPY/AgRP neurones and excite POMC neurones (Ibrahim et al., 2003, Muroya et al., 1999, Mountjoy 
et al., 2007, Fioramonti et al., 2007). GE and GI neurones are also present in the brainstem, 
particularly in the AP, NTS and DMV (Marty et al., 2007). The glucose-sensing elements of the 
brainstem may then relay detected changes in glucose to the hypothalamus (Marty et al., 2007). 
Glucose is sensed by pancreatic β-cells at which it acts to modulate the release of insulin. This 
facilitates the maintenance of blood glucose levels within a certain range, as insulin release 
stimulates the uptake of blood glucose into peripheral tissues. Glucose is also sensed peripherally by 
most tissues, which take it up via glucose transporters (GLUTs) to use as metabolic fuel. Blood 
glucose regulation is a complex process and an in depth discussion of the mechanisms regulating it is 
beyond the scope of this thesis. 
It has also been established that naturally occurring sweet substances such as glucose, fructose, 
sucrose and sweet tasting D-amino acids can be sensed by the heterodimeric sweet taste receptor 
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T1R2/T1R3 (Nelson et al., 2001, Li et al., 2002), which can also sense synthetic sweeteners such as 
aspartame and saccharin (Nelson et al., 2001, Li et al., 2002). T1R2/T1R3 is expressed in taste buds 
of the oral cavity and the GI tract (Nelson et al., 2001, Dyer et al., 2005, Bezencon et al., 2007, Mace 
et al., 2009). The gut is thus capable of sensing sweet stimuli. Recent research has revealed links 
between dietary sugars and gastrointestinal chemosensing, which appears to regulate glucose 
absorption and enteroendocrine GLP-1 secretion (Le Gall et al., 2007, Mace et al., 2007, Mace et al., 
2009, Margolskee et al., 2007, Jang et al., 2007). 
1.5.2. Fatty acid sensing 
It is now widely accepted that fatty acids can act in the CNS to influence energy homeostasis. 
However the molecular mechanisms are largely unknown. Lipid infusions into the carotid artery have 
been shown to activate the LH, but to inhibit the activity of several other hypothalamic nuclei 
including the ARC, DMH, PVN and VMH (Cruciani-Guglielmacci et al., 2004). ICV infusion of the long-
chain fatty acid (LCFA) oleic acid reduces food intake and hepatic glucose production (Obici et al., 
2002, Morgan et al., 2004). This is thought to be at least partly due to a reduction in NPY and AgRP 
expression (Obici et al., 2002). Octanoic acid showed no such effect, suggesting that the actions of 
fatty acids are specific, and may be related to their chain length or degree of saturation. Inhibiting 
hypothalamic carnitine palmitoyl transferase 1 (CPT-1) (Obici et al., 2003), which is involved in 
mediating the mitochondrial import of LCFA-CoA for β-oxidation, also reduces food intake. The 
effect on feeding is thus thought to be due to the accumulation of intracellular LFCA-CoA, rather 
than to the fatty acids themselves (Figure 1.7.) (Obici et al., 2003, Lam et al., 2005, He et al., 2006). 
Fatty acids are thought to regulate the conductance of a variety of ion channels; inhibiting, for 
example, the KATP channel abolishes the effect of oleic acid on hepatic glucose production (Pocai et 
al., 2005). Beta-oxidation is also influenced by ghrelin levels; ghrelin stimulates β-oxidation of fatty 
acids by increasing hypothalamic expression of CPT-1 (Andrews et al., 2008).  
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Figure 1.7. Schematic diagram illustrating the mechanism by which hypothalamic fatty acid 
sensing may influence food intake. 
Glucose is metabolised intracellularly to malonyl CoA. Malonyl-CoA inhibits CPT-1, the enzyme which 
mediates the transfer of long chain acyl-CoA into the mitochondrion to undergo β-oxidation. This 
results in an intracellular accumulation of long chain acyl-CoA, the pool of which is added to by 
metabolism of exogenous LCFAs. It is believed that it is this accumulation of long chain acyl-CoA that 
signals energy surplus rather than the fatty acids themselves (Obici et al., 2003, Lam et al., 2005, He 
et al., 2006). 
ACC, Acetyl-CoA carboxylase; MCD, Malonyl-CoA decarboxylase; FAS, fatty acid synthase; LCFAs, 
long chain fatty acids; CPT-1, carnitine palmitoyl transferase-1; TCA cycle, tricarboxylic acid cycle. 
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Although these effects of fatty acids are reported to be mediated by actions on cellular metabolism, 
some of the biological effects bear the characteristics of cell surface receptor involvement (Sauer et 
al., 2000, Louet et al., 2001). The identification of fatty acid receptors has offered an alternative 
mechanism of action for free fatty acids (FFAs). Activation of fatty acid receptors appears to be 
dependent on carbon chain length of the FFA. Several medium- and long-chain FFAs have been 
identified as ligands for the FFA1 (previously termed GPR40), GPR84 and GPR120 receptors (Briscoe 
et al., 2003, Itoh et al., 2003, Kotarsky et al., 2003, Hirasawa et al., 2005, Wang et al., 2006). The 
FFA1 is expressed in the pancreas, gut and brain, and fatty acids with long carbon chains activate 
FFA1 more potently. FFA1 has been shown to regulate the FFA-mediated release of gastric inhibitory 
peptide and GLP-1 from the gut, and to influence the FFA-mediated enhancement of insulin release 
from β-cells of the pancreas (Itoh et al., 2003, Steneberg et al., 2005, Briscoe et al., 2006, 
Christiansen et al., 2008, Edfalk et al., 2008, Tan et al., 2008). The GPR84 is activated by medium 
length fatty acids and is expressed on the cells of the immune system, where it may play a role in 
monocyte/macrophage activation (Wang et al., 2006). The GPR120 is activated by both medium and 
long chain fatty acids and is expressed in gut tissue where it influences secretion of GLP-1 (Hirasawa 
et al., 2005).  Short-chain FFAs activate FFA2 and FFA3 (previously termed GPR43 and GPR41, 
respectively) found in adipose and immune tissue (Brown et al., 2003, Le Poul et al., 2003, Nilsson et 
al., 2003). Short-chain FFAs are produced by anaerobic fermentation of dietary carbohydrate fibres, 
and FFA2 and FFA3 could thus be classified as carbohydrate intake sensors rather than lipid intake 
sensors (Wellendorph et al., 2009a). The agonists and expression patterns of these receptors are 
summarised in table 1.1.  
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Receptor Agonist Expression 
FFA1 Long- and medium-chain FFAs Pancreasa 
Braina 
Gastrointestinal tractb 
FFA2 Short-chain FFAs Adipose tissuec 
Spleend 
Gastrointestinal tracte 
Bone marrowf 
FFA3 Short-chain FFAs Immune cellsf 
Adipose tissuef 
GPR84 Medium-chain FFAs Leukocytesg 
Monocytesg 
Macrophagesg 
GPR120 Long- and medium-chain FFAs Gastrointestinal tracth 
Adipose tissue h 
Lungh 
Table 1.1. Free fatty acid receptors, their agonists and expression patterns. 
FFA, Free fatty acid receptor; GPR, G protein-coupled receptor. 
aInformation from (Briscoe et al., 2003); bInformation from (Edfalk et al., 2008); cInformation from 
(Hong et al., 2005); dInformation from (Le Poul et al., 2003); eInformation from (Karaki et al., 2006); 
fInformation from (Brown et al., 2003, Le Poul et al., 2003); gInformation from (Wang et al., 2006); 
hInformation from (Miyauchi et al., 2009). 
  
57 
 
1.5.3. Protein/amino acid sensing 
There is growing evidence that the gut and the CNS are able to sense the products of protein 
digestion. Diets high in protein have a powerful satiating effect which is greater than that of 
carbohydrate or fat (Westerterp-Plantenga et al., 1999, Lejeune et al., 2006). They have been shown 
to reduce food intake, facilitate weight loss and improve body composition in animal models and in 
man (Hannah et al., 1990, Jean et al., 2001, Kinzig et al., 2007, Potier et al., 2009). It does not appear 
that these effects are secondary to changes in palatability; studies have demonstrated that ingestion 
of high protein diets do not cause conditioned taste aversion and that protein ingestion leads to 
typical behavioural satiety sequences (Harper and Peters, 1989, Bensaid et al., 2003). The 
mechanisms by which these effects are mediated are currently unclear, though there are several 
candidate pathways, which are discussed in detail in section 3.1.1. 
GPR93 is a family A receptor which has recently been described as responsive to peptone, a peptide 
mixture resembling gastrointestinal proteolytic degradation products. It is highly expressed in the 
small intestine (Choi et al., 2007a) and it is suggested to be the missing link for previously described 
protein hydrolysate-mediated increases in CCK expression and release in intestinal cells (Nemoz-
Gaillard et al., 1998, Nishi et al., 2001). It has been shown that peptone stimulation of GPR93 in 
enteroendocrine cells in vitro activates G-protein signalling cascades, which ultimately promote CCK 
gene transcription and CCK release (Choi et al., 2007a, Choi et al., 2007b). The precise ligands 
responsible for activating the GPR93 remain to be determined. 
Proteins are composed of amino acids, and ingested proteins are broken down into amino acids in 
the lumen of the gut or within enterocytes before they are assimilated into the body. Receptor 
systems have now been identified that respond to L-amino acids and these will be discussed in detail 
in section 2.1.3. Amino acids are the components of protein and there is evidence for direct 
hypothalamic amino acid sensing influencing food intake (Blouet et al., 2009). The mechanisms of 
protein-induced satiety involved and their sites of action remain unclear. This thesis aims to 
determine the effects of individual amino acids on satiety and to investigate the mechanism through 
which these effects are mediated. 
1.6. Aims 
The aims of this thesis are to determine: 
1) Which amino acids acutely reduce food intake following oral and i.p. administration in the early 
light phase in rats.  
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2) The hypothalamic and brainstem areas activated following oral administration of appetite-
reducing amino acids in rats. 
3) The effect of central administration of amino acids that reduce appetite following peripheral 
admistration in rats. 
4) The effects of appetite-reducing amino acids on gut hormone release in vivo and in vitro.  
5) Whether those amino acids that reduce food intake in rats also do so in mice. 
6) Whether appetite-reducing amino acids induce conditioned taste aversion.  
7) The effects of chronic administration of the most effective appetite-reducing amino acid on 
cumulative food intake and body weight gain in rats.  
The studies conducted to fulfill these aims will elucidate the role of amino acids in satiety and their 
putative clinical utility.  
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CHAPTER 2: THE EFFECT OF 
SPECIFIC AMINO ACIDS ON 
FOOD INTAKE IN THE RAT  
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2.1. Introduction 
2.1.1. Protein composition and satiety 
It is well established that protein induces satiety more effectively than other macronutrients (Stubbs 
et al., 1996, Crovetti et al., 1998, Westerterp-Plantenga et al., 1999, Lejeune et al., 2006). It appears 
that the type of protein influences its satiety effects. Of the different proteins tested, whey protein is 
reported to have the largest effect on satiety (Anderson et al., 2004). For example, it has been 
shown that a whey protein pre-load reduces short-term food intake in humans to a greater extent 
than a pre-load of casein, soy protein and egg albumin (Anderson et al., 2004). Whey protein has 
also been shown to result in higher circulating levels of CCK and GLP-1 compared to casein (Hall et 
al., 2003), and to reduce hunger to a greater extent than casein or soy (Veldhorst et al., 2009, Hall et 
al., 2003). It is possible that the specific amino acids generated by protein digestion may be 
responsible for the magnitude of the resulting satiation.  The amounts of the individual amino acids 
comprising the protein within a meal may therefore determine which satiety pathway is activated 
and to what degree. 
2.1.2. Protein and amino acids 
After ingestion of a protein meal, there is a sharp transient rise in the amino nitrogen content of the 
portal blood (Rerat et al., 1985). Amino acids are actively absorbed from the gut and individual 
amino acids can be found at millimolar concentrations in the general circulation following a high 
protein meal (Fafournoux et al., 1982). While there are potential mechanisms which sense protein to 
generate satiety ‘signals’, the recent identification of a family of promiscuous L-amino acid receptors 
has highlighted the possibility of the amino acid products of protein breakdown signalling to regulate 
food intake. 
2.1.3. Family C GPCRs 
G-protein-coupled receptors (GPCRs) are implicated in many important physiological processes. 
GPCRs are the targets for approximately 40% of currently marketed drugs and over 60% of drugs in 
development (Lundstrom, 2005). Those which are not olfactory receptors have been classified into 
three families, A, B and C, based on phylogenetic analysis of their 7-transmembrane domain (7TM) 
(Kolakowski, 1994). Family C of the human GPCRs contains 22 receptor subtypes, including eight 
metabotropic glutamate (mGlu) receptors, two γ-aminobutyric acid type B (GABAB) receptors, the 
calcium-sensing receptor, three taste1 receptors, the G-protein-coupled receptor family C, group 6, 
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subtype A (GPRC6A) and seven orphan receptors (Bjarnadottir et al., 2005, Brauner-Osborne et al., 
2007). Aside from the orphan members of the family, all the family C GPCRs have a very large 
extracellular Venus flytrap (VFT) domain, which has been shown to contain a dimerisation interface 
and an orthosteric binding site for the endogenous agonists (Kunishima et al., 2000, Tsuchiya et al., 
2002, Muto et al., 2007). This VFT domain is attached, via a cysteine-rich domain (CRD), to the 7TM, 
G protein-activating domain (Figure 2.1.). The VFT domain of the family C GPCRs is phylogenetically 
related to a class of bacterial periplasmic binding proteins (O'Hara et al., 1993, Felder et al., 1999). 
Interestingly, these periplasmic binding proteins are involved in nutrient uptake (Quiocho and 
Ledvina, 1996) and it thus appears that family C 7TM receptors have preserved the binding sites for 
nutrient-like compounds. It is thought that the agonist binding domain and the signalling domain of 
receptors in this family were once separate components that merged during evolution (Conklin and 
Bourne, 1994). 
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Figure 2.1. Model of a dimeric family C 7-transmembrane domain receptor in its open-
closed/active conformation. 
The locations of the venus fly trap domain (VFT), cysteine rich domain (CRD), and 7-transmembrane 
domain (7TM) and orthosteric and allosteric ligand binding sites are indicated (adapted from 
(Wellendorph et al., 2009a)).  
VFT 
CRD 
7TM 
Orthosteric agonists 
(L-amino acids, divalent cations, 
sugars) 
Allosteric enhancers (L-amino 
acids, divalent cations) 
Allosteric enhancers (purinic 
ribonucleotides) 
Allosteric enhancers (Ca2+) 
63 
 
Three of these family C GPCRs have been shown to be sensitive to L-amino acids. These are the 
calcium sensing receptor (CaR), the taste receptor type 1 member 1/taste receptor type 1 member 3 
dimer (T1R1/T1R3), and the G-protein coupled receptor family C group 6 member A (GPRC6A). Each 
of these receptors is discussed in detail below. 
2.1.3.1. The calcium-sensing receptor (CaR) 
The primary ligands of the CaR are calcium ions (Brown et al., 1993) and it functions to regulate the 
release of hormones important for the maintenance of calcium homeostasis. However, it also has a 
role in other physiological processes, including gastric acid secretion (Dufner et al., 2005), hepatic 
bile secretion (Canaff et al., 2001), and insulin release from the β cells of the pancreas (Squires et al., 
2000). CaR is also responsive to other inorganic cations, including Mg2+, Ba2+, Sr2+ and Gd3+. It has 
also been demonstrated to be sensitive to L-amino acids  and, whilst recognising many L-amino 
acids, it is particularly responsive to aromatic amino acids such as L-tryptophan and L-phenylalanine 
(Conigrave et al., 2000). CaR appears to be insensitive to, or only weakly activated by, acidic, basic 
and branched-chain amino acids (Conigrave et al., 2000). Whereas other family C receptors are 
directly activated by amino acids and are positively modulated by Ca2+, CaR is directly activated by 
Ca2+ and is positively modulated by amino acids (Conigrave et al., 2000). Amino acids require a 
minimum concentration of extracellular Ca2+ to cause receptor activation, as they act as allosteric 
enhancers at CaR. However, experiments have determined that amino acid sensing is possible at 
physiological concentrations of Ca2+ (around 1mM) (Conigrave et al., 2004, Conigrave and Hampson, 
2006). CaR may therefore play a role in amino acid sensing. It is expressed in organs involved in 
calcium homeostasis, but is also found in the stomach, the lower GI tract, the liver and the pancreas 
(Ray et al., 1997, Sheinin et al., 2000, Canaff et al., 2001, Squires et al., 2000). The expression pattern 
in human, mouse and rat is shown in Table 2.1. A potential physiological role for the positive 
modulation of CaR by amino acids has been demonstrated; the CaR mediates L-amino acid-
stimulated gastric acid release from stomach parietal cells ex vivo (Busque et al., 2005), and CCK 
release from duodenal enteroendocrine cell lines (Hira et al., 2008). Activation of the CaR also 
inhibits parathyroid hormone release from human parathyroid cells (Conigrave et al., 2004). The 
expression of CaR in the taste tissue of the tongue (San Gabriel et al., 2009) suggests that it may 
mediate the sensing of the taste of calcium and amino acids. The CaR knockout mouse has a severe 
phenotype which includes severely dysfunctional calcium homeostasis, retarded growth and 
premature death (Ho et al., 1995). It is thus difficult to use this model to specifically determine 
whether CaR has a physiological role in energy homeostasis.  
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Human CaR Mouse CaR Rat CaR 
Thyroida 
Large intestineb 
Lens epithelial cellsc 
Pancreasd 
Stomache 
Aortaf 
Parathyroid cellsg 
Boneh 
Parathyroid cellsi 
Thyroida 
Kidneyj 
Braink 
Liverl 
Parathyroid cellsm 
Table 2.1. Known tissue expression pattern of CaR orthologues in human, mouse and rat. 
Information displayed is indicative of data confirming the presence in a particular tissue. Absence 
from the table means that data have not been described, not that the CaR has been confirmed not 
to be present in other tissues. Distribution of CaR in the mouse has not been comprehensively 
studied. 
aInformation from (Garrett et al., 1995); bInformation from (Sheinin et al., 2000); cInformation from 
(Chattopadhyay et al., 1997); dInformation from (Squires et al., 2000); eInformation from (Ray et al., 
1997); fInformation from (Ziegelstein et al., 2006); gInformation from (Gogusev et al., 1997); 
hInformation from (Mentaverri et al., 2006); iInformation from (Mallya et al., 2005); jInformation 
from (Riccardi et al., 1995); kInformation from (Ruat et al., 1995); lInformation from (Canaff et al., 
2001). 
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2.1.3.2. The T1R1/T1R3 taste receptor 
The taste receptor type 1 member 1 (T1R1) GPCR was first identified from a small subset of receptor 
cells in taste buds of mouse and rat circumvallate papillae. The gene which encodes it, Gpr70, is 
located on chromosome 4 along with the saccharin preference locus (Sac) in the mouse (Hoon et al., 
1999). Sac was initially identified as having a role in the recognition of several sweet substances. Sac 
‘taster’ mice, which possess a Sac gene which differs by two amino acids from that of sac ‘non-
tasters’, are about five fold more sensitive to sucrose, saccharin and other sweeteners than Sac non-
tasters (Nelson et al., 2001, Montmayeur et al., 2001, Max et al., 2001). Sac was subsequently found 
to code for the taste receptor type 1 member 3 (T1R3) GPCR (Nelson et al., 2001, Kitagawa et al., 
2001, Montmayeur et al., 2001, Max et al., 2001, Sainz et al., 2001, Bachmanov et al., 2001). 
The T1R receptor class has a third member, T1R2, which dimerises with T1R3 to form a sweet taste 
receptor with a broad sensitivity for sweet substances including glucose and sweet tasting D-amino 
acids. This dimer is expressed in the GI tract where it is thought to play a role in glucose homeostasis 
by regulating glucose absorption (Margolskee et al., 2007, Mace et al., 2007, Mace et al., 2009) and 
secretion of the incretin gut hormone GLP-1 (Jang et al., 2007).  
Nelson et al. demonstrated that cells transfected with either mouse T1R1 or T1R3 were insensitive 
to L-amino acids, but that when both receptors were transfected together, the T1R1 and T1R3 
combine to function as a broadly tuned L-amino acid receptor sensitive to most amino acids which 
are perceived as sweet, for example, alanine, glutamine, serine, threonine and glycine (Nelson et al., 
2002). It has been shown that the mouse T1R1/T1R3 has a particular affinity for aliphatic (including 
branched chain), amidic, charged, sulphur- and hydroxyl-containing L-amino acids, but not the 
aromatic amino acids (Nelson et al., 2002, Zhao et al., 2003, Iwasaki et al., 1985). Notably, unlike the 
rodent T1R1/T1R3, the human T1R1/T1R3 amino acid taste receptor is reported to be substantially 
more sensitive to L-glutamate and L-aspartate than to other L-amino acids (Li et al., 2002). T1R1 is 
expressed in circumvallate and fungiform papillae in mouse taste tissue which do not express T1R3 
(Kim et al., 2003), suggesting that in some cells it might operate as a homodimer or a heterodimer 
with other members of the family C GPCRs. In addition, T1R3 knockout mice are able to utilise T1R3-
independent means to identify and discriminate between glutamate and sucrose, indicative of 
possible alternative dimerisation or other compensating  pathways (Delay et al., 2006). 
The T1R1/T1R3 heterodimer is also thought to contribute to the perception of savoury taste 
(umami), which is a fifth basic taste quality along with sweet, salty, bitter and sour (Nelson et al., 
2002, Li et al., 2002). This umami taste is powerfully elicited by monosodium glutamate (MSG) 
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(Ikeda, 1909, Kurihara and Kashiwayanagi, 1998, Maga, 1983). Hallmarks of umami taste are its 
potentiation by purine nucleotides such as inosine monophosphate (IMP) and activation by the 
mGluR-agonist L-AP4 (Kurihara and Kashiwayanagi, 1998). The T1R1/T1R3 heterodimer is not 
thought to be the sole umami receptor; contributions are also made by two variant metabotropic 
glutamate receptors: the taste-specific mGluR4 which is expressed in rat taste buds from the 
posterior tongue (Chaudhari et al., 1996, Chaudhari et al., 2000, Yang et al., 1999) and the truncated 
mGluR1 (San Gabriel et al., 2005). However, the extent of the role of the mGluRs in umami taste 
sensing has been debated, especially as genetic ablation of T1R receptors in mice has yielded 
conflicting results; Damak et al. showed that T1R3 knockout mice have a reduced but not abolished 
preference for MSG, whilst Zhao et al. showed that knocking out the T1R1 eliminated all preference 
for umami stimuli (Damak et al., 2003, Zhao et al., 2003). 
Expression of the T1R1 and T1R3 subunits has been most thoroughly described in the taste tissue. 
T1R3 is expressed in all lingual papillae, as well as in taste buds of the palate (Kitagawa et al., 2001, 
Max et al., 2001, Montmayeur et al., 2001, Nelson et al., 2001, Sainz et al., 2001). T1R1 has been 
shown to be expressed primarily in fungiform taste buds (Hoon et al., 1999) but Kim et al. report 
more widespread expression (Kim et al., 2003). Outside of the taste tissue, expression data is 
limited. The expression patterns of the T1R1 and T1R3 reported to date are summarised in Table 2.2. 
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 Humana Mousea Rat 
T1R1 Taste tissueb 
Stomach 
Duodenum 
Jejunum 
Ileum 
Colon 
Taste tissuec 
Stomach 
Duodenum 
Ileum 
Colon 
Hypothalamusd 
Hippocampusd 
Cortex of the braind 
Taste tissuee 
Stomachf 
Jejunumg 
T1R3 Taste tissueb 
Stomach 
Duodenum 
Jejunum 
Ileum 
Colon 
Taste tissuec 
Stomach 
Duodenum 
Jejunum 
Ileum 
Colon 
Hypothalamusd 
Hippocampusd 
Cortex of the braind 
Jejunumg 
Table 2.2. Known tissue expression pattern of T1R1 and T1R3 orthologues in human, mouse and 
rat. 
aInformation from (Bezencon et al., 2007); bInformation from (Raliou et al., 2009); cInformation from 
(Kim et al., 2003); dInformation from (Ren et al., 2009); eInformation from (Hoon et al., 1999);   
fInformation from (Nakamura et al., 2010); gInformation from (Mace et al., 2007).  
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Signal transduction from the T1R receptors is mediated by the G protein gustducin (Ruiz-Avila et al., 
2001). Gustducin is a heterotrimeric G-protein made up of α-gustducin, Gβ3 and Gγ13 (Huang et al., 
1999). Upon activation, gustducin separates into α and βγ subunits. In a pathway which is common 
to bitter, sweet and umami transduction, the βγ subunit activates phospholipase Cβ2 (PLCβ2), which 
hydrolyses phosphatidylinositol-4,5-bisphosphate (PIP2) to produce the second messengers inositol 
1,4,5-triphosphate (IP3) and diacylglycerol (DAG). Binding of IP3 to IP3R3 leads to Ca
2+ release from 
intracellular stores which activates transient receptor potential cation channel subfamily M member 
5 (TRPM5) channels. Activation of TRPM5 leads to Na+ entry, membrane depolarization and 
generation of an action potential in taste cells (Liu and Liman, 2003, Prawitt et al., 2003). This 
pathway is illustrated in Figure 2.2. It appears that, at least in mice, α-gustducin is involved in the 
detection of glutamate, as α-gustducin knockout mice have compromised preference for, and 
presumably detection of, glutamate (Ruiz et al., 2003). 
T1R1, T1R3, PLCβ2, α-gustducin and Trpm5 are expressed in human stomach, duodenum, jejunum, 
ileum and colon (Bezencon et al., 2007). In the mouse, there is a similar expression pattern, and a 
high degree of colocalisation of these receptor subunits and signalling molecules throughout the 
gastrointestinal tract (Bezencon et al., 2007). These studies indicate that there may be a 
physiological chemosensing role for T1R1/T1R3 in the gut (Hofer et al., 1996, Dyer et al., 2005, 
Bezencon et al., 2007). Alpha-gustducin is expressed in the PYY- and GLP-1-producing L-cells of the 
intestine (Rozengurt et al., 2006, Rozengurt and Sternini, 2007). No colocalisation of Trpm5 with 
CCK, PYY, ghrelin, orexin A or GLP-1 has been detected in the intestine (Bezencon et al., 2007). 
However, this does not prove that T1R1/T1R3 does not modulate the behaviour of cell types 
expressing these hormones, as it might modulate their release via an alternative intracellular 
signalling pathway. The taste receptor subunits have not, however, been shown to be expressed in 
L-cells and so their potential modulatory role in these cell types is disputed.  
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Figure 2.2. Schematic diagram illustrating the signal transduction pathway downstream of 
T1R1/T1R3 in taste cells. 
Binding of umami compounds toT1R1/T1R3 activates the heterodimeric G proteins gustducin or Gα 
leading to the release of the Gβγ subunits and the subsequent stimulation of phospholipase C (PLC).  
Activation of PLC hydrolyses phosphatidylinositol-4,5-bisphosphate (PIP2) to produce the second 
messengers IP3 and diacylglycerol (DAG). Binding of IP3 to IP3R3 leads to Ca
2+ release from 
intracellular stores which activates TRPM5 channels. Activation of TRPM5 leads to Na+ entry, 
membrane depolarization and generation of action potential of taste cells. DAG may activate protein 
kinase C (PKC) which leads to the closure of potassium channels and depolarization of the cell 
membrane. Umami-responsive cells are proposed to release adenosine 5’-triphosphate (ATP) which 
is detected by the taste axons. These taste axons then convey information from taste cells to the 
brain. 
T1R1/T1R3, Taste receptor type 1 member 1/taste receptor type 1 member 3 dimer; PIP2, 
Phosphatidylinositol 4,5-bisphosphate; PLC, phospholipase C; DAG, diacylglycerol; PKC, Protein 
kinase C; IP3, Inositol 1,4,5-trisphosphate; IP3R3, IP3 receptor; TRPM5, Transient receptor potential 
cation channel subfamily M member 5; ATP, Adenosine triphosphate.  
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The first evidence that T1R1/T1R3 might have a chemosensing role in the alimentary system was the 
finding that it can regulate the expression of peptide, glucose and amino acid transporters in the gut. 
Specifically, activation of T1R1/T1R3 in the rat jejunum down-regulates expression of the 
oligopeptide transporter, PepT1, and up-regulates expression of the glucose transporter GLUT2 and 
the L-Glu/L-Asp transporter Excitatory Amino Acid Transporter 1 (EAAC1) (Mace et al., 2009). The 
sweet taste receptor T1R2/T1R3 is also able to decrease PepT1 expression and increase GLUT2 
expression in the jejunum. It has therefore been hypothesised that a taste receptor-coordinated 
transport network exists within the GI tract whereby there is cross-regulation of expression of 
nutrient transporters; i.e., sugars can regulate expression of amino acid/peptide transporters via 
T1R2/T1R3 and amino acids can regulate glucose transport via T1R1/T1R3. This system may also 
incorporate other nutrients (Mace et al., 2009). The finding that α-gustducin is also expressed in the 
pancreas suggests that this system may also play a role in regulating pancreatic secretions (Hofer 
and Drenckhahn, 1998), though T1R1 has not been reported to be expressed in the pancreas. 
T1R1/T1R3 and the intracellular signalling molecules postulated to mediate its effects have been 
shown to be present in tissues important in the control of food intake. Thus the chemosensing role 
of T1R1/T1R3 may be involved in the regulation of food intake. Hypothalamic T1R1 expression is 
increased following food deprivation and is higher in lean wildtype mice compared to obese ob/ob 
mice (Ren et al., 2009). This indicates a potential central nutrient sensing role for T1R1/T1R3. 
However, mice lacking T1R1 or T1R3 are not reported to display a metabolically altered phenotype 
(Zhao et al., 2003). 
2.1.3.3. The G-protein coupled receptor family C group 6 member A (GPRC6A) 
The GPRC6A is an extracellular cation-sensing receptor responsive to L-amino acids. The human 
GPRC6a (hGPRC6A) gene sequence was identified in the chromosome band 6q22.31 in 2004 by 
homology searches of known human family C GPCRs, and was subsequently cloned from human 
kidney tissue (Wellendorph and Brauner-Osborne, 2004). Three isoforms of the receptor were 
cloned; the longest and most abundant form was named isoform 1 and had an open reading frame 
(ORF) of 2778 nucleotides, coding for 926 amino acids. Isoform 2 differed from isoform 1 by an in-
frame deletion of a 525 base pair fragment comprised of nucleotides 810-1335, coding for amino 
acids 270-445 in the protein sequence. Isoform 3 was the least abundant and again differed from 
isoform 1 by an in-frame 212 base pair deletion of nucleotides, in this case nucleotides 1336-1548 
coding for amino acids 445-516. These deletions are restricted to the amino terminal domain (ATD) 
but are so large as to probably entail profound differences in tertiary structure of the receptors. The 
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same research group subsequently cloned the mouse orthologue of GPRC6A, which has 80% amino 
acid identity with hGPRC6A and 82% identity in the ATD (Wellendorph and Brauner-Osborne, 2004). 
This homologue also appears to have 3 isoforms (Kuang et al., 2005). The rat homologue (rGPRC6A) 
has also been cloned using mRNA from rat circumvallate taste papilla. Unlike hGPRC6A and 
mGPRC6A, no splice variant forms of rGPRC6a have been identified (Wellendorph et al., 2007). 
Gene expression studies have been carried out for the human, mouse and rat homologues 
(Wellendorph and Brauner-Osborne, 2004, Wellendorph et al., 2007, Kuang et al., 2005). The tissues 
expressing GPRC6A in each species are listed in Table 2.3., with data being representative of the 
expression of isoform 1 (the most abundant isoform) for human and mouse. Isoforms 2 and 3 of 
hGPRC6A have lower levels of expression in all tissues which express isoform 1 except the kidney, 
where isoforms 1 and 2 are expressed at similar levels (Wellendorph and Brauner-Osborne, 2004). 
Moderate levels of mGPRC6A isoform 2 have been detected in the spleen and lung with lower levels 
found in the liver. Isoform 3 of mGPRC6A has also been detected in the lung (Kuang et al., 2005). 
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  Human GPRC6Aa Mouse GPRC6Ab Rat GPRC6Ae 
High levels Brain 
Skeletal muscle 
Testis 
Leucocytes 
Liver 
Heart 
Kidney 
Spleen 
Lung 
Liver 
Spleen 
Heart 
Bonec 
Testisd 
Fatd 
Geschmacksstreifen 
(taste tissue) 
Mesenteric arteriesf 
Low levels Lung 
Pancreas 
Placenta 
Ovary 
Kidney 
Skeletal muscle 
Brain 
Kidney 
Liver 
Lung 
Brain 
Not expressed Thymus 
Prostate 
Small intestine 
Colon 
Tongue 
 Heart 
Testis 
Skeletal muscle 
Spleen 
Table 2.3. Known tissue expression pattern of GPRC6A orthologues in human, mouse and rat. 
In human and mouse homologues for which multiple isoforms exist, data shows expression of 
isoform 1, the most abundant isoform. 
aInformation from (Wellendorph and Brauner-Osborne, 2004); bInformation from (Kuang et al., 
2005); cInformation from (Pi et al., 2005); dInformation from (Luo et al., 2010); eInformation from 
(Wellendorph et al., 2007); fInformation from (Harno et al., 2008).  
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Experiments investigating the pharmacology of the hGPRC6A have been handicapped by the lack of 
a robust in vitro model of hGPRC6A functionality. In cell lines manipulated to express the hGPRC6A, 
the receptor appears to remain internalised and is not translocated to the cell surface. Other 
members of the family C GPCRs, such as the GABABR, depend hugely on heterodimerisation (Mohler 
and Fritschy, 1999) and it is possible this is the case for GPRC6A (Wellendorph et al., 2005). The 
receptor with the highest sequence identity with the hGPRC6A is the goldfish odorant receptor 5.24 
(Speca et al., 1999). In an endeavour to increase cell surface expression of hGPRC6A, a chimeric 
receptor composed of the 7TM and carboxyl terminus domains of the 5.24 odorant receptor and the 
ATD domain of hGPRC6A was created. The presence of the 7TM domain of the 5.24 odorant 
receptor allowed cell surface expression whilst the ATD contains the ligand binding pocket of native 
hGPRC6A, thus theoretically maintaining hGPRC6A ligand specificity. This chimeric receptor model 
was used as a tool to investigate potential ligands for hGPRC6A (Wellendorph et al., 2005). Exposure 
of tsA murine mammary adenocarcinoma cells transfected with the chimeric receptor to L-arginine, 
L-lysine, L-alanine, glycine, L-serine, L-ornithine and L-citrulline resulted in an increase in intracellular 
Ca2+, with the greatest responses induced by L-arginine, L-ornithine and L-lysine (see Table 2.4). 
The rGPRC6A has also been transiently expressed in tsA cells (Wellendorph et al., 2007). Using this 
model, it was determined that L-ornithine, glycine and L-citrulline were the most potent α-amino 
acid agonists at the rGPRC6A. The agonist pharmacology of the GPRC6A orthologues is shown in 
Table 2.4. 
In contrast to hGPRC6A, mGPRC6A is trafficked to the cell surface when transiently expressed in an 
in vitro model (Wellendorph et al., 2005). Screening of potential ligands revealed L-arginine, L-lysine 
and L-ornithine as the most potent activators. Although displaying a similar pattern of agonist 
preferences to hGPRC6A, mGPRC6a does not respond to L-citrulline or L-glutamic acid, and it also 
appears to have a lower sensitivity than hGPRC6A (Wellendorph et al., 2005). However, this may 
reflect factors independent of receptor pharmacokinetics, such as receptor expression level. 
Christiansen et al. used a chimeric G-protein, GαqG66D, to enhance the measurable response 
(Christiansen et al., 2007). The L-amino acid response of mGPRC6A is augmented by the divalent 
cations Ca2+ and Mg2+ at physiologically relevant concentrations (Christiansen et al., 2007) and Mg2+ 
has also been shown to be a positive modulator of the rGPRC6A response (Wellendorph et al., 2007). 
One study has demonstrated a direct activation of hGPRC6A by Ca2+and Mg2+ (Pi et al., 2005). 
It has been suggested that mGPRC6A preferentially signals through the Gq intracellular pathway 
(Wellendorph et al., 2005). Responses to the agonists of mGPRC6A can be almost completely 
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blocked by chelating intracellular calcium with 1,2-bis(2-aminophenoxy)-ethane-N,N,N’,N’-
tetraacetic acid-acetoxymethyl ester (BAPTA-AM) before stimulation (Wellendorph et al., 2005). The 
Gq protein subunit activates phospholipase C (PLC). PLC in turn hydrolyses phosphatidylinositol 4,5-
bisphosphate (PIP2) to diacyl glycerol (DAG) and (IP3). DAG remains bound to the membrane and acts 
as a second messenger that activates Protein Kinase C (PKC). IP3 is released as a soluble structure 
into the cytosol. It diffuses through the cytosol to bind to IP3 receptors, particular IP3 responsive 
calcium channels in the endoplasmic reticulum. These channels specifically allow the passage of 
calcium into the cytoplasm. The increasing cytosolic concentration of calcium causes a cascade of 
intracellular activity.  
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 Human GPRC6Aa Mouse GPRC6Ab Rat GPRC6Aa 
EC50 (pEC50 ± S.E.M.) (µM) 
L-Orn 112 (3.96 ± 0.05) 63.6 (4.20 ± 0.001) 264 (3.59 ± 0.05) 
Gly 263 (3.58 ± 0.04) 538 (3.30 ± 0.09) 455 (3.36 ± 0.10) 
L-Cit 287 (3.56 ± 0.09) >1000 615 (3.21 ± 0.03) 
L-Ser 623 (3.21 ± 0.07) 1160 (2.94 ± 0.03) 859 (3.08 ± 0.07) 
L-Lys 169 (3.77 ± 0.05) 135 (3.97 ± 0.18) >1000 
L-Ala 173 (3.76 ± 0.02) 486 (3.41 ± 0.18) >1000 
L-Arg 44.1 (4.38 ± 0.11) 284 (3.58 ± 0.08) >1000 
L-Met 854 (3.07 ± 0.04) >1000 >1000 
L-Cys >1000 356 (3.46 ± 0.09d) >1000d 
L-Gln 590 (3.23 ± 0.05) >1000 >1000 
Table 2.4. Agonist pharmacology of L-α-amino acids at GPRC6A orthologues. 
Other L-amino acids which were tested did not induce any response and so are not shown. 
aData obtained (using the hGPRC6A/5.24 chimeric receptor) from (Wellendorph et al., 2005). bData 
obtained from (Christiansen et al., 2007). Cells used were also transfected with the GαqG66D protein 
to enhance measurable response. cData obtained from (Wellendorph et al., 2007). Due to effects at 
mock-transfected cells when testing at high concentrations, exact potencies could only be calculated 
for the first four compounds listed. dL-Cys displayed a small but significant effect on mock-
transfected cells at high concentrations (≥1 mM) and so the potency may be slightly overestimated. 
GPRC6A, G-protein coupled receptor family C group 6 member A; EC50, half maximal effective 
concentration (concentration of an agent which induces a response halfway between the baseline 
and maximum after some specified exposure time); pEC50, negative logarithm of the EC50.  
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The role of GPRC6A has been further elucidated by the creation of knockout models. Global exon-2 
and exon-6 GPRC6A null mice models have been produced. Exon-2 codes for residues 66-167 of the 
mGPRC6A (Kuang et al., 2005) and knockout of exon-2 should thus disable nutrient sensing by the 
VFT domain. Exon-6, however, encodes the entire heptahelical 7TM domain and C-terminal domain 
and should eliminate the receptor’s signalling function (Kuang et al., 2005, Wellendorph et al., 2007). 
Surprisingly, the phenotypes of these two models are markedly different (Pi et al., 2008, 
Wellendorph et al., 2009b). The exon-2 null mouse displayed a multi-system phenotype, featuring 
normal body weight but an increased fat mass, decreased lean body mass, hyperglycaemia and 
insulin resistance, proteinuria, renal calcium and phosphate wasting, impaired bone mineral density 
and defective testicular function resulting in low serum testosterone levels (Pi et al., 2008). GPRC6A 
may thus regulate energy homeostasis and adiposity, though it is also possible that the alterations in 
lean and fat mass are secondary to the testosterone deficiency. In the exon-6 null mouse, however, 
no phenotypic disturbance was observed (Wellendorph et al., 2009b). If the disparity between these 
models is real, the results would suggest that the nutrient-sensing function of exon-2 is critical to the 
processing of normal metabolic signals arising from basic amino acids and/or divalent cations, but 
that the signalling function of exon-6 is redundant. Such a situation might arise if GPRC6A normally 
operates in heterodimers with an unidentified signalling partner. If this is the case, the cloned 
GPRC6A subunit might be analogous to the T1R1 subunit whose heterodimeric partner is T1R3. 
Alternatively, the loss of the signalling function might activate compensatory developmental 
pathways more effectively than the loss of the sensing domain. Although GPRC6A is suggested to be 
a nutrient sensing receptor (Conigrave and Hampson, 2006), it has not to date been detected in the 
stomach or intestine, suggesting that it is more likely to sense circulating amino acids rather than 
those within the gut lumen. 
More recently, it has been suggested that GPRC6A is directly involved in regulating non-genomic 
effects of androgens (Pi et al., 2010). It was reported that GPRC6A mediates the rapid signalling 
response to testosterone and other steroids in various cell culture models (Pi et al., 2010). In 
addition, GPRC6A null mice were found to have an impaired rapid response to exogenous 
testosterone and failed to fully restore seminal vesicle size (a measure of androgen tissue 
responsiveness) following orchidectomy (Pi et al., 2010). Paradoxically, exogenous testosterone 
administered to GPRC6A null mice increased serum LH levels, suggesting that GPRC6A may regulate 
the hypothalamic-pituitary axis (Pi et al., 2010). A single nucleotide polymorphism (SNP) in the 
GPRC6A coding region in a Japanese population has been associated with susceptibility to prostate 
cancer (Takata et al., 2010). As the GPRC6A null mouse has lower levels of estradiol and 
testosterone, and they appear to be less sensitive to the effects of testosterone (Pi et al., 2010), it is 
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possible that genetic variations at the GPRC6A locus might affect prostate cancer susceptibility by 
altering GPRC6A-mediated sex hormone production or sensitivity (Takata et al., 2010). 
An additional ligand for GPRC6A has been recently discovered. The osteoblast-produced hormone 
osteocalcin has been found to act via the GPRC6A in the Leydig cells of mouse testes (Oury et al., 
2011). Osteocalcin is pro-osteoblastic and is implicated in bone mineralisation and calcium 
homeostasis, potentially explaining the observed bone phenotype in the GPRC6A exon-2 knockout 
mouse. In addition, osteocalcin induces pancreatic beta cells to release insulin and stimulates fat 
cells to release adiponectin, which increases insulin sensitivity, which might explain the metabolic 
phenotype observed in the GPRC6A exon-2 knockout mouse (Lee et al., 2007a). It is also thought 
that GPRC6A mediates the osteocalcin-induced negative feedback on insulin release from the 
pancreas to influence osteoblastic differentiation; i.p. injection of osteocalcin stimulates ERK activity 
in the pancreas and increases serum insulin levels in WT mice, but these responses are markedly 
attenuated in the GPRC6A exon-2 knockout mouse (Pi et al., 2011). 
2.1.3. Promiscuous amino acid receptors 
It is now well established that ingested nutrients stimulate the release of hormones from the gut, 
pancreas and other organs, as well as directly influencing hypothalamic neurones following 
absorption (Blouet and Schwartz, 2010). However, the molecular nature of the chemosensors 
involved has remained unclear. Recent identification of the promiscuous amino acid-activated 7TM 
receptors discussed above in these tissues suggests a possible mechanism for the effects of protein 
on appetite. As described above, L-amino acids have been shown to act as ligands for the T1R1/ 
T1R3 taste receptor, the CaR, and the GPRC6A. This subset of amino acid-sensing receptors appear 
to be relatively non-selective in their ligand profiles. However, the studies outlined above suggest 
that they do have a preference for particular classes of amino acids (Figure 2.3.). They therefore 
provide a potential means of mediating responses to all 20 proteinogenic L-amino acids (Conigrave 
and Hampson, 2006, Wellendorph and Brauner-Osborne, 2009). Importantly, however, the data on 
receptor response to particular amino acids were collected using in vitro models and so cannot 
automatically be assumed to be representative of the in vivo situation. In addition, some of these 
data came from studies using hybrid receptors, which are not necessarily representative of 
physiology. 
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Figure 2.3. L-amino acid selectivity profiles at GPRC6A, the T1R1/T1R3 heterodimer and CaR. 
All 20 of the proteinogenic amino acids were tested against the GPRC6A, the T1R1/T1R3 
heterodimer and CaR, except for L-tyrosine, which wasn’t tested at the T1R1/T1R3 due to 
insolubility. Data have been normalised to allow comparison of relative amino acid preferences. 
The CaR data was generated by calculating the potentiating effect of each of the 20 amino acids (at 
10 mM concentrations) on the Ca2+ response. The numbers represent the percentage response 
relative to that of L-histidine (100%) (Conigrave et al., 2000). The GPRC6A data is based on reported 
EC50 values of all 20 L-amino acids from the mouse GPRC6A measured in the presence of 1mMCa
2+ 
and 1 mM Mg2+ (Christiansen et al., 2007), here normalised to the L-lysine response (set to 100%). 
The T1R1/T1R3 data was generated by determining the number of mouse responsive cells measured 
in the presence of 2.5mM IMP (Nelson et al., 2002) as a percentage of those responsive to L-cysteine 
(100%). Responses to amino acids were recorded using FURA-2 acetomethyl ester to measure 
intracellular calcium-induced fluorescence. Figure is adapted from, and normalisations were 
performed by, (Wellendorph et al., 2009a). 
GPRC6A, The G-protein coupled receptor family C group 6 member A; T1R1/T1R3, taste receptor 
type 1 member 1/taste receptor type 1 member 3 dimer; CaR, Calcium-sensing receptor; EC50, half 
maximal effective concentration (concentration of an agent which induces a response halfway 
between the baseline and maximum after some specified exposure time); IMP, Inosine 
monophosphate.  
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Protein is known to be more satiating than other macronutrients. On ingestion, protein is broken 
down into its constituent amino acids. The CaR, T1R1/T1R3 dimer and the GPRC6A appear to be 
capable of sensing all 20 proteinogenic amino acids. Amino acids are the building blocks of protein, 
and the ability to sense proteinogenic amino acids may be of great evolutionary importance. These 
receptors may mediate the satiating effects of proteins following their breakdown into amino acids. 
The purpose of this chapter is to determine whether individual specific amino acids can modulate 
food intake in rodents. Although there is greater evidence for the effects of protein on satiety, rather 
than on food intake as a direct measure, measuring a subjective feeling such as hunger or satiety is 
difficult in rodents. Acute food intake following amino acid administration was therefore used as a 
surrogate for satiation.  
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2.2. Hypothesis 
Oral and i.p. administration of specific amino acids will reduce food intake in rats. 
2.3. Aims 
I aim to investigate the effects of specific amino acids on food intake and to evaluate whether or not 
the effects are likely to be mediated by one of the promiscuous L-amino acid receptors. In order to 
do this I will investigate: 
- The effect of oral administration of various amino acids on food intake in the early light 
phase following an overnight fast in male rats. 
- The effect of i.p. administration of various amino acids on food intake in the early light phase 
following an overnight fast in male rats. 
- The relationship between the effects of specific amino acids on food intake and their 
reported efficacy at the GPRC6A, T1R1/T1R3 and CaR. 
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2.4. Materials and Methods 
2.4.1. Materials 
All amino acids were purchased from Sigma Aldrich (Poole, Dorset, U.K.). 
2.4.2. Animals 
Male Wistar rats (specific pathogen free (SPF); Charles River, Margate, Kent, U.K.) weighing between 
200-250g were maintained in individual cages under controlled conditions of temperature (21-23ºC) 
and light (12 hours light, 12 hours dark; lights on at 07:00) with ad libitum access to food (RM1 diet, 
Special Diet Services Ltd., Witham, Essex, U.K.) and water (unless otherwise stated). All animal 
procedures conducted were approved by the British Home Office under the Animals (Scientific 
Procedures) Act 1986 (Project Licence number 7062/19b1). 
2.4.3. The effect of oral administration of amino acids on food intake in rats 
2.4.3.1. The effect of oral administration of specific L-amino acids on food intake in the early light 
phase following an overnight fast in rats. 
Male Wistar rats were singly housed and handled daily for two weeks prior to the study to 
familiarise them to the partial restraint experienced during oral gavage. The rats were also 
acclimatised to the administration procedure by receiving two oral gavages of water in the week 
prior to the study. Rats were fasted overnight and then received an oral gavage of water or one of 
various L-amino acids, at a dose of 4000µmol/kg (n = 4-8), in the early light phase. A total of 6 
studies were performed as outlined in Table 2.5. The gavage volumes vary between studies due to 
the differing solubilities of the amino acids. Gavage volumes were, however, consistent within each 
individual study. Amino acids which dissolved to the required dose in a volume of 2ml were tested in 
the same studies. The majority of the remaining amino acids were soluble to the required dose in a 
volume of 3.5ml and so they were tested together. The remaining amino acids were soluble in a 
volume of 6.5ml and so they were also tested together. The proteinogenic amino acids not listed in 
Table 2.5. were not tested as they were insoluble in a volume suitable for oral gavage. Following oral 
gavage, rats were returned to their home cages and given a pre-weighed amount of chow and free 
access to water. The food was reweighed at 1, 2, 4, 8 and 24 hours post-administration. Preliminary 
studies showed that L-cysteine consistently reduced food intake 0-1 hours post administration, and 
it was therefore used as a positive control in each study. 
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Study Gavage volume Treatments (n number) 
Study 1 2ml 
Water (n = 6) 
L-Arginine (n = 7) 
L-Lysine (n = 6) 
L-Proline (n = 7) 
L-Cysteine (n = 4) 
Study 2 2ml 
Water (n = 9) 
L-Arginine (n = 9) 
L-Lysine (n = 9) 
L-Cysteine (n = 4) 
Study 3 3.5ml 
Water (n = 7) 
L-Citrulline (n = 6) 
L-Threonine (n = 6) 
L-Valine (n = 7) 
L-Cysteine (n = 4) 
Study 4 3.5ml 
Water (n = 7) 
L-Alanine (n = 6) 
L-Serine (n = 7) 
L-Valine (n = 7) 
L-Cysteine (n = 4) 
Study 5 3.5ml 
Water (n = 7) 
Glycine (n = 7) 
L-Ornithine (n = 7) 
L-Taurine (n = 6) 
L-Cysteine (n = 4) 
Study 6 6.5ml 
Water (n = 7) 
L-Glutamine (n = 6) 
L-Histidine (n = 7) 
L-Methionine (n = 7) 
L-Cysteine (n = 4) 
Table 2.5. Outline of oral gavage feeding studies performed 
A total of six studies were performed. Male Wistar rats received an oral gavage of water or amino 
acids in the early light phase. All amino acids were administered at a dose of 4000µmol/kg. The n 
numbers for each group vary between 4 and 9. L-cysteine was used as a positive control. 
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The amino acids L-cysteine, L-lysine and L-arginine were found to reduce food intake following oral 
administration. These amino acids were therefore investigated further in dose-response studies. 
2.4.3.2. The effect of oral administration of L- and D- enantiomers of anorectic amino acids on food 
intake in the early light phase following an overnight fast in rats. 
2.4.3.2.1. The effect of oral administration of L-cysteine or D-cysteine on food intake in the early light 
phase following an overnight fast in rats. 
Rats were fasted overnight and then received an oral gavage of water or L-cysteine at a dose of 
1000, 2000 or 4000µmol/kg, or D-cysteine at a dose of 4000µmol/kg (n = 7-8), in the early light 
phase. Following oral gavage, rats were returned to their home cages and given a pre-weighed 
amount of chow and free access to water. The food was reweighed at 1, 2, 4, 8 and 24 hours post-
injection.  
2.4.3.2.2. The effect of oral administration of L-arginine or D-arginine on food intake in the early light 
phase following an overnight fast in rats. 
Rats were fasted overnight and then received an oral gavage of water or L-arginine at a dose of 
1000, 2000, or 4000µmol/kg or D-arginine at a dose of 4000µmol/kg (n = 7-8), in the early light 
phase. Following oral gavage, rats were returned to their home cages and given a pre-weighed 
amount of chow and free access to water. The food was reweighed at 1, 2, 4, 8 and 24 hours post-
injection.  
2.4.3.2.3. The effect of oral administration of L-lysine or D-lysine on food intake in the early light 
phase following an overnight fast in rats. 
Rats were fasted overnight and then received an oral gavage of water or L-lysine, at a dose of 1000, 
2000, or 4000µmol/kg or D-lysine at a dose of 4000µmol/kg (n = 8), in the early light phase. 
Following oral gavage, rats were returned to their home cages and given a pre-weighed amount of 
chow and free access to water. The food was reweighed at 1, 2, 4, 8 and 24 hours post-injection. 
2.4.3.3. The effect of oral administration of L-cysteine, L-lysine and L-arginine on behaviour in the 
early light phase following an overnight fast in rats. 
Rats were fasted overnight and then received an oral gavage of water or L-arginine, L-cysteine or L-
lysine (4000µmol/kg) (n = 8-10) in the early light phase. These doses were chosen as they were the 
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highest doses given in studies 2.4.3.2.1. – 2.4.3.2.3. and thus are the most likely to induce non-
specific effects. Following injection, rats were returned to their home cages, chow was returned, and 
their behaviours monitored for 1 hour post-injection by an investigator blinded to the experimental 
treatment. Behaviour was recorded for 1 hour as the reduction in food intake in studies 2.4.3.2.1. – 
2.4.3.2.3. appeared to occur only in the first hour. Behaviour was classified into one of 12 categories: 
feeding, drinking, rearing, locomotion, grooming, pica, bed-making, head-down, sleeping, tremors, 
climbing and stationary (Table 2.6.), modified from (Abbott et al., 2001). Each rat was observed for 
three 5-second periods every 5 minutes and the behaviour in each period noted. Each rat therefore 
had a total of 36 behaviours recorded per hour. 
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Behaviour Description of behaviour 
Feeding Rat eating chow 
Drinking Rat drinking water from its bottle 
Rearing Rat with front paws off of the cage floor 
Locomotion Rat with all four legs moving 
Grooming Rat grooming 
Pica Rat eating anything other than chow 
Bed-making Rat manipulating bedding 
Head-down Rat standing with its nose lowered/pointed 
towards cage floor 
Sleeping Rat sleeping 
Tremors Rat exhibiting tremors 
Climbing Rat climbing cage 
Stationary Rat standing or sitting still 
Table 2.6. Classification of behaviours monitored for scoring of rat behaviours. 
Observed rat behaviours were classified into one of 12 categories listed and the total number of 
behaviours scored for one hour post-injection. Table is adapted from (Abbott et al., 2001). 
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2.4.4. The effect of i.p. administration of amino acids on food intake in rats. 
2.4.4.1. The effect of i.p. administration of various L-amino acids on food intake in the early light 
phase following an overnight fast in rats. 
Male Wistar rats were singly housed and handled daily for two weeks prior to the study to 
familiarise them to the partial restraint experienced during i.p. injection. The rats were acclimatised 
to the injection procedure by receiving two i.p. injections of saline (volume of 2ml) in the week prior 
to the study. Overnight-fasted rats received an i.p. injection of saline or one of various L-amino acids, 
at a dose of 2000μmol/kg (n = 4-9), in the early light phase. A total of 6 studies were performed as 
outlined in Table 2.7. The injection volumes vary between studies due to differing solubilities of the 
amino acids. Injection volumes were, however, consistent within each individual study. Amino acids 
were which dissolved to the required dose in a volume of 2ml were tested in the same studies. 
Those which did not (L-histidine and L-methionine) were tested in a separate study using a volume 
of 3ml. Following i.p. injection, rats were returned to their home cages and given a pre-weighed 
amount of chow and free access to water. The food was reweighed at 1, 2, 4, 8 and 24 hours post-
injection. Preliminary studies showed that L-cysteine consistently potently reduced food intake 0-1 
hours post administration, and it was therefore used as a positive control in each study.  
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Study Injection volume Treatment (n number) 
Study 1 2ml 
Water (n = 6) 
L-Arginine (n = 7) 
L-Ornithine (n = 5) 
Glycine (n = 7) 
L-Cysteine (n = 4) 
Study 2 2ml 
Water (n = 7) 
L-Alanine (n = 6) 
L-Glutamine (n = 6) 
L-Serine (n = 7) 
L-Cysteine (n = 4) 
Study 3 2ml 
Water (n = 7) 
L-Citrulline (n = 7) 
L-Lysine (n = 7) 
L-Threonine (n = 7) 
L-Cysteine (n = 4) 
Study 4 2ml 
Water (n = 10) 
L-Lysine (n = 9) 
L-Ornithine (n = 9) 
L-Cysteine (n = 4) 
Study 5 2ml 
Water (n = 7) 
L-Proline (n = 7) 
L-Taurine (n = 7) 
L-Valine (n = 7) 
L-Cysteine (n = 4) 
Study 6 3ml 
Water (n = 8) 
L-Histidine (n = 9) 
L-Methionine (n = 8) 
L-Cysteine (n = 4) 
Table 2.7. Outline of i.p. feeding studies performed. 
A total of six studies were performed. Male Wistar rats were injected intraperitoneally with saline or 
amino acids in the early light phase. All amino acids were administered at a dose of 2000µmol/kg. 
The n numbers for each group vary between 4 and 9. L-cysteine was used as a positive control. 
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2.4.4.2. The effect of i.p. administration of L- and D- enantiomers of anorectic amino acids on food 
intake in the early light phase following an overnight fast in rats. 
2.4.4.2.1. The effect of i.p. administration of L-cysteine on food intake in the early light phase 
following an overnight fast in rats. 
Rats were fasted overnight and then received an i.p. injection of saline or 500μmol/kg, 
1000μmol/kg, 2000μmol/kg or 6000μmol/kg L-cysteine (n = 8) in the early light phase. Following 
injection, rats were returned to their home cages and given a pre-weighed amount of chow and free 
access to water. The food was reweighed at 1, 2, 4, 8 and 24 hours post-injection.  
2.4.4.2.2. The effect of i.p. administration of L-lysine on food intake in the early light phase following 
an overnight fast in rats. 
Rats were fasted overnight and then received an i.p. injection of saline or 500μmol/kg, 1000μmol/kg 
or 2000µmol/kg L-lysine (n = 7-8), in the early light phase. Following injection, rats were returned to 
their home cages and given a pre-weighed amount of chow and free access to water. The food was 
reweighed at 1, 2, 4, 8 and 24 hours post-injection.  
2.4.4.2.3. The effect of i.p. administration of L-arginine on food intake in the early light phase in 
overnight fasted rats. 
Rats were fasted overnight and then received an i.p. injection of saline or 500μmol/kg, 
1000μmol/kg, 2000μmol/kg or 6000μmol/kg L-arginine (n = 8) in the early light phase. Following 
injection, rats were returned to their home cages and given a pre-weighed amount of chow and free 
access to water. The food was reweighed at 1, 2, 4, 8 and 24 hours post-injection.  
2.4.4.2.4. The effect of i.p. administration of the L- and D- enantiomers of cysteine and arginine on 
food intake in the early light phase on overnight fasted rats. 
Rats were fasted overnight and then received an i.p. injection of saline or L-cysteine, D-cysteine, L-
arginine or D-arginine, at a dose of 2000µmol/kg (n = 7-8) in the early light phase. Following 
injection, rats were returned to their home cages and given a pre-weighed amount of chow and free 
access to water. The food was reweighed at 1, 2, 4, 8 and 24 hours post-injection.  
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2.4.4.2.5. The effect of i.p. administration of the L- and D- enantiomers of lysine and arginine on food 
intake in the early light phase in overnight fasted rats. 
Rats were fasted overnight and then received an i.p. injection of saline or L-lysine, D-lysine, L-
arginine or D-arginine, at a dose of 2000µmol/kg (n = 7-8), in the early light phase. Following 
injection, rats were returned to their home cages and given a pre-weighed amount of chow and free 
access to water. The food was reweighed at 1, 2, 4, 8 and 24 hours post-injection. The L-arginine and 
D-arginine groups were repeated in this study to confirm the reduction in food intake induced by D-
arginine in study 2.4.4.2.4. 
2.4.4.3. The effect of i.p. administration of L-cysteine, L-lysine and L-arginine on behaviour in the 
early light phase following an overnight fast in rats. 
Rats were fasted overnight and then received an i.p. injection of saline or L-arginine, L-cysteine or L-
lysine (2000µmol/kg) (n = 9-10) in the early light phase. These doses were chosen as they were the 
doses given in studies within 2.4.4.1. Following injection, rats were returned to their home cages, 
chow was returned, and their behaviours monitored for 1 hour post-injection by an investigator 
blinded to the experimental treatment, as described in study 2.4.3.3. Behaviour was again recorded 
for 1 hour as the reduction in food intake at these doses in studies 2.4.4.2.1 – 2.4.4.2.3. appeared to 
occur only in the first hour. 
2.4.5. Correlation of food intake reduction with GPRC6A, T1R1/T1R3 and CaR activation. 
2.4.5.1. Data compilation 
Data collected in studies 2.4.3.1. and 2.4.4.1 were converted to 0-1 hour food intake as a percentage 
of control. For controls, and amino acids tested multiple times, mean values were used. 
2.4.5.2. Correlation of receptor activation and food intake 
Data on activation of mouse orthologues of GPRC6A, T1R1/T1R3 and CaR activation by amino acids 
collated in Figure 2.3. (Wellendorph et al., 2009a) and, where available, was plotted against the 
percentage food intake compared to control, for both oral (study 2.4.3.1.) and i.p. (study 2.4.4.1.) 
administration. The correlation coefficient was calculated using Excel. 
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2.4.6. Statistical Analysis 
Food intake data are shown as mean values ± standard error of the mean (S.E.M.). Behavioural data 
are represented as median and interquartile range. Data from the food intake studies were analysed 
using a one-way analysis of variance (ANOVA) test, followed by post hoc Dunnett’s test (GraphPad 
Prism 5 software, GraphPad software Inc., San Diego, California, U.S.A.). For the behavioural studies, 
differences between the treatment groups were determined using the Kruskal-Wallis one-way 
ANOVA on ranks, followed by a post hoc Dunn’s test (Stata 9, Statacorp, College Station, Texas, 
U.S.A.). Significance of correlations was determined using GraphPad Prism 5 software. In all cases, p 
< 0.05 was considered to be statistically significant. 
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2.5. Results 
2.5.1. The effect of oral administration of amino acids in rats 
2.5.1.1. The effect of oral administration of specific L-amino acids on food intake in the early light 
phase following an overnight fast in rats. 
2.5.1.1.1. Study 1 
Oral administration of 4000µmol/kg L-arginine, L-lysine or L-proline did not significantly affect food 
intake over any of the time points measured. Oral administration of 4000µmol/kg L-cysteine 
significantly reduced food intake 0-1 hours post-gavage (0-1 hour food intake, water:  (water: 7.9 ± 
0.9g vs. L-cysteine: 3.4 ± 0.5g, p < 0.01 vs. water, n = 4-6 per group) (Figure 2.4.A). L-Cysteine did not 
alter food intake at any of the subsequent time points measured (Figure 2.4.B-F). 
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Figure 2.4. The effect of oral administration of L-arginine, L-lysine, L-proline and L-cysteine on food 
intake in the early light phase following an overnight fast in rats. 
Rats were orally gavaged with (i) water, (ii) 4000µmol/kg L-arginine, (iii) 4000µmol/kg L-lysine, (iv) 
4000µmol L-proline or (v) 4000µmol/kg L-cysteine. (A) 0-1 hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 
hour; (E) 8-24 hour; (F) 0-24 hour food intake post injection. Data are expressed as mean ± S.E.M. ** 
= p < 0.01 vs. water; n = 4-7 per group. 
A B 
C D 
E F 
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2.5.1.1.2. Study 2 
Study 1 revealed a trend for a reduction in food intake following oral administration of L-arginine 
and L-lysine. These amino acids were therefore tested again for their effects on food intake 
following oral administration using larger n numbers. Oral administration of 4000µmol/kg of L-
arginine, L-lysine and L-cysteine all significantly reduced food intake 0-1 hours post-gavage (0-1 hour 
food intake, water: 8.3 ± 0.5g vs. L-arginine: 6.3 ± 0.6g, p < 0.05 vs. water; L-lysine: 6.5 ± 0.6g, p < 
0.05 vs. water; L-cysteine: 3.4 ± 0.2g, p < 0.001 vs. water, n = 4-9 per group) (Figure 2.5. A). The 
reductions in food intake induced by L-arginine and L-cysteine were sufficient to make reductions 
over the longer cumulative 0-2 hour time period statistically significant (0-2 hour food intake, water: 
11.7 ± 0.8g vs. L-arginine: 9.1 ± 0.7g, p < 0.05 vs. water; L-cysteine: 8.4 ± 1.2g, p < 0.05 vs. water, n = 
4-9 per group) (Figure 2.6. A). The reduction in food intake induced by L-lysine was also sufficient to 
make the longer 0-8 hour time period statistically significant (0-8 hour food intake, water: 16.3 ± 
0.7g vs. L-lysine: 13.2 ± 0.5g, p < 0.05 vs. water, n = 9 per group) (Figure 2.6. B). L-arginine, L-lysine 
and L-cysteine did not alter food intake at any of the subsequent time points measured (Figure 2.5. 
B-F). 
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Figure 2.5. The effect of oral administration of L-arginine, L-lysine, and L-cysteine on food intake in 
the early light phase following an overnight fast in rats. 
Rats were orally gavaged with (i) water, (ii) 4000µmol/kg L-arginine, (iii) 4000µmol/kg L-lysine or (iv) 
4000µmol/kg L-cysteine. (A) 0-1 hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 hour; (E) 8-24 hour; (F) 0-24 
hour food intake post injection. Data are expressed as mean ± S.E.M. * = p < 0.05 vs. water; *** = p < 
0.001 vs. water; n = 4-9 per group. 
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Figure 2.6. The effect of oral administration of L-arginine, L-lysine and L-cysteine on cumulative 
food intake in the early light phase after an overnight fast in rats. 
Rats were orally gavaged with (i) water, (ii) 4000µmol/kg L-arginine, (iii) 4000µmol/kg L-lysine or (iv) 
4000µmol/kg L-cysteine. (A) 0-2 hour; (B) 0-8 hour food intake post injection. Data are expressed as 
mean ± S.E.M. * = p < 0.05 vs. water; ** = p < 0.01 vs. water; n = 4-9 per group. 
  
A B 
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2.5.1.1.3. Study 3 
Oral administration of 4000µmol/kg of L-citrulline or L-threonine did not significantly affect food 
intake over any of the time points measured. Oral administration of 4000µmol/kg L-valine and L-
cysteine significantly reduced food intake 0-1 hours post-gavage (0-1 hour food intake, water: 6.5 ± 
0.6g vs. L-valine: 4.8 ± 0.4g, p < 0.05 vs. water; L-cysteine: 2.4 ± 0.4g, p < 0.001 vs. water, n = 4-7 per 
group) (Figure 2.7. A). Oral administration of 4000µmol/kg L-cysteine significantly increased food 
intake 1-2 hours post-gavage (1-2 hour food intake, water: 3.0 ± 0.7g vs. L-cysteine: 6.1 ± 0.4g, p < 
0.05 vs. water, n = 4-7 per group) (Figure 2.7. B). No amino acid treatment significantly affected food 
intake at any other time point measured (Figure 2.7. B-F). 
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Figure 2.7. The effect of oral administration of L-citrulline, L-threonine, L-valine and L-cysteine on 
food intake in the early light phase following an overnight fast in rats. 
Rats were orally gavaged with (i) water, (ii) 4000µmol/kg L-citrulline, (iii) 4000µmol/kg L-threonine, 
(iv) L-valine or (iv) 4000µmol/kg L-cysteine. (A) 0-1 hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 hour; (E) 
8-24 hour; (F) 0-24 hour food intake post injection. Data are expressed as mean ± S.E.M. * = p < 0.05 
vs. water; *** = p < 0.001 vs. water; n = 4-7 per group. 
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2.4.1.1.4. Study 4 
Study 3 revealed a reduction in food intake following oral administration of L-valine. This amino acid 
was therefore tested again for its effects on food intake following oral administration in study 4. Oral 
administration of 4000µmol/kg of L-alanine, L-serine or L-valine did not significantly affect food 
intake over any of the time points measured, though they reduced food intake by a similar 
magnitude to L-valine in study 3. Oral administration of 4000µmol/kg L-cysteine significantly 
reduced food intake 0-1 hours post-gavage (0-1 hour food intake, water: 8.0 ± 0.9 g vs. L-cysteine: 
2.7 ± 0.7g, p < 0.001 vs. water, n = 4-7 per group) (Figure 2.8. A). L-Cysteine did not induce 
alterations in food intake over any of the subsequent time points measured (Figure 2.8. B-F). 
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Figure 2.8. The effect of oral administration of L-alanine, L-serine, L-valine and L-cysteine on food 
intake in the early light phase following an overnight fast in rats. 
Rats were orally gavaged with (i) water, (ii) 4000µmol/kg L-alanine, (iii) 4000µmol/kg L-serine, (iv) L-
valine or (iv) 4000µmol/kg L-cysteine. (A) 0-1 hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 hour; (E) 8-24 
hour; (F) 0-24 hour food intake post injection. Data are expressed as mean ± S.E.M. *** = p < 0.001 
vs. water; n = 4-7 per group. 
A B 
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2.4.1.1.5. Study 5 
Oral administration of 4000µmol/kg glycine, L-ornithine or L-taurine did not significantly affect food 
intake over any of the time points measured. Oral administration of 4000µmol/kg L-cysteine 
significantly reduced food intake 0-1 hours post-gavage (0-1 hour food intake, water: 6.1 ± 0.6g vs. L-
cysteine: 2.8 ± 1.0g, p < 0.05 vs. water, n = 4-7 per group) (Figure 2.9. A). L-Cysteine did not alter 
food intake at any of the subsequent time points measured (Figure 2.9. B-F). 
  
101 
 
0-1 hr
W
at
er
G
ly
ci
ne
L-
O
rn
ith
in
e
L-
Ta
ur
in
e
L-
C
ys
te
in
e
0
2
4
6
8
10
*
F
o
o
d
 i
n
ta
k
e
 (
g
)
1-2 hr
W
at
er
G
ly
ci
ne
L-
O
rn
ith
in
e
L-
Ta
ur
in
e
L-
C
ys
te
in
e
0
2
4
6
8
F
o
o
d
 i
n
ta
k
e
 (
g
)
2-4 hr
W
at
er
G
ly
ci
ne
L-
O
rn
ith
in
e
L-
Ta
ur
in
e
L-
C
ys
te
in
e
0
2
4
6
F
o
o
d
 i
n
ta
k
e
 (
g
)
4-8 hr
W
at
er
G
ly
ci
ne
L-
O
rn
ith
in
e
L-
Ta
ur
in
e
L-
C
ys
te
in
e
0
2
4
6
F
o
o
d
 i
n
ta
k
e
 (
g
)
8-24 hr
W
at
er
G
ly
ci
ne
L-
O
rn
ith
in
e
L-
Ta
ur
in
e
L-
C
ys
te
in
e
0
10
20
30
F
o
o
d
 i
n
ta
k
e
 (
g
)
0-24 hr
W
at
er
G
ly
ci
ne
L-
O
rn
ith
in
e
L-
Ta
ur
in
e
L-
C
ys
te
in
e
0
10
20
30
40
50
F
o
o
d
 i
n
ta
k
e
 (
g
)
 
Figure 2.9. The effect of oral administration of glycine, L-ornithine, L-taurine and L-cysteine on 
food intake in the early light phase following an overnight fast in rats. 
Rats were orally gavaged with (i) water, (ii) 4000µmol/kg glycine, (iii) 4000µmol/kg L-ornithine, (iv) L-
taurine or (iv) 4000µmol/kg L-cysteine. (A) 0-1 hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 hour; (E) 8-24 
hour; (F) 0-24 hour food intake post injection. Data are expressed as mean ± S.E.M. * = p < 0.05 vs. 
water; n = 4-7 per group. 
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2.4.1.1.6. Study 6 
Oral administration of 4000µmol/kg L-glutamine or L-methionine did not significantly affect food 
intake over any of the time points measured. Oral administration of 4000µmol/kg L-cysteine 
significantly reduced food intake 0-1 hours post-gavage (0-1 hour food intake, water: 7.6 ± 0.6g vs. L-
cysteine: 2.1 ± 0.7g, p < 0.001 vs. water, n = 4-7 per group) (Figure 2.10. A). Oral administration of 
4000µmol/kg L-cysteine significantly increased food intake 1-2 hours post-gavage (1-2 hour food 
intake, water: 2.2 ± 0.8g vs. L-cysteine: 6.0 ± 1.0g, p < 0.05 vs. water, n = 4-7 per group) (Figure 2.10. 
B). Oral administration of L-histidine significantly reduced food intake 4-8 hours post-gavage (4-8 
hour food intake, water: 4.0 ± 0.8g vs. L-histidine: 1.2 ± 0.6g, p < 0.05 vs. water, n = 7 per group) 
(Figure 2.10. D). L-Methionine significantly reduced food intake in the 0-2 hour (0-2 hour food 
intake, water: 9.8 ±0.8g vs. L-methionine: 7.7 ± 1.1g, p < 0.05 vs. water, n = 7 per group) and 0-8 
hour time periods (0-8 hour food intake, water: 14.9 ± 0.8g vs. L-methionine: 11.9 ± 0.5g, p < 0.05 vs. 
water, n = 7 per group) (Figure 2.11. A and B). No amino acid treatment significantly affected food 
intake at any other time point measured (Figure 2.10. B-F). 
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Figure 2.10. The effect of oral administration of L-glutamine, L-histidine, L-methionine and L-
cysteine on food intake in the early light phase following an overnight fast in rats. 
Rats were orally gavaged with (i) water, (ii) 4000µmol/kg L-glutamine, (iii) 4000µmol/kg L-histidine, 
(iv) L-methionine or (iv) 4000µmol/kg L-cysteine. (A) 0-1 hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 
hour; (E) 8-24 hour; (F) 0-24 hour food intake post injection. Data are expressed as mean ± S.E.M. * = 
p < 0.05 vs. water; *** = p < 0.001 vs. water; n = 4-7 per group. 
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Figure 2.11. The effect of oral administration of L-glutamine, L-histidine, L-methionine and L-
cysteine on cumulative food intake in the early light phase following an overnight fast in rats. 
Rats were orally gavaged with (i) water, (ii) 4000µmol/kg L-glutamine, (iii) 4000µmol/kg L-histidine, 
(iv) L-methionine or (iv) 4000µmol/kg L-cysteine. (A) 0-1 hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 
hour; (E) 8-24 hour; (F) 0-24 hour food intake post injection. Data are expressed as mean ± S.E.M. * = 
p < 0.05 vs. water; n = 4-7 per group. 
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2.5.1.2. The effect of oral administration of the L- and D- enantiomers of the anorectic amino acids 
on food intake in the early light phase following an overnight fast in rats. 
2.5.1.2.1. The effect of oral administration of L-cysteine and D-cysteine on food intake in the early 
light phase following an overnight fast in rats. 
The 2000µmol/kg and 4000µmol/kg does of L-cysteine significantly reduced 0-1 hour food intake 
compared to water treated animals (0-1 hour food intake, water: 6.8 ±0.6g vs. 2000µmol/kg L-
cysteine: 4.3 ± 0.6g, p < 0.05 vs. water; 4000µmol/kg L-cysteine: 2.7 ± 0.3g, p < 0.001 vs. water, n = 
7-8 per group) (Figure 2.12. A). L-Cysteine at a dose of 1000µmol/kg and D-cysteine at a dose of 
4000µmol/kg did not significantly affect food intake. Food intake was unchanged by any treatment 
at any other time point measured (Figure 2.12. B-F).  
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Figure 2.12. The effect of oral administration of L-cysteine and D-cysteine on food intake in the 
early light phase following an overnight fast in rats. 
Rats were orally gavaged with (i) water, (ii) 1000µmol/kg, (iii) 2000µmol/kg, (iv) 4000µmol/kg L-
cysteine or (v) 4000µmol/kg D-cysteine. (A) 0-1 hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 hour; (E) 8-24 
hour; (F) 0-24 hour food intake post injection. Data are expressed as mean ± S.E.M. * = p < 0.05 vs. 
water; *** = p < 0.001 vs. water; n = 6-8 per group.  
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2.5.1.2.2. The effect of oral administration of L-arginine and D-arginine on food intake in the early 
light phase following an overnight fast in rats. 
The 4000µmol/kg dose of both L-arginine and D-arginine significantly reduced 0-1 hour food intake 
compared to water treated animals (0-1 hour food intake, water: 7.7 ±0.5g vs. 4000µmol/kg L-
arginine: 4.6 ±0.5g, p < 0.01 vs. water; 4000µmol/kg D-arginine: 5.0 ± 0.6g, p < 0.01 vs. water, n = 7-8 
per group) (Figure 2.13. A). No other dose of L-arginine tested significantly affected food intake 
during this time period. The significant reductions in food intake induced by 4000µmol/kg of L-
arginine and D-arginine were sufficient to make reduction in the longer cumulative 0-4 hour time 
period statistically significant (0-4 hour food intake, water: 14.8 ±0.8 vs. 4000µmol/kg L-arginine: 
10.9 ± 1.2g, p < 0.05 vs. water; 4000µmol/kg D-arginine: 10.6 ± 1.3g, p < 0.05 vs. water, n = 7-8 per 
group) (Figure 2.14. A). The significant reduction in food intake induced by 4000µmol/kg D-arginine 
was also sufficient to make reductions in longer cumulative time periods statistically significant i.e. 
the 8 hour time period (0-8 hour food intake, water: 17.6 ±0.6g vs. 4000µmol/kg D-arginine: 13.0 ± 
1.1g, p < 0.01 vs. water, n = 7-8 per group) (Figure 2.14. B) and the 24 hour time period (0-24 hour 
food intake, water: 41.6 ± 1.9g vs. 4000µmol/kg D-arginine: 35.1 ± 2.2g, p < 0.05 vs. water, n = 7-8 
per group) (Figure 2.14. C). No treatment significantly affected food intake at any other time period 
measured (Figure 2.13. B-F). 
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Figure 2.13. The effect of oral administration of L-arginine and D-arginine on food intake in the 
early light phase following an overnight fast in rats. 
Rats were orally gavaged with (i) water, (ii) 1000µmol/kg, (iii) 2000µmol/kg, (iv) 4000µmol/kg L-
arginine or (v) 4000µmol/kg D-arginine. (A) 0-1 hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 hour; (E) 8-24 
hour; (F) 0-24 hour food intake post injection. Data are expressed as mean ± S.E.M. * = p < 0.05 vs. 
water; ** = p < 0.01 vs. water; n = 7-8 per group. 
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Figure 2.14. The effect of oral administration of L-arginine and D-arginine on cumulative food 
intake in the early light phase following an overnight fast in rats. 
Rats were orally gavaged with (i) water, (ii) 1000µmol/kg, (iii) 2000µmol/kg, (iv) 4000µmol/kg L-
arginine or (v) 4000µmol/kg D-arginine. (A) 0-4 hour; (B) 0-8 hour food intake post injection. Data 
are expressed as mean ± S.E.M. * = p < 0.05 vs. water; ** = p < 0.01 vs. water; n = 7-8 per group. 
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2.5.1.2.3. The effect of oral administration of L-lysine and D-lysine on food intake in the early light 
phase following an overnight fast in rats. 
The 4000µmol/kg dose of L-lysine significantly reduced 0-1 hour food intake compared to water 
treated animals (0-1 hour food intake, water: 5.8 ± 1.1g vs. 4000µmol/kg L-lysine: 3.9 ± 0.8g, p < 0.05 
vs. water; n = 6-8 per group) (Figure 2.15. A). Administration of 4000µmol/kg D-lysine tended to 
reduce 0-1 hour food intake but this effect was not significant. The 2000µmol/kg dose of L-lysine 
significantly increased 1-2 hour food intake compared to water treated animals (1-2 hour food 
intake, water: 1.8 ± 1.8g vs. 2000µmol/kg L-lysine: 4.4 ± 1.5g, p < 0.05 vs. water; n = 8 per group) 
(Figure 2.15. B). No other treatment significantly affected food intake during any other time point 
measured (Figure 2.15. C-F). 
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Figure 2.15. The effect of oral administration of L-lysine and D-lysine on food intake in the early 
light phase following an overnight fast in rats. 
Rats were orally gavaged with (i) water, (ii) 1000µmol/kg, (iii) 2000µmol/kg, (iv) 4000µmol/kg L-
lysine or (v) 4000µmol/kg D-lysine. (A) 0-1 hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 hour; (E) 8-24 
hour; (F) 0-24 hour food intake post injection. Data are expressed as mean ± S.E.M. * = p < 0.05 vs. 
water; n = 6-8 per group.  
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2.5.1.3. The effect of oral administration of L-cysteine, L-lysine and L-arginine on behaviour in the 
early light phase following an overnight fast in rats. 
For behavioural studies, animals were observed 3 times every 5 minutes, totalling 18 observations 
per animal per half hour or 36 per hour. Median values of number of observations per behaviour per 
group were then calculated and differences between groups were determined. Oral administration 
of L-cysteine, L-lysine or L-arginine at the beginning of the light phase in overnight-fasted rats did 
not significantly reduce feeding behaviour over the 0-30 minute (Table 2.8.), 30-60 minute (Table 
2.8.) or 0-60 minute (Table 2.9.) time periods, although all three amino acids tended to reduce 
feeding behaviour over 0-60 minutes. There were no abnormal behaviours or alterations in 
locomotor activity compared to water treated controls over the 0-30 minute (Table 2.8.), 30-60 
minute (Table 2.8.) or 0-60 minute (Table 2.9.) time periods. 
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Table 2.8. Rat behaviours 0-30 and 30-60 minutes following oral administration of water or 4000µmol/kg L-arginine, L-cysteine or L-lysine.                   
Table summarising the behaviours recorded for 0-30 and 30-60 minutes post-oral administration of water or 4000µmol/kg of L-cysteine, L-lysine or L-
arginine. Each animal was observed 3 times every 5 minutes, totalling 18 observations per animal per half hour. Data are presented as median number of 
observations (interquartile range). n = 4-9 per group. 
Behaviour 0-30 minutes 30-60 minutes 
Water L-Arginine L-Cysteine L-Lysine Water L-Arginine L-Cysteine L-Lysine 
Feeding 9 (9-14) 12 (9-12) 6 (5.25-6.75) 11 (9-12) 6 (6-12) 6 (6-9) 5.5 (3.75-7.5) 9 (6-9) 
Drinking 3 (0-3) 3 (0-3) 0 (0-0.75) 3 (0-3) 3 (0-3) 0 (0-3) 0 (0-0.75) 0 (0-3) 
Rearing 2 (0-3) 0 (0-3) 1 (1-1.5) 2 (1-3) 2 (0-3) 2 (1-3) 6 (4.5-6.5) 2 (0-5) 
Locomotion 3 (2-4) 4 (3-5) 3.5 (2.75-4) 2 (1-3) 1 (0-2) 3 (2-4) 1.5 (0-3.25) 1 (0-3) 
Grooming 0 (0-0) 0 (0-0) 3 (1.5-4.25) 0 (0-3) 3 (0-3) 2 (0-3) 0 (0-0) 1 (0-3) 
Pica 0 (0-0) 0 (0-0) 0 (0-0.75) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Bed-making 0 (0-0) 0 (0-0) 0 (0-0.5) 0 (0-0) 0 (0-2) 0 (0-0) 0 (0-0) 0 (0-0) 
Head down 0 (0-0) 0 (0-0) 1.5 (0-3.75) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Sleep 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 1.5 (0-6) 0 (0-0) 
Tremors 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Climbing 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Stationary 0 (0-0) 0 (0-1) 0 (0-0.25) 0 (0-0) 1 (0-3) 1 (0-2) 0 (0-0.25) 3 (1-3) 
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Table 2.9. Rat behaviours 0-60 minutes following oral administration of water or 4000µmol/kg L-arginine, L-cysteine or L-lysine. 
Table summarising the behaviours recorded 0- 60 minutes post-oral administration of water or 4000µmol/kg of L-cysteine, L-lysine or L-arginine. Each 
animal was observed 3 times every 5 minutes, totalling 36 observations per animal per hour. Data are presented as median number of observations 
(interquartile range). n = 4-9 per group. 
Behaviour 0-60 minutes 
Water L-Arginine L-Cysteine L-Lysine 
Feeding 20 (18-21) 17 (15-21) 10 (9-12.75) 18 (15-21) 
Drinking 3 (3-4) 3 (0-3) 1.5 (0-3) 3 (0-3) 
Rearing 4 (0-6) 3 (1-4) 8 (5.5-9) 5 (2-7) 
Locomotion 4 (3-6) 8 (6-8) 4.5 (3.75-5.75) 3 (3-5) 
Grooming 3 (0-3) 2 (0-3) 3 (1.5-4.25) 1 (0-6) 
Pica 0 (0-0) 0 (0-0) 0 (0-0.75) 0 (0-0) 
Bed-making 0 (0-2) 0 (0-3) 0 (0-0.5) 0 (0-0) 
Head down 0 (0-0) 0 (0-0) 1.5 (0-3.8) 0 (0-0) 
Sleep 0 (0-0) 0 (0-0) 1.5 (0-6) 0 (0-0) 
Tremors 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Climbing 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Stationary 1 (0-3) 2 (0-3) 0.5 (0-1) 3 (1-3) 
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2.5.2. The effect of intraperitoneally administered amino acids on food intake. 
2.5.2.1. The effect of i.p. administration of specific L-amino acids on food intake in the early light 
phase following an overnight fast in rats. 
2.5.2.1.1. Study 1 
Intraperitoneal administration of 2000µmol/kg of L-ornithine or glycine did not significantly affect 
food intake over any of the time points measured. Intraperitoneal administration of 2000µmol/kg L-
arginine and L-cysteine significantly reduced food intake 0-1 hours post-injection (0-1 hour food 
intake, saline: 5.5 ± 0.7g vs. L-arginine: 2.8 ± 0.5g, p < 0.05 vs. saline; L-cysteine: 2.0 ± 1.6g, p < 0.05 
vs. saline, n = 4-7 per group) (Figure 2.16. A). No amino acid treatment significantly affected food 
intake at any other time point measured (Figure 2.16. B-F). 
  
116 
 
0-1 hr
S
al
in
e
L-
A
rg
in
in
e
G
ly
ci
ne
L-
O
rn
ith
in
e
L-
C
ys
te
in
e
0
2
4
6
8
**
F
o
o
d
 i
n
ta
k
e
 (
g
)
1-2 hr
S
al
in
e
L-
A
rg
in
in
e
G
ly
ci
ne
L-
O
rn
ith
in
e
L-
C
ys
te
in
e
0
1
2
3
4
5
F
o
o
d
 i
n
ta
k
e
 (
g
)
2-4 hr
S
al
in
e
L-
A
rg
in
in
e
G
ly
ci
ne
L-
O
rn
ith
in
e
L-
C
ys
te
in
e
0
2
4
6
F
o
o
d
 i
n
ta
k
e
 (
g
)
4-8 hr
S
al
in
e
L-
A
rg
in
in
e
G
ly
ci
ne
L-
O
rn
ith
in
e
L-
C
ys
te
in
e
0
1
2
3
4
5
F
o
o
d
 i
n
ta
k
e
 (
g
)
8-24 hr
S
al
in
e
L-
A
rg
in
in
e
G
ly
ci
ne
L-
O
rn
ith
in
e
L-
C
ys
te
in
e
0
10
20
30
F
o
o
d
 i
n
ta
k
e
 (
g
)
0-24 hr
S
al
in
e
L-
A
rg
in
in
e
G
ly
ci
ne
L-
O
rn
ith
in
e
L-
C
ys
te
in
e
0
10
20
30
40
50
F
o
o
d
 i
n
ta
k
e
 (
g
)
 
Figure 2.16. The effect of i.p. administration of L-arginine, L-ornithine, glycine and L-cysteine on 
food intake in the early light phase following an overnight fast in rats. 
Rats received an i.p. injection of (i) saline, (ii) 4000µmol/kg L-arginine, (iii) 4000µmol/kg L-ornithine, 
(iv) glycine or (iv) 4000µmol/kg L-cysteine. (A) 0-1 hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 hour; (E) 8-
24 hour; (F) 0-24 hour food intake post injection. Data are expressed as mean ± S.E.M. * = p < 0.05 
vs. saline; n = 4-7 per group. 
A B 
C D 
E F 
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2.5.2.1.2. Study 2 
Intraperitoneal administration of 2000µmol/kg of L-alanine, L-glutamine or L-serine did not affect 
food intake at any of the time points measured. Intraperitoneal administration of 2000µmol/kg L-
cysteine significantly reduced food intake 0-1 hours post-injection (0-1 hour food intake, saline: 6.0 ± 
0.4g vs. L-cysteine: 2.0 ± 0.4g, p < 0.001, n = 4-7 per group) (Figure 2.17. A). No amino acid treatment 
significantly affected food intake at any other time point measured (Figure 2.17. B-F). 
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Figure 2.17. The effect of i.p. administration of L-alanine, L-glutamine, L-serine and L-cysteine on 
food intake in the early light phase following an overnight fast in rats. 
Rats received an i.p. injection of (i) saline, (ii) 4000µmol/kg L-alanine, (iii) 4000µmol/kg L-glutamine, 
(iv) L-serine or (iv) 4000µmol/kg L-cysteine. (A) 0-1 hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 hour; (E) 
8-24 hour; (F) 0-24 hour food intake post injection. Data are expressed as mean ± S.E.M. *** = p < 
0.001 vs. saline; n = 4-7 per group. 
E F 
A B 
C D 
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2.5.2.1.3. Study 3 
Intraperitoneal administration of 2000µmol/kg of L-citrulline, L-lysine or L-threonine did not 
significantly affect food intake over any of the time points measured. Intraperitoneal administration 
of 2000µmol/kg L-cysteine significantly reduced food intake 0-1 hours post-injection (0-1 hour food 
intake, saline: 6.4 ± 0.7g vs. L-cysteine: 3.2 ± 1.2, p < 0.05, n = 4-7 per group) (Figure 2.18. A). No 
amino acid treatment significantly affected food intake at any other time point measured (Figure 
2.18. B-F). 
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Figure 2.18. The effect of i.p. administration of L-citrulline, L-lysine, L-threonine and L-cysteine on 
food intake in the early light phase following an overnight fast in rats. 
Rats received an i.p. injection of (i) saline, (ii) 4000µmol/kg L-citrulline, (iii) 4000µmol/kg L-lysine, (iv) 
L-threonine or (iv) 4000µmol/kg L-cysteine. (A) 0-1 hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 hour; (E) 
8-24 hour; (F) 0-24 hour food intake post injection. Data are expressed as mean ± S.E.M. * = p < 0.05 
vs. saline; n = 4-7 per group. 
E F 
A B 
C D 
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2.5.2.1.4. Study 4 
Study 1 revealed a trend for reduced food intake following i.p. administration of L-ornithine and 
study 3 revealed a trend for reduced food intake following i.p. administration of L-lysine. These 
amino acids were therefore tested again for effects on food intake following i.p. administration in 
study 4. Intraperitoneal administration of 2000µmol/kg of L-ornithine did not significantly affect 
food intake over any of the time points measured. Intraperitoneal administration of 2000µmol/kg L-
lysine and L-cysteine significantly reduced food intake 0-1 hours post-injection (0-1 hour food intake, 
saline: 6.6 ± 0.8g vs. L-lysine: 4.3 ± 0.7g, p < 0.01 vs. saline; L-cysteine: 3.0 ± 1.2g, p < 0.01 vs. saline, 
n = 4-10 per group) (Figure 2.19. A). No amino acid treatment significantly affected food intake at 
any other time point measured (Figure 2.19. B-F). 
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Figure 2.19. The effect of i.p. administration of L-lysine, L-ornithine and L-cysteine on food intake 
at the beginning of the light phase following an overnight fast in rats. 
Rats received an i.p. injection of (i) saline, (ii) 4000µmol/kg L-lysine, (iii) 4000µmol/kg L-ornithine or 
(iv) 4000µmol/kg L-cysteine. (A) 0-1 hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 hour; (E) 8-24 hour; (F) 
0-24 hour food intake post injection. Data are expressed as mean ± S.E.M. ** = p < 0.01 vs. saline; n 
= 4-10 per group. 
E F 
A B 
C D 
123 
 
2.5.2.1.5. Study 5 
Intraperitoneal administration of 2000µmol/kg of L-proline, L-taurine, L-valine or L-cysteine did not 
significantly affect food intake at any of the time points measured (Figure 2.20. B-F). However, L-
cysteine tended to reduce 0-1 hour food intake (p = 0.15).  
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Figure 2.20. The effect of i.p. administration of L-proline, L-taurine, L-valine and L-cysteine on food 
intake in the early light phase following an overnight fast in rats. 
Rats received an i.p. injection of (i) saline, (ii) 4000µmol/kg L-proline, (iii) 4000µmol/kg L-taurine, (iv) 
4000µmol/kg L-valine or (v) L-cysteine. (A) 0-1 hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 hour; (E) 8-24 
hour; (F) 0-24 hour food intake post injection. Data are expressed as mean ± S.E.M. n = 4-7 per 
group. 
E F 
A B 
C D 
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2.5.2.1.6. Study 6 
Intraperitoneal administration of 2000µmol/kg of L-histidine or L-methionine did not significantly 
affect food intake over any of the time points measured. Intraperitoneal administration of 
2000µmol/kg L-cysteine significantly reduced food intake 0-1 hours post-injection (0-1 hour food 
intake, saline: 6.6 ± 0.3g vs. L-cysteine: 2.3 ± 1.1g, p < 0.001 vs. saline, n = 4-9 per group) (Figure 
2.21. A). No amino acid treatment significantly affected food intake at any other time point 
measured (Figure 2.21. B-F). 
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Figure 2.21. The effect of i.p. administration of L-histidine, L-methionine and L-cysteine on food 
intake in the early light phase following an overnight fast in rats. 
Rats received an i.p. injection of (i) saline, (ii) 4000µmol/kg L-histidine, (iii) 4000µmol/kg L-
methionine or (iv) 4000µmol/kg L-cysteine. (A) 0-1 hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 hour; (E) 
8-24 hour; (F) 0-24 hour food intake post injection. Data are expressed as mean ± S.E.M. ** = p < 
0.05 vs. saline; *** = p < 0.001; n = 4-10 per group. 
E F 
A B 
C D 
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2.5.2.1. The effect of i.p. administration of the L- and D- enantiomers of the anorectic amino acids 
on food intake in the early light phase following an overnight fast in rats. 
2.5.2.1.1. The effect of i.p. administration of L-cysteine on food intake in the early light phase 
following an overnight fast in rats. 
Intraperitoneal administration of 2000µmol/kg and 6000µmol/kg L-cysteine significantly reduced 
food intake 0-1 hour post-injection compared to saline (0-1 hour food intake, saline: 5.3 ± 0.5g vs. 
2000µmol/kg L-cysteine: 2.3 ± 0.5g, p < 0.05 vs. saline; 6000µmol/kg L-cysteine: 1.3 ± 1.2g, p < 0.001 
vs. saline, n = 8 per group) (Figure 2.22. A). The 6000µmol/kg dose of L-cysteine also significantly 
reduced food intake 1-2 hours post-injection compared to saline (1-2 hour food intake, saline: 3.6 
±0.5g vs. 6000µmol/kg L-cysteine: 1.2 ± 0.3g, p < 0.01 vs. saline, n = 8 per group) (Figure 2.22. B). 
Doses of 1000µmol/kg and 2000µmol/kg L-cysteine significantly increased food intake 1-2 hours 
post-injection compared to saline (1-2 hour food intake, saline: 3.6 ± 0.5g vs. 1000µmol/kg L-
cysteine: 5.4 ± 0.6g, p < 0.05 vs. saline; 2000µmol/kg L-cysteine: 5.7 ± 0.3g, p < 0.01 vs. saline, n = 8 
per group) (Figure 2.22. B). The reduction in food intake achieved following administration of 
6000µmol/kg L-cysteine was sufficient to make reductions over longer, cumulative periods 
statistically significant i.e. the 2 hour (0-2 hour food intake, saline: 8.8 ± 0.5g vs. 6000µmol/kg L-
cysteine: 2.5 ± 0.4g, p < 0.001 vs. saline, n = 8 per group), 4 hour (0-4 hour food intake, saline: 10.6 ± 
0.8g vs. 6000µmol/kg L-cysteine: 6.0 ± 0.7g, p < 0.01 vs. saline, n = 8 per group) and 8 hour (0-8 hour 
food intake, saline: 39.9 ± 1.6g vs. 6000µmol/kg L-cysteine: 34.6 ± 1.4g, p < 0.001 vs. saline, n = 8 per 
group) time periods (Figure 2.23.). No treatment significantly affected food intake at any other time 
point measured (Figure 2.22. B-F). 
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Figure 2.22. The effect of i.p. administration of L-cysteine on food intake in the early light phase 
following an overnight fast in rats. 
Rats received an i.p. injection of (i) saline, (ii) 500µmol/kg, (iii) 1000µmol/kg,(iv) 2000µmol/kg or (v) 
6000µmol/kg L-cysteine. (A) 0-1 hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 hour; (E) 8-24 hour; (F) 0-24 
hour food intake post injection. Data are expressed as mean ± S.E.M. * = p < 0.05 vs. saline; ** = p < 
0.01 vs. saline; *** = p < 0.001 vs. saline; n = 8 per group. 
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Figure 2.23. The effect of i.p. administration of L-cysteine on cumulative food intake in the early 
light phase following an overnight fast in rats. 
Rats received an i.p. injection of (i) saline, (ii) 500µmol/kg, (iii) 1000µmol/kg, (iv) 2000µmol/kg or (v) 
6000µmol/kg L-cysteine. (A) 0-2 hour; (B) 0-4 hour; (C) 0-8 hour food intake post injection. Data are 
expressed as mean ± S.E.M. ** = p < 0.01 vs. saline; *** = p < 0.001 vs. saline; n = 8 per group. 
  
A B 
C 
130 
 
2.5.2.1.2. The effect of i.p. administration of L-arginine on food intake in the early light phase 
following an overnight fast in rats. 
Intraperitoneal administration of 2000µmol/kg L-arginine significantly reduced food intake 0-1 hour 
post-injection compared to saline treated animals (0-1 hour food intake, saline: 5.2 ± 0.6g vs. 
2000µmol/kg L-arginine: 2.5 ± 0.4g, p < 0.01 vs. saline, n = 9-10 per group) (Figure 2.24. A). No 
treatment significantly affected food intake at any other time point measured (Figure 2.24. B-F). 
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Figure 2.24. The effect of i.p. administration of L-arginine on food intake in the early light phase 
following an overnight fast in rats. 
Rats received an i.p. injection of (i) saline, (ii) 500µmol/kg, (iii) 1000µmol/kg, or (iv) 2000µmol/kg L-
arginine. (A) 0-1 hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 hour; (E) 8-24 hour; (F) 0-24 hour food 
intake post injection. Data are expressed as mean ± S.E.M. ** = p < 0.01 vs. saline; n = 9-10 per 
group. 
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2.5.2.1.3. The effect of i.p. administration of L-lysine on food intake in the early light phase following 
an overnight fast in rats. 
Intraperitoneal administration of 2000µmol/kg L-lysine significantly reduced food intake 0-1 hour 
post-injection compared to saline-treated animals (0-1 hour food intake, saline: 6.8 ± 0.7g vs. 
2000µmol/kg L-lysine: 3.9 ± 0.4g, p < 0.05 vs. saline, n = 8 per group) (Figure 2.25. A). No treatment 
significantly affected food intake at any other time point measured (Figure 2.25. B-F). 
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Figure 2.25. The effect of i.p. administration of L-lysine on food intake in the early light phase 
following an overnight fast in rats. 
Rats received an i.p. injection of (i) saline, (ii) 500µmol/kg, (iii) 1000µmol/kg,(iv) 2000µmol/kg L-
cysteine. (A) 0-1 hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 hour; (E) 8-24 hour; (F) 0-24 hour food 
intake post injection. Data are expressed as mean ± S.E.M. * = p < 0.05 vs. saline; n = 7-8 per group. 
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2.5.2.1.4. The effect of i.p. administration of L-cysteine, D-cysteine, L-arginine and D-arginine on food 
intake in the early light phase following an overnight fast in rats. 
Intraperitoneal administration of 2000µmol/kg L-cysteine, L-arginine and D-arginine significantly 
decreased food intake 0-1 hour post-injection compared to saline (0-1 hour food intake, saline: 5.6 ± 
0.7g vs. L-cysteine: 2.4 ± 0.4g, p < 0.001 vs. saline; L-arginine: 3.1 ± 0.8g, p < 0.05 vs. saline; D-
arginine: 3.1 ± 0.6g, p < 0.05 vs. saline, n = 7-8 per group) (Figure 2.26. A). D-Cysteine at the same 
dose had no effect on food intake. Treatment with 2000µmol/kg L-cysteine significantly increased 
food intake 1-2 hours post-injection (1-2 hour food intake, saline: 1.5 ± 0.9g vs. L-cysteine: 5.0 ± 0.8g, 
p < 0.01 vs. saline, n = 7-8 per group) (Figure 2.26. B). No treatment significantly affected food intake 
at any other time point measured (Figure 2.26. C-F). 
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Figure 2.26. The effect of i.p. administration of L-cysteine, D-cysteine, L-arginine and D-arginine on 
food intake in the early light phase following an overnight fast in rats. 
Rats received an i.p. injection of (i) saline, (ii) 2000µmol/kg L-cysteine, (iii) 2000µmol/kg D-cysteine, 
(iv) 2000µmol/kg L-arginine, (v) 2000µmol/kg D-arginine. (A) 0-1 hour; (B) 1-2 hour; (C) 2-4 hour; (D) 
4-8 hour; (E) 8-24 hour; (F) 0-24 hour food intake post injection. Data are expressed as mean ± 
S.E.M. * = p < 0.05 vs. saline; ** = p < 0.01 vs. saline; *** = p < 0.001 vs. saline; n = 7-8 per group. 
L-Cys, L-cysteine; D-Cys, D-cysteine; L-Arg, L-arginine; D-Arg, D-arginine. 
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2.5.2.1.5. The effect of i.p. administration of L-lysine, D-lysine, L-arginine and D-arginine on food 
intake in the early light phase following an overnight fast in rats. 
Intraperitoneal administration of 2000µmol/kg of L-lysine, D-lysine, L-arginine and D-arginine 
significantly reduced food intake 0-1 hours post-injection compared to saline (0-1 hour food intake, 
saline: 5.7 ± 0.6g vs. L-lysine: 2.9 ± 0.6g, p < 0.01 vs. saline; D-lysine: 3.0 ± 0.5g, p < 0.01 vs. saline; L-
arginine: 2.0 ± 0.3g, p < 0.001 vs. saline; D-arginine: 3.6 ± 0.5g, p < 0.05 vs. saline, n = 7-8 per group) 
(Figure 2.27. A). These reductions in food intake were sufficient to make reductions over longer 
cumulative periods statistically significant i.e. the 2 hour time period (0-2 hour food intake, saline: 
8.7 ± 0.7g vs. L-lysine: 5.5 ± 0.8g, p < 0.01 vs. saline; D-lysine: 6.0 ± 0.7g, p < 0.05 vs. saline; L-
arginine: 4.7 ± 0.4g, p < 0.001 vs. saline; D-arginine: 6.3 ± 0.5g, p < 0.05 vs. saline, n = 7-8 per group) 
(Figure 2.28. A). The reduction in food intake induced by L-arginine administration was also sufficient 
to make the reduction over the even longer cumulative time periods statistically significant i.e. the 4 
hour (0-4 hour food intake, saline: 10.9 ± 0.6g vs. L-arginine: 8.1 ± 0.4g, p < 0.05 vs. saline, n = 7-8 
per group) and 24 hour (0-24 hour food intake, saline: 41.2 ± 0.8g vs. L-arginine: 34.9 ± 1.2g, p < 0.01 
vs. saline, n – 7-8 per group) time points (Figure 2.28. B and C). No treatment significantly affected 
food intake at any other time point measured (Figure 2.27. B-F). 
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Figure 2.27. The effect of i.p. administration of L-lysine, D-lysine, L-arginine and D-arginine on food 
intake in the early light phase following an overnight fast in rats. 
Rats received an i.p. injection of (i) saline, (ii) 2000µmol/kg L-lysine, (iii) 2000µmol/kg D-lysine, (iv) 
2000µmol/kg L-arginine, (v) 2000µmol/kg D-arginine. (A) 0-1 hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 
hour; (E) 8-24 hour; (F) 0-24 hour food intake post injection. Data are expressed as mean ± S.E.M. * = 
p < 0.05 vs. saline; ** = p < 0.01 vs. saline; *** = p < 0.001 vs. saline; n = 7-8 per group. 
L-Lys, L-lysine; D-Lys, D-lysine; L-Arg, L-arginine; D-Arg, D-arginine. 
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Figure 2.28. The effect of i.p. administration of L-lysine, D-lysine, L-arginine and D-arginine on 
cumulative food intake in the early light phase following an overnight fast in rats. 
Rats received an i.p. injection of (i) saline, (ii) 2000µmol/kg L-lysine, (iii) 2000µmol/kg D-lysine, (iv) 
2000µmol/kg L-arginine, (v) 2000µmol/kg D-arginine. (A) 0-2 hour; (B) 0-4 hour. Data are expressed 
as mean ± S.E.M. * = p < 0.05 vs. saline; ** = p < 0.01 vs. saline; *** = p < 0.001 vs. saline; n = 7-8 per 
group. 
L-Lys, L-lysine; D-Lys, D-lysine; L-Arg, L-arginine; D-Arg, D-arginine. 
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2.5.2.3. The effect of i.p. administration of L-cysteine, L-lysine and L-arginine on behaviour in the 
early light phase following an overnight fast in rats. 
For behavioural studies, animals were observed 3 times every 5 minutes, totalling 18 observations 
per animal per half hour or 36 per hour. Median values of number of observations per behaviour per 
group were then calculated and differences between groups were determined. Intraperitoneal 
administration of L-cysteine, L-lysine or L-arginine in the early light phase in overnight-fasted rats did 
not significantly reduce feeding behaviour over the 0-30 minute (Table 2.10.), 30-60 minute (Table 
2.10.) or 0-60 minute (Table 2.11.) time periods. There were no abnormal behaviours or alterations 
in locomotor activity compared to saline treated controls over the 0-30 minute (Table 2.10.), 30-60 
minute (Table 2.10.) or 0-60 minute (Table 2.11.) time periods. 
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Table 2.10. Rat behaviours 0-30 and 30-60 minutes following i.p. administration of saline or 2000µmol/kg L-arginine, L-cysteine or L-lysine. 
Table summarising the behaviours recorded for 0-30 and 30-60 minutes post-oral administration of saline or 2000µmol/kg of L-cysteine, L-lysine or L-
arginine. Each animal was observed 3 times every 5 minutes, totalling 18 observations per animal per half hour. Data are presented as median number of 
observations (interquartile range). n = 8-10 per group. 
Behaviour 0-30 minutes 30-60 minutes 
Saline L-Arginine L-Cysteine L-Lysine Saline L-Arginine L-Cysteine L-Lysine 
Feeding 12 (10.75-
12.75) 
11(3.75-12) 5 (3-9) 8 (6-9) 3 (2-5) 7 (5-10) 6 (3-9) 6 (6-12) 
Drinking 0 (0-0) 3 (0-3) 0 (0-1) 0 (0-3) 3 (0-3) 1 (0-2) 0 (0-3) 0 (0-3) 
Rearing 1.5 (1-3.25) 2 (0.5-2) 3 (2-5) 1 (0-2) 4 (2-5) 1 (0-3) 2 (0-3) 3 (1-3) 
Locomotion 3 (2.75-4) 2.5 (2-3) 4 (4-4) 3 (2-5) 1 (1-4) 3 (1-3) 2 (2-3) 0 (0-3) 
Grooming 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-1) 0 (0-3) 0 (0-1) 0 (0-1) 0 (0-3) 
Pica 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Bed-making 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-1) 0 (0-0) 0 (0-0) 0 (0-0) 
Head down 0 (0-0) 0 (0-4.5) 3 (0-6) 0 (0-3) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Sleep 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-1) 0 (0-0) 0 (0-0) 0 (0-0) 
Tremors 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Climbing 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Stationary 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-1) 0 (0-2.3) 0 (0-3) 4 (0-5) 1 (0-3) 
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Table 2.11. Rat behaviours 0-60 minutes following i.p. administration of saline or 2000µmol/kg L-arginine, L-cysteine or L-lysine. 
Table summarising the behaviours recorded for the first hour post-oral administration of saline or 2000µmol/kg of L-cysteine, L-lysine or L-arginine. Each 
animal was observed 3 times every 5 minutes, totalling 36 observations per animal per hour. Data are presented as median number of observations 
(interquartile range). n = 8-10 per group. 
Behaviour 0-60 minutes 
Saline L-Arginine L-Cysteine L-Lysine 
Feeding 15 (10.5-18) 15 (8.75-15.75) 14 (9-21) 15 (10-21) 
Drinking 2.5 (0-4.25) 3 (0-4.75) 3 (0-3) 3 (0-3) 
Rearing 7 (4.75-14.75) 4.5 (4-6.5) 4 (2-5) 3 (1-5) 
Locomotion 4 (2.75-5.5) 4 (3-6) 6 (4-8) 6 (5-7) 
Grooming 0 (0-3.25) 2 (0.25-3) 0 (0-1) 0 (0-1) 
Pica 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Bed-making 0 (0-0) 0 (0-1.5) 0 (0-0) 0 (0-3) 
Head down 0 (0-1.5) 5 (0.75-5.75) 3 (0-3) 3 (0-6) 
Sleep 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Tremors 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Climbing 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Stationary 0 (0-3) 0 –(0-6) 3 (3-5) 0 (0-3) 
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2.5.3. Correlation of food intake reduction with GPRC6A, T1R1/T1R3 and CaR activation 
2.5.3.1. Compilation of results from screening studies 
Food intake following each amino acid administration was calculated as a percentage of the food 
intake following control treatment. Where a treatment was administered more than once, the mean 
food intake as a percentage of the control for each study. Figure 2.29. A shows food intake as a 
percentage of that in the water control group for each amino acid for one hour following oral 
gavage. Figure 2.29. B shows food intake as a percentage of that in the saline control group for each 
amino acid for one hour following i.p. injection. This data is not amenable to statistical analysis, but 
suggests that of the amino acids tested, L-lysine, L-arginine and L-cysteine are the most potent 
anorectic agents. It is possible that other amino acids reduce food intake to a similar degree, for 
example oral administration of L-alanine and L-valine appear to reduce food intake by a similar 
magnitude to L-arginine and L-lysine but L-lysine, L-arginine and L-cysteine significantly reduced food 
intake most consistently. 
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Figure 2.29. Food intake one hour following A: oral, and B: i.p. amino acid treatment expressed as a percentage of that following control treatment. 
Data are expressed as mean ± S.E.M.  
A B 
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2.5.3.2. Correlation of food intake reduction with GPRC6A, T1R1/T1R3 and CaR activation 
The data in Figure 2.29. were plotted against the available data compiled in Figure 2.3. for each 
amino acid. Food intake following oral amino acid administration was not correlated with activation 
of the GPRC6A or CaR (Figure 2.30. A and C). There was a negative correlation between food intake 
and activation of the T1R1/T1R3 but this was not statistically significant (r10=-0.54, p=0.07). Similarly, 
food intake following i.p. amino acid administration was not correlated with activation of the 
GPRC6A or CaR for either route of administration (Figure 2.31. A and C). There was a negative 
correlation between food intake and activation of the T1R1/T1R3, which was statistically significant 
(r10 = -0.57, p < 0.05). 
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Figure 2.30. Correlation between food intake following oral administration of amino acids and (a) 
GPRC6A activation, (b) T1R1/T1R3 activation and (c) CaR activation. 
Data on receptor activation is from (Wellendorph et al., 2009a). Each data point represents an 
individual amino acid. 
r5 = -0.04, p = 0.90 
 
r10 = -0.54, p = 0.07 
 
r8=-0.22, p=0.50 
 
r8=-0.22, p=0.50 
 
r10 = -0.22, p = 0.78 
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Figure 2.31. Correlation between food intake following i.p. administration of amino acids and (a) 
GPRC6A activation, (b) T1R1/T1R3 activation and (c) CaR activation. 
Data on receptor activation is from (Wellendorph et al., 2009a). Each data point represents an 
individual amino acid. 
r5 = -0.03, p = 0.59 
 
r10 = -0.57, p < 0.05 
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2.6. Discussion 
The studies described in this chapter aimed to determine the effects of peripherally administered 
amino acids on food intake in rodents. They identified L-cysteine as causing acute potent anorectic 
effects. L-Cysteine, whether administered by oral gavage or i.p. injection, induced a reduction in 
food intake 1 hour post-administration. On average, orally administered L-cysteine at a dose of 
4000μmol/kg reduced food intake 1 hour post-gavage by approximately 62%. Following i.p. 
administration, L-cysteine at a dose of 2000μmol/kg also reduced food intake, though to a lesser 
degree. Further experiments determined that following oral or i.p. administration, L-cysteine 
reduced acute food intake dose-dependently. The other amino acids which consistently reduced 
acute food intake were L-lysine and L-arginine. However, these amino acids were not as potent at 
reducing food intake. In addition, they failed to reduce food intake in a dose-dependent manner, 
with only the highest doses administered reducing food intake (2000μmol/kg intraperitoneally and 
4000μmol/kg orally). It is, however, possible that using a smaller range of doses starting at 
1000μmol/kg intraperitoneally or starting at 2000μmol/kg orally may have revealed a dose response 
relationship. 
For the most part, these amino acids did not robustly affect food intake at any time points outside of 
0-1 hour post-administration. In several studies, L-cysteine increased food intake between 1 and 2 
hours post-administration. This was likely a ‘rebound hyperphagia’ effect due to the potent 
reduction in food intake and relative food restriction 1 hour post-administration (Lauzurica et al., 
2010). 
Several other amino acids appeared to reduce food intake at different time points. Oral 
administration of L-valine significantly reduced 0-1 hour food intake in study 3 of the oral 
administration studies. When L-valine was re-tested, the magnitude of food intake reduction was 
similar but it did not reach statistical significance. These effects may represent type 1 errors, some of 
which are likely to occur when performing a series of so many experiments. Alternatively, they may 
reflect physiologically relevant effects. Oral administration of L-methionine significantly reduced 
food intake 0-2 and 0-8 hours post-administration. L-Cysteine is a non-essential amino acid which 
can be synthesised by the body if there are sufficient quantities of L-methionine available, which 
provides the required sulphur moiety for cysteine synthesis. It is possible, therefore, that this later 
reduction in food intake reflects metabolism of L-methionine to L-cysteine. Oral administration of L-
histidine reduced food intake at the 4-8 hour time point. L-Histidine is in the same family of amino 
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acids as L-lysine and L-arginine and it is possible that this effect reflects a similar, but less potent 
effect, to that of L-arginine and L-lysine. 
These studies suggest that, in general, the anorectic effects of amino acids are acute. It has been 
shown that ingestion of a protein pre-load reduces energy intake at a buffet meal within this 1 hour 
time-frame compared to pre-loads composed of different macronutrients (Bertenshaw et al., 2008). 
It is therefore possible that amino acids mediate this effect. Other studies have shown that a protein 
pre-load reduces energy intake at a buffet meal served after this time frame and that the pre-load 
increases the time before spontaneous commencement of feeding (Bertenshaw et al., 2008, 
Marmonier et al., 2000, Marmonier et al., 2002). Amino acids administered alone may have a more 
acute effect than ingested protein. A protein preload would need to be broken down into smaller 
polypeptides, and subsequently into individual amino acids before the amino acids would be able to 
interact with amino acid sensing receptors. This may not happen within one hour. Following 
ingestion of whey protein, for example, the plasma levels of several amino acids continue to increase 
up to 1 hour post ingestion of the protein (Aziz et al., 2005). If individual amino acids do mediate the 
satiety induced by protein ingestion, it is therefore feasible that the effects might not be seen until 
later time points.  
If amino acids caused nausea or abdominal pain they would also likely reduce food intake. L-
cysteine, L-lysine and L-arginine all reduced acute food intake without significantly altering animal 
behaviour. However further investigations, such as conditioned taste aversion studies are necessary 
to demonstrate that these amino acids do not induce satiety secondary to nausea. 
GPRC6A, T1R1/T1R3 and CaR are reported to be unresponsive to the D-enantiomers of amino acids 
(Wellendorph et al., 2009a). In the studies described in this chapter, only the L-enantiomer of 
cysteine reduced food intake 1 hour post-injection or gavage. However, both the L- and D- 
enantiomers of lysine and arginine reduced food intake 1 hour post injection or gavage (although 
the reduction induced by oral D-lysine was not statistically significant). This suggests that L-cysteine 
reduces food intake via a mechanism that responds specifically to only L-amino acids, and does not 
respond to D-enantiomers. The 7TM promiscuous receptors are selective for L-amino acids, and thus 
may be responsible. The ability of D-arginine and D-lysine to reduce food intake suggests that the 
anorectic effects of these amino acids are not mediated by these receptors. However, the 
T1R2/T1R3 sweet taste receptor is reported to be activated by the D-enantiomers of certain amino 
acids (Wellendorph et al., 2009a), and thus may mediate the reduction in food intake. However, the 
response of T1R2/T1R3 to D-arginine and D-lysine has not been reported. 
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The amino acids tested in this chapter have widely varying pH values at the different concentrations 
tested. L-Arginine and L-lysine, for example, are very basic amino acids. It is possible that the 
anorectic effects are secondary to alterations in pH in the stomach or the general circulation. 
However, the lack of behavioural responses in the rats makes this unlikely. In addition, the stomach 
is extremely proficient at coping with wide pH ranges. The pH of L-cysteine is extremely unlikely to 
have caused the anorectic effects observed. It is a fairly neutral amino acid and so is unlikely to have 
caused discomfort. In addition, the D-enantiomer of cysteine results in a solution of the same pH but 
did not reduce food intake. 
Correlating the effect of amino acids on food intake with their effects on receptor activation 
suggests that amino acids may mediate their anorectic effects through the T1R1/T1R3. Achieving 
significance in correlations of this nature is difficult due to the limited n number; there are only a 
finite number of amino acids, still fewer which are sufficiently soluble to obtain robust data on food 
intake. However, ligand/receptor response data has been gathered using the mouse orthologues of 
the receptors. It has been demonstrated that, at least for the GPRC6A and T1R1/T1R3, the in vitro 
response of these receptors to different amino acids differs between rats and mice (Wellendorph et 
al., 2007, Li et al., 2002, Nelson et al., 2002). In addition, the methods by which these results were 
obtained were different for each receptor, and different derivations of the ‘normalised response’ 
were used. Furthermore, the data on ligand preferences has been collected using in vitro techniques 
which, as previously discussed, may not accurately reflect their behaviour in vivo. Also, these data do 
not account for half-life or amino acid transport mechanisms across the gut lumen. In addition, for 
these correlations, an assumption has been made that receptor activation would be linearly related 
to physiological action (i.e. mediation of food intake). Relating food intake data to reported data on 
receptor activation is thus useful to guide further investigation, but must be regarded with caution. 
These studies suggest that amino acids can regulate food intake. Further investigation is required to 
investigate the physiological relevance of these studies. The patterns of food intake reduction seem 
to be different for L-cysteine (a sulphur containing amino acid) and L-lysine and L-arginine (both 
basic amino acids). L-Cysteine reduces food intake in a dose-dependent manner, whilst L-arginine 
and L-lysine seem to require a threshold concentration to be reached before inducing a reduction in 
food intake. This, coupled with the disparate observations following administration of the D-
enantiomers, is suggestive of separate mechanisms mediating the effects of L-cysteine and of L-
lysine and L-arginine. I therefore carried out studies to investigate the mechanisms by which these 
amino acids reduce food intake. 
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CHAPTER 3: 
INVESTIGATING THE 
MECHANISMS MEDIATING 
THE ANORECTIC EFFECT OF 
SPECIFIC AMINO ACIDS  
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3.1. Introduction 
3.1.1. Protein and satiety 
Satiety is defined as the absence of hunger felt following a meal, whereas satiation refers to the 
processes involved in the termination of a meal. There is evidence to suggest that protein can 
modulate both satiety and satiation. Protein has been shown in both humans and rodents to have a 
powerful satiating effect which is greater than that of carbohydrate and fat. This effect can be 
observed acutely following a high protein meal (Stubbs et al., 1996, Crovetti et al., 1998) and also on 
a high protein diet (Westerterp-Plantenga et al., 1999, Lejeune et al., 2006). Using visual analogue 
scales or other self-reported measures of fullness, it has been shown that human subjects ingesting 
a meal with an increased percentage of energy coming from protein feel more satiated than those 
ingesting a meal containing a lower percentage of protein (Stubbs et al., 1996, Crovetti et al., 1998, 
Vandewater and Vickers, 1996). Both Barkeling et al. (Barkeling et al., 1990) and Johnson et al. 
(Johnson and Vickers, 1993) have shown that volunteers have lower energy intake when consuming 
homogenous meals with a higher percentage of energy coming from protein, compared to meals 
containing a lower percentage of energy from protein. 
It has also been shown that ingestion of a high protein ‘pre-load’ induces a subsequent reduction in 
energy intake three to four and three quarter hours later (Barkeling et al., 1990, Johnson and 
Vickers, 1993, Booth et al., 1970, Latner and Schwartz, 1999). In addition, when subjects are free to 
spontaneously start a test-meal after a pre-load, a high-protein preload has been shown to increase 
the delay between pre-load and test-meal compared with an equicaloric high fat or high-
carbohydrate preload (Marmonier et al., 2000, Marmonier et al., 2002). Furthermore, Teff et al. 
reported that a 210kcal protein pudding was as satiating as a 400kcal carbohydrate pudding since 
the two preloads led subjects to consume similar amounts at a later test meal (Teff et al., 1989). 
These studies suggest that high protein food induces greater satiety than food with a lower protein 
content. 
Several high protein diet studies, lasting from 24 hours to up to 4 days, have shown that 24 hour 
satiety is increased and hunger is decreased with a high protein diet compared to a lower protein 
diet (Westerterp-Plantenga et al., 1999, Lejeune et al., 2006). In volunteers fed a high protein diet 
where protein intake exceeds protein requirement, satiety is positively correlated with absolute 
protein intake (Lejeune et al., 2006). 
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3.1.1.1. Peripheral mechanisms involved in protein-induced satiety 
3.1.1.1.1. Gluconeogenesis as a metabolic signal in protein-induced satiety 
The de novo production of glucose from amino acids in the liver has been postulated to be a signal in 
protein-induced satiety. A high protein diet induces hepatic gluconeogenesis from precursors 
including amino acids, and this process could contribute to the satiating effects of protein via 
modulation of glucose metabolism and central glucose signalling (Azzout-Marniche et al., 2007). 
Intestinal gluconeogenesis and glucose portal sensing through portal vagus afferent fibres has also 
been proposed as an alternative mechanism for protein-induced satiety (Mithieux et al., 2005). 
However, the relevance and physiological significance of intestinal gluconeogenesis has been the 
subject of debate (Potier et al., 2009), and protein-induced satiety is not abolished by vagotomy in 
the rat (L'Heureux-Bouron et al., 2003), suggesting portal sensing does not mediate the satiating 
effects of protein. The role of the vagus nerve in mediating the satiating effects of protein is 
discussed further in section 3.1.1.1.4. The amino acids which were shown to reduce food intake in 
the studies described in chapter 2 have also been shown to influence blood glucose and plasma 
insulin levels. Arginine has been demonstrated to induce insulin release from pancreatic beta cells 
(Thams and Capito, 1999). In contrast, cysteine and lysine ingestion have been shown to reduce 
blood glucose levels following oral gavage in rats and oral administration in humans, respectively, 
suggesting that these amino acids are not substrates for gluconeogenesis, but may improve insulin 
sensitivity (Jain et al., 2009, Kalogeropoulou et al., 2009). 
A high protein diet can influence glucose homeostasis. Rats fed a high protein diet for two weeks 
were found to have significantly increased fasting blood glucose and plasma insulin (Usami et al., 
1982). It has also been shown that humans with insulin-dependent diabetes mellitus who consume a 
diet high in protein (on average 1.87g/kg per day) had a lower insulin sensitivity than those patients 
who consumed a normal protein diet (on average 0.74g/kg per day) (Linn et al., 1996). These data 
suggest that a high protein diet might have detrimental effects on insulin sensitivity. However, other 
studies have produced contrasting results. For example, Yang et al. showed that rats with high fat 
diet-induced non-alcoholic steatohepatitis had improved insulin sensitivity when soy protein was 
included in the diet (Yang et al., 2011). It is possible that specific amino acid signals may mediate 
these contrasting effects. 
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3.1.1.1.2. Peripheral satiety hormones 
Protein-induced satiety may be mediated by increased secretion of the anorectic gut hormones CCK, 
GLP-1 and PYY, or by reduced secretion of the orexigenic hormone ghrelin. The experimental 
evidence, however, is inconsistent, especially when comparisons are made between acute and 
chronic studies. 
3.1.1.1.2.1. Peripheral satiety hormones following acute protein ingestion 
Acutely, a high protein preload was found by Smeets et al. not to alter circulating concentrations of 
GLP-1 and PYY when compared to a normal protein preload in humans (Smeets et al., 2008). 
However, Hall et al. did demonstrate that these gut hormones were increased after an extremely 
high protein preload when compared to a nutritionally balanced preload in human subjects (Hall et 
al., 2003). In addition, a study by Batterham et al. has found significantly higher plasma PYY 
responses to a high protein meal in both lean and obese subjects (Batterham et al., 2006). CCK has 
also been shown to be released postprandially in response to protein. In normal and overweight 
humans, a high protein pre-load increased the duration of the post-prandial rise in circulating CCK 
compared to an equicaloric glucose preload (Bowen et al., 2006a, Hall et al., 2003). 
The Smeets study found that a high protein preload induced no differences in plasma ghrelin 
compared to a normal protein preload in human subjects (Smeets et al., 2008). However, other 
studies have observed that the postprandial suppression of ghrelin is prolonged after a high-protein 
preload compared to a high carbohydrate preload (Bowen et al., 2006a, Bowen et al., 2006b). Some 
reports have suggested that protein ingestion has a smaller acute suppressive effect on plasma 
ghrelin concentrations than ingestion of other macronutrients, and that it may even increase ghrelin 
levels (Erdmann et al., 2003, Greenman et al., 2004). However, a number of more recent studies 
provide convincing evidence that protein can suppress post-prandial circulating ghrelin levels more 
potently and/or for longer than carbohydrates (Al Awar et al., 2005, Blom et al., 2006, Tannous dit El 
Khoury et al., 2006, Bowen et al., 2006b, Bowen et al., 2006a, Leidy et al., 2007, Foster-Schubert et 
al., 2008). 
3.1.1.1.2.2. Peripheral satiety hormones following chronic protein ingestion 
The effects of high protein diets on anorectic gut hormones are complex and contradictory. 
Circulating GLP-1 levels have been reported to be higher following a meal in humans fed a high 
protein diet for four days compared to those fed a normal protein diet (Lejeune et al., 2006). A high 
protein diet in rodents has been demonstrated to increase postprandial PYY release (Batterham et 
al., 2006, Calbet and Holst, 2004). Chronic intake of a high protein diet does not alter circulating 
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ghrelin compared to a normal protein diet in humans (Lejeune et al., 2006, Moran et al., 2005), 
suggesting that the chronic satiating effects of protein are not mediated by altered ghrelin secretion. 
3.1.1.1.4. Vagal mediated protein-induced satiety 
The role of the vagus in mediating the satiating effects of protein is unclear. Intraperitoneal protein 
infusion in rats activates vagal afferent fibres, and high protein feeding induces c-fos expression in 
neurones within the vagal afferent-receiving NTS  (Faipoux et al., 2008). In addition, intraduodenal 
protein activates vagal afferent fibres (Darcel et al., 2005). Contrary to these findings, high protein 
diets are still able to reduce food intake in vagotomised rats (Tome et al., 2009, L'Heureux-Bouron et 
al., 2003, Yox et al., 1991). These results suggest that the satiating effects of protein are not 
mediated by vagal signalling, or that this satiating effect is mediated by multiple mechanisms. 
Peripheral information sensed by the brainstem is signalled to the hypothalamus. It has been shown 
that ingestion of a high protein meal increases the number of POMC neurones expressing c-fos in 
the ARC, and decreases the number of non-POMC neurones expressing c-fos in rats (Faipoux et al., 
2008). However, the mechanism by which the behaviour of these ARC neurones is altered is 
currently unknown. It is possible that, rather than acting via the vagus nerve, protein may be sensed 
directly by the CNS. 
3.1.1.2. Central mechanisms involved in protein-induced satiety 
3.1.1.2.1. Plasma amino acids as central satiety signals 
It is known that dietary composition can influence extracellular levels of amino acids in the brain 
(Gustafson et al., 1986, Block and Harper, 1991) and specifically in the hypothalamus (Currie et al., 
1995). It is possible that changes in plasma amino acid concentrations following protein digestion 
and absorption may be directly sensed by the CNS, or that they result in changes in ICV amino acid 
concentrations that then modulate CNS pathways. Specific amino acids have specific biochemical 
roles, and different sensing mechanisms may therefore mediate their effects. Histidine and tyrosine, 
as precursors of histamine and dopamine, have been hypothesised to be particularly important. 
However, a diet supplemented with five percent histidine or tyrosine has been reported not to alter 
food intake in rats (Bassil et al., 2007). Leucine is a branched-chain amino acid which is capable of 
stimulating muscle protein synthesis (Combaret et al., 2005).  ICV administration of leucine, or an 
increase in dietary leucine, reduces food intake and body weight (Cota et al., 2006, Zhang et al., 
2007). This effect appears to be specific to leucine, as ICV leucine alone has the same effect on food 
intake as administration of a mixture of amino acids (Morrison et al., 2007). Evidence suggests that 
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circulating amino acids can activate neurones in the ARC and the brainstem. The anterior piriform 
cortex (APC) is also thought to be involved in amino acid sensing (Cota et al., 2006, Faipoux et al., 
2008, Gietzen and Magrum, 2001, Hao et al., 2010). It has been shown that the timing of the 
changes in circulating amino acid levels is important (Luhovyy et al., 2007); the anorectic effects of 
protein can be enhanced by timing the test meal to coincide with the optimal circulating amino acid 
profile (Luhovyy et al., 2007). 
3.1.1.2.2. Amino acids as signals of energy availability 
AMP-activated protein kinase (AMPK) and the mammalian target of rapamycin (mTOR) may be 
involved in the satiety induced by high protein diets (Ropelle et al., 2008). AMPK is the downstream 
component of a kinase cascade, and acts as an intracellular sensor of cellular energy change. It is 
activated by a reduction in intracellular ATP/AMP ratio. AMPK phosphorylates and inactivates acetyl-
CoA carboxylase (ACC) and thus switches on pathways which acquire energy (e.g. fatty acid 
oxidation) at the expense of those which utilise energy (Blouet and Schwartz, 2010). A high protein 
diet or ICV leucine administration reduces hypothalamic AMPK and ACC phosphorylation in rats, 
similar to an increase in ATP/AMP ratio (Blouet et al., 2009). 
The intracellular signalling molecule mTOR is sensitive to both amino acid and growth factor 
signalling, and is also described as a metabolic sensor. A high protein diet or ICV administration of a 
combination of free amino acids or leucine, activates hypothalamic mTOR (Morrison et al., 2007, 
Ropelle et al., 2008). AMPK and mTOR may have reciprocal functions; it has been shown in vitro that 
mTOR is inhibited by AMPK-dependent mechanisms (Inoki et al., 2003, Cota et al., 2006). In addition, 
AMPK and mTOR may have a common signalling pathway (Kimura et al., 2003) and both are 
implicated in the regulation of hypothalamic neuropeptides. High protein diets modulate both AMPK 
and mTOR within the same neuronal populations in the ARC and PVN. Activation of mTOR and/or 
suppression of AMPK phosphorylation decreases the levels of mRNA coding for the orexigenic 
peptides NPY and AgRP in the ARC, and increases expression of POMC mRNA (Morrison et al., 2007, 
Ropelle et al., 2008). 
3.1.2. Protein composition and satiety 
The discrepancies observed between studies where high protein meals were given may be due to 
variations in the amino acid content of the particular proteins involved. The specific amino acids 
generated by protein digestion may be responsible for the magnitude of the resulting satiation.  
Furthermore, the prevalence of individual amino acids within a meal may determine which protein 
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satiety pathway is activated. For example, Veldhorst et al. showed that whey (which is high in 
branched chain amino acids and in cysteine) has a greater suppressive effect on hunger ratings 
compared to casein (high in proline) or soy protein when protein is contributing 10% of the total 
energy intake. Ingestion of whey resulted in higher plasma levels of lysine, as well as of leucine, 
isoleucine, tryptophan and threonine. At a higher concentration of protein (25%), whey induced a 
higher increase in plasma GLP-1 and insulin, and reduced levels of ghrelin to a greater degree when 
compared to casein and/or soy protein (Veldhorst et al., 2009). Burton-Freeman also showed that 
pre-meal satiety was increased with whey protein preloads compared to control, low protein 
preloads (Burton-Freeman, 2008). In these female subjects, CCK concentration patterns predicted 
subjective satiety. Hall et al. reported that a whey protein preload reduced subsequent energy 
intake compared to a casein preload (Hall et al., 2003). It has also been shown that diets specifically 
supplemented with the β-lac fraction of whey protein reduce food intake and body weight gain in 
rats compared to diets supplemented with the whole milk protein (whey and casein) or other whey 
fractions, independent of palatability (Pichon et al., 2008). Assessment of protein fractions in 
protein-induced satiety has also been carried out in humans. It has been shown that milk protein 
most potently increases CCK and GLP-1 levels compared to whey or pea protein hydrolysate, whilst a 
whey protein/pea protein hydrolysate mixture increased levels of PYY and decreased levels of 
ghrelin more potently than milk protein (Diepvens et al., 2008). 
Because protein is ultimately broken down into its constituent amino acids, I hypothesised that 
individual amino acids might play a role in the regulation of food intake. Experiments described in 
the previous chapter indicated that administration of L-cysteine, L-arginine and L-lysine could reduce 
food intake in rats. Further investigation is required to determine how these effects are mediated. 
The aim of the experiments in this chapter was to investigate whether the anorectic effects of these 
amino acids might be mediated by one or more of the mechanisms discussed above. 
3.1.3. Amino acid biochemistry 
Amino acids are molecules which comprise an amine group, a carboxylic acid group, a side chain that 
varies between different amino acids and an additional hydrogen atom, all branching from a central 
carbon atom (Figure 3.1.). 
The carbon atom next to the carboxyl group is called the α-carbon. Amino acids with a side chain 
bonded to the α-carbon are referred to as alpha amino acids (as in Figure 3.1.). These are the most 
common form of amino acids found in nature. In amino acids that have a carbon chain attached to 
the α-carbon, such as lysine, the carbons are labelled in order as α, β, γ, δ, and so on. In some amino 
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acids the amine group is attached to the β or γ-carbon, and these are correspondingly referred to as 
beta or gamma amino acids. 
Amino acids are generally classified by the properties of their side-chain into four groups. These four 
groups of side-chains are 1) non-polar, which make the amino acid hydrophobic; 2) polar, which 
make the amino acid hydrophilic; 3) positively charged, which make the amino acid strongly 
hydrophilic and basic when in an aqueous solution; or 4) negatively charged, which make the amino 
acid strongly hydrophilic and acidic when in an aqueous solution. Although many hundreds of 
molecules classify as amino acids, only 20 amino acids are used in the synthesis of proteins in 
mammals – the proteinogenic amino acids. These proteinogenic amino acids are classified in 
Appendix I. 
The phrase ‘branched-chain amino acids’ or BCAA refers to the amino acids with non-linear aliphatic 
side chains; leucine, isoleucine, and valine. Proline is the only proteinogenic amino acid with a side 
group linked to the α-amino group, and is thus also the only proteinogenic amino acid containing a 
secondary amine at this position. Chemically, therefore, proline is an imino acid, since it lacks a 
primary amino group. However, it is still classed as an amino acid in the current biochemical 
nomenclature, and may also be referred to as an ‘N-alkylated alpha-amino acid’. 
Of the amino acids, eight are referred to as essential amino acids because the human body cannot 
synthesize them from other compounds at the levels required for normal growth, and they must 
thus be obtained from food. These eight are isoleucine, leucine, lysine, methionine, phenylalanine, 
threonine, tryptophan and valine. In addition, cysteine, taurine, tyrosine, histidine and arginine are 
also semi-essential amino acids in children, because the metabolic pathways required for their 
synthesis are not fully developed.  
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Figure 3.1. Molecular structure of an amino acid. 
An amino acid comprises an amine group (circled in red), a carboxylic acid group (circled in blue) a 
side chain which varies between amino acids (represented by ‘R’, circled in purple) and a hydrogen 
atom branching from a central carbon atom. 
 
 
Variable side chain 
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159 
 
Of the standard α-amino acids, all but glycine are chiral molecules. Chiral molecules lack an internal 
plane of symmetry and so have a non-superimposable mirror image (Figure 3.2.). The two forms of 
any particular amino acid are called stereoisomers, and individually are enantiomers of each other. 
These enantiomers are optically active and are defined by their optical activity. The enantiomer 
known as the Dextrorotatory enantiomer, or D-enantiomer will rotate a plane of polarised light 
passed through it to the right; the Levorotatory enantiomer, or L-enantiomer will rotate the plane of 
polarised light to the left (Figure 3.2.). The most easily recognisable analogy of chirality is human 
hands; the left hand is a mirror image of the right hand but the hands are non-superimposable. The 
term chirality is accordingly derived from the Greek word for hand, χειρ (cheir). L-amino acids are 
the only enantiomers which are found in endogenous proteins in mammals. 
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Figure 3.2. The L- and D-enantiomers of a generic amino acid. 
Figure adapted from (Alberts et al., 2004). 
NH2, amine group; C, central carbon atom; COOH, carboxylic acid group; H, hydrogen atom; R, side 
chain group; L, L-enantiomer; D, D-enantiomer. 
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3.1.4. Amino acid metabolism 
The oxidation of amino acids begins with the removal of the amino group by a transaminase enzyme, 
producing a keto-acid which is then fed into the citric acid cycle to provide energy. The amino group 
is utilised in the biosynthesis of other amino acids or excreted as urea. The breakdown of the carbon 
skeletons of the 20 common amino acids yields one of seven intermediate molecules: α-
ketoglutarate, succinyl CoA, pyruvate, fumarate, oxaloacetic acid, acetoacetate or acetyl CoA. The 
first five of these intermediates are substrates for gluconeogenesis and the amino acids which form 
them are thus glucogenic. Acetoacetate and acetyl CoA are substrates for ketogenesis and so the 
amino acids that form them are ketogenic. 
3.1.5. Amino acid transport 
Amino acid transport is a complex process, involving numerous transporters grouped into several 
‘systems’ which transport amino acids with similar biochemical properties. Based on functional 
studies in kidney and intestine, and the amino acid profiles in the urine of individuals with different 
aminoacidurias, five transport activities have been proposed (Broer, 2008): 1) The ‘neutral system’ 
or ‘methionine preferring system’ transporting all neutral amino acids; 2) The ‘basic system’ 
transporting cationic amino acids together with cysteine; 3) The ‘acidic system’ transporting 
glutamate and aspartate; 4) The ‘iminoglycine system’ transporting proline, hydroxyproline and 
glycine; and 5) The β-amino acid system. The fine details of these transport systems are beyond the 
scope of this thesis, and have been comprehensively reviewed relatively recently (Broer, 2008, 
Hundal and Taylor, 2009). However, certain characteristics of these transporter families are 
important in the context of the work described in this thesis and are therefore briefly discussed 
below.  
3.1.5.1. The ‘neutral system’ 
The transport of neutral amino acids from the small intestinal lumen into epithelial cells is mediated 
by the ‘B0’ and ‘ASC’ systems, both of which are Na+ dependent. Transport of these amino acids out 
of the cell via the basolateral epithelium is mediated by the ‘L’ and ‘T’ systems, which are sodium 
independent. The A system mediates amino acid influx at the basolateral membrane.  
3.1.5.2. The ‘basic system’  
The transport of cationic amino acids into epithelial cells from the small intestine lumen is mediated 
by the ‘b0/+’ system which concurrently effluxes a neutral amino acid, and also by inducible 
transporters. Efflux at the basolateral membrane is mediated by the ‘L’ and ‘y+L’ systems.  
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3.1.5.3. The ‘acidic system’ 
The transport of anionic amino acids into epithelial cells from the small intestinal lumen is mediated 
by the ‘ASC system’ which concurrently expels a neutral amino acid, and which also requires passage 
of one molecule of Na+ in both directions. It is also mediated by the XAG system which is Na+ and K+ 
dependent. Efflux mechanisms at the basolateral membrane have yet to be elucidated.  
3.1.5.4. The ‘iminoglycine system’ 
Proline and glycine are transported across the apical intestinal membrane via the Imino acid carrier, 
coupled with transport of H+. Proline can also cross the apical membrane via the Na+-dependent 
IMINO carrier. Transport of proline and glycine across the basolateral membrane of intestinal 
epithelial cells has not been described.  
3.1.5.5. The β-amino acid system 
The β-amino acid system transports β-amino acids but will not be discussed further as only α-amino 
acids are investigated in detail in the experiments described in this thesis. 
It is important to consider these transport systems when evaluating the effects of amino acids 
described in this thesis. Rate of absorption of amino acids from the gut lumen will depend on 
competition for transporters, as well as Na+ concentrations in many cases. For example, absorption 
of L-arginine and L-lysine from the gut lumen will depend on the same transporter family and will 
thus compete for transporters. The amino acid transporters responsible for apical and basolateral 
transport in the small intestine are also largely responsible for amino acid reabsorption in the renal 
tubules. Amino acid clearance from the body and half-life of amino acids in the circulation will 
depend on the action of these transporters. 
Furthermore, certain amino acid transporters have been demonstrated to directly influence cellular 
responses in the gut. For example, the glutamine-induced secretion of GLP-1 from L-cells has been 
suggested to be driven, in part, by membrane depolarisation associated with the small inward 
current generated by Na+-coupled glutamine uptake via the SLC38A2 (SNAT2) transporter, a system 
A transporter (Reimann et al., 2006). The system A transporters are also modulated by hormone 
levels; insulin and glucagon stimulate the activity of these transporters in the liver and skeletal 
muscle (Fehlmann et al., 1979, Shotwell et al., 1983). 
In chapter 2, I showed that L-cysteine, L-arginine and L-lysine acutely reduce food intake. I will 
therefore now consider these three amino acids in more detail. 
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3.1.6. Cysteine 
Cysteine is an α-amino acid with a structure as shown in Appendix I. The thiol side group is 
susceptible to oxidation to give the disulphide derivative cystine, which serves an important 
structural role in many proteins. Cysteine can also be metabolised into pyruvate and is thus one of 
the glucogenic amino acids. 
Cysteine is found in most high protein foods such as meat, cheese, eggs and yoghurt, as well as oats, 
wheat germ and certain vegetables. Although classified as a non-essential amino acid, in rare cases, 
cysteine may be essential for infants, the elderly, and individuals with specific metabolic diseases or 
who suffer from malabsorption syndromes. Cysteine can usually be synthesised by the human body 
under normal physiological conditions if there is a sufficient quantity of methionine available.  
3.1.7. Lysine 
Lysine is an essential amino acid which is metabolised in mammals to give acetyl-CoA, via an initial 
transamination reaction involving α-ketoglutarate. Lysine is thus a ketogenic amino acid. Its 
structure is shown in Appendix I. Lysine is the limiting amino acid (the essential amino acid found in 
the smallest quantity in a particular foodstuff) in most cereal grains, but is plentiful in most pulses, 
as well as in most meat and dairy products, and in foods rich in proteins such as soy. A food is 
considered to contain sufficient lysine if it has at least 51mg of lysine per gram of protein (i.e. the 
protein is composed of at least 5.1% lysine by weight). L-Lysine is a necessary building block for 
many proteins in the body. It plays a major role in calcium absorption, building muscle protein, 
recovering from surgery or sports injuries, and the synthesis of hormones, enzymes and antibodies. 
3.1.8. Arginine 
Arginine is an α-amino acid with a structure as shown in Appendix I. Although arginine is a 
nonessential amino acid which can be manufactured by the body, this biosynthetic pathway does 
not produce sufficient arginine for normal survival and growth, and therefore some arginine must 
still be consumed through the diet. Arginine is found in a wide variety of foods including dairy 
products, red meats, poultry and seafood, as well as flour, oatmeal and various nuts. Arginine plays 
an important role in cell division, the healing of wounds, removing ammonia from the body, immune 
function, and the release of hormones. Arginine also stimulates the secretion of growth hormone 
and is used in growth hormone stimulation tests. Arginine is metabolised to α-ketogluarate and is 
thus a glucogenic amino acid. 
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3.2. Hypothesis 
L-Arginine, L-cysteine and L-lysine reduce food intake by both centrally and peripherally mediated 
mechanisms. 
3.3. Aims 
I aim to investigate the mechanisms mediating the anorectic effects of L-arginine, L-cysteine and L-
lysine. In order to do this I will investigate: 
- The hypothalamic and/or brainstem areas which show neuronal activation following oral 
administration of L-arginine, L-cysteine and l-lysine. 
- The effect of ICV administration of L-arginine, L-cysteine and L-lysine on food intake in the 
rat. 
- The effect of both oral and i.p. administration of L-arginine, L-cysteine and L-lysine on 
plasma levels of specific gut hormones in the rat. 
- The effect of amino acids on GLP-1 release from the NCI-H716 L-cell cell line. 
- The effect of oral and i.p. administration of L-arginine, L-cysteine and L-lysine on plasma 
levels of insulin. 
- The effect of oral and i.p. administration of L-arginine, L-cysteine and L-lysine on food intake 
in the mouse. 
- The effect of oral administration of L-arginine monohydrochloride and L-lysine 
monohydrochloride salts on food intake in rats and mice. 
  
165 
 
3.4. Materials and Methods 
3.4.1. Materials 
All amino acids were purchased from Sigma Aldrich (Poole, Dorset, U.K.). All cannulation materials 
were purchased from Plastics One Inc. (Roanoke, Virginia, U.S.A.). Unless otherwise stated all 
chemicals were purchased from Sigma Aldrich (Poole, Dorset, U.K.). 
3.4.2. Animals 
Male Wistar rats (specific pathogen free (SPF); Charles River, Margate, Kent, U.K.) weighing between 
200-250g (unless otherwise stated) were maintained in individual cages under controlled conditions 
of temperature (21-23°C) and light (12 hours light, 12 hours dark; lights on at 07:00) with ad libitum 
access to food (RM1 diet, Special Diet Services Ltd., Witham, Essex, U.K.) and water (unless 
otherwise stated). 
Male C57BL/6 mice (SPF; Harlan, Bicester, Oxon, U.K.) weighing 18-20g were maintained in 
individual cages under controlled conditions of temperature, light and diet as above. All animal 
procedures conducted were approved by the British Home Office under the Animals (Scientific 
Procedures) Act 1986 (Project Licence number 70/6402). 
3.4.3. The effect of oral administration of L-arginine, L-cysteine, L-lysine and glycine on 
hypothalamic c-fos-like immunoreactivity in rats. 
3.4.3.1. C-fos-like immunoreactivity 
Cellular fos (c-fos) is the cellular homolog of the viral fos (v-fos) oncogene of the Finkel-Biskis-Jinkins 
murine osteosarcoma virus, from which it receives its name. It is a protein encoded by the FOS gene. 
FOS is a proto-oncogene belonging to the immediate early gene family of transcription factors which 
is rapidly and temporarily expressed in certain neurones in response to stimulation. It is therefore 
used as a marker of neuronal activity in the CNS (Morgan and Curran, 1991). Transcriptional 
activation of the FOS gene occurs within minutes of neuronal stimulation, with the accumulation of 
mRNA reaching its peak approximately 30 minutes later and peak Fos protein levels being attained 
by 90 minutes post-stimulation (Gillen and Briski, 1997). Several different types of stimulus have 
been shown to induce expression of c-Fos in CNS neurones, including many pharmacological agents 
(Herrera and Robertson, 1996). C-Fos protein is routinely detected using immunohistochemical 
methods. The c-fos like immunoreactivity (cFLI) observed following peripheral administration of 
specific amino acids would indicate the neurones these amino acids are activating. Anorectic amino 
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acids may, for example, be acting directly on hypothalamic or brain neurones, or indirectly via vagal 
brainstem signalling or by mediating the release of gut hormones that act on the CNS. 
Materials 
0.01M PBS (Appendix III) 
PBS/formaldehyde solution (PBS/FA solution) 
0.01M PBS 
4% (v/v) formaldehyde (VWR International Ltd., Poole, Dorset, U.K.) 
40% (w/v) sucrose solution (Appendix III) 
Antifreeze (Appendix III) 
0.01M PBS 
30% (v/v) ethylene glycol 
20% (v/v) glycerol 
Netwell meshed-insert wells and Netwell reagent trays (VWR International Ltd., Poole, 
Dorset, U.K.) 
PBS/tween solution 
0.01M PBS 
0.05% (v/v) Tween-20 
Methanol/hydrogen peroxide (H2O2) solution 
Methanol 
0.6% (v/v) H2O2 
Blocking solution 
0.01M PBS 
3% (v/v) goat serum (Generon, Maidenhead, Berkshire, U.K.) 
0.25% (v/v) Triton-X-100 
Primary antibody diluent (same as blocking solution) 
Rabbit anti c-fos (AB-5) primary antibody (Merck Chemicals Ltd., Nottingham, 
Nottinghamshire, U.K.) 
Secondary antibody diluent 
0.01M PBS 
0.3% (w/v) BSA 
0.25% (v/v) Triton X-100 
Biotinylated goat anti-rabbit IgG secondary antibody (Vector Laboratories, Orton Southgate, 
Peterborough, U.K.) 
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0.1M Tris/HCl solution (pH 7.6) (Appendix III) 
Streptavidin-Biotin complex conjugated with horseradish peroxidase (ABC/HRP) kit (Dako UK 
Ltd., Ely, Cambridgeshire, U.K.) 
Diaminobenzidine (DAB) solution 
0.01M PBS 
0.5mg/ml DAB 
0.01% (v/v) H2O2 
Poly-L-lysine-coated slides (VWR) 
50% (v/v), 70% (v/v) and 100% ethanol solutions 
Xylene (BDH, Poole, Dorset, U.K.) 
DPX mounting medium (BDH) 
3.4.3.2. Injections 
Male Wistar rats (200-250g) were handled individually for at least 10 minutes daily for three weeks 
to acclimatise them to the partial restraint experienced during injections. This was particularly 
important for this study as acute stressors (such as restraint) have been shown to induce high levels 
of c-fos expression in the hypothalamus of rats (Liu et al., 2007). Throughout this three week period 
the rats received five 2ml oral gavages of water to further acclimatise them to the administration 
procedure. Rats were fasted overnight prior to each of these gavages. Rats were fasted overnight 
(randomised according to body weight; n = 4-6 per group) and received an oral gavage of 2ml of 
either water or 4000µmol/kg L-arginine, L-cysteine, L-lysine or glycine. These doses were based on 
the results from experiments described in chapter 2 in which L-arginine, L-cysteine and L-lysine 
induced potent reductions in food intake in the first hour following gavage. Glycine was used as a 
control amino acid, as it had no effect on food intake (chapter 2). 
Ninety minutes post gavage the rats were killed by i.p. injection of 2.5ml pentobarbitone and then 
transcardially perfused with ice-cold 0.01M PBS to flush the vasculature of blood, maintained under 
constant pressure using an intravenous giving set. Subsequently, PBS/FA solution was perfused 
through the circulation using the same system to fix the neural tissue. The 90 minute time point was 
chosen as peak c-fos protein expression occurs 90 minutes after stimulus exposure (Gillen and Briski, 
1997). Furthermore, this time point is in keeping with similar studies that have been performed 
(Kawasaki et al., 2006). Following perfusion and fixation, the brains were removed and stored in 
PBS/FA solution at 4°C and left overnight for further fixation. After 24 hours, the brains were 
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transferred to 40% sucrose solution to dehydrate them for cryopreservation. They were then frozen 
in isopentane chilled to -80°C and then stored at -80°C until sectioning. 
To provide a positive control for this experiment (for the immunocytochemistry technique), an ad 
libitum fed male Wistar rat was i.p. injected with 10ml/kg of hypertonic saline (1.5M NaCl). 
Peripheral administration of hypertonic saline robustly induces c-fos expression in the SON and PVN 
(Sharp et al., 1991, Penny et al., 2005). Ninety minutes post-injection, the rat was killed and its brain 
harvested as described above. 
3.4.3.3. Immunohistochemistry (IHC) 
Forty micrometre coronal brain sections of the whole hypothalamus were cut using a freezing sled 
microtome (Shandon Southern Products, Ltd., Runcorn, Cheshire, U.K.) and collected into 24-well 
plates containing antifreeze. Sections were stored in antifreeze at -20°C until IHC analysis. 
For IHC, selected sections were transferred into Netwell meshed-insert wells held in Netwell reagent 
trays. SON/PVN sections from the positive control animals were included. Sections were first washed 
in PBS/tween three times for five minutes each time. They were then incubated in methanol/H2O2 
solution for 15 minutes to quench endogenous peroxidase enzyme activity. Sections were then 
washed in PBS/tween a further three times before being incubated in blocking solution for two 
hours. This step was required to try and reduce background staining. A 1:20,000 dilution of primary 
antibody was prepared in primary antibody diluent. The sections were then incubated overnight in 
the primary antibody solution. After the overnight primary antibody incubation, the sections were 
again washed with PBS/tween three times for five minutes each. A 1:400 dilution of secondary 
antibody was prepared in secondary antibody diluent. The sections were then incubated in the 
secondary antibody solution for two hours. The sections were then washed in PBS/tween three 
times for five minutes each time. A working solution of ABC/HRP was prepared by diluting (1:200) 
reagents from the ABC/HRP kit using Tris/HCl solution. Sections were incubated in the working 
ABC/HRP solution for one hour before again being washed in PBS/tween three times. The sections 
were stained in DAB solution for ten minutes. 
The sections were then floated onto poly-L-lysine-coated slides and allowed to dry for a few hours 
before being dehydrated in 50, 70 and 100% ethanol washes, delipidated in xylene and mounted and 
coverslipped using DPX mounting medium. The slides were allowed to dry overnight before being 
viewed under a light microscope. 
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Using a light microscope, the slides were inspected for cFLI-positive nuclei, which were counted by 
an observer blinded to the treatment. The numbers counted within defined hypothalamic nuclei, 
including SON, ARC, PVN, AHA, VMN, DMN and LHA, according to the rat brain atlas of Paxinos and 
Watson (Paxinos and Watson, 1998), were recorded. 
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3.4.4. The effect of oral administration of L-arginine, L-cysteine and L-lysine on brainstem c-fos-like 
immunoreactivity in rats. 
Brains harvested in study 3.4.3. were used for this study. Forty micrometre coronal brain sections of 
the brainstem were cut using a freezing sled microtome and collected into 24-well plates containing 
antifreeze. Sections were stored in antifreeze at -20°C until IHC analysis. Selected sections 
underwent an IHC protocol as described in section 3.4.3.3. SON/PVN sections of the hypothalamus 
of the hypertonic saline-injected animals were used as a positive control for the IHC staining. 
Using a light microscope, the slides were inspected for cFLI-positive nuclei, which were counted by 
an observer blinded to the treatment. The numbers counted within defined brainstem areas, 
including the AP and NTS according to the rat brain atlas of Paxinos and Watson (Paxinos and 
Watson, 1998), were recorded. 
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3.4.5. The effect of ICV administration of specific amino acids in rats 
Materials 
Isofluorane (Abbott Laboratories Ltd, Kent, U.K.). 
Amoxicillin 
Flucloxacillin 
10% (w/v) bovidine-iodine (Betadine) solution (Seton Healthcare, Oldham, Lancashire, U.K.) 
22-gauge stainless steel cannulae and plastic-topped wire stylets (Plastics One Inc.) 
Dental cement (Associated Dental Products Ltd., Kemdent Works, Swindon, Wiltshire, U.K.) 
Buprenorphine (Temgesic; Schering-Plough Ltd., Welwyn Garden City, Hertfordshire, U.K.) 
3.4.5.1. Intracerebroventricular (ICV) cannulation and injections 
Male Wistar rats were anaesthetised with 2L/minute O2 and 4% inhaled isofluorane (Abbott 
Laboratories Ltd, Kent, U.K.). Animals were placed in the induction chamber until they lost the pedal 
reflex. Once anaesthetised, animals were administered prophylactic antibiotics, amoxicillin and 
flucloxacillin (both 37.5mg/kg), by i.p. injection to reduce the risk of post-operative infection.  
Anaesthetised rats were placed on a stereotaxic frame (David Kopf Instruments, supplied by Clark 
Electromedical Instruments, Reading, Berkshire, U.K.), with the incisor bar positioned 3mm below 
the interaural line to assume a flat skull position. Animals were maintained on 2L/minute O2 and 4% 
isofluorane administered through a mask attached to the frame. The surgical area was cleaned with 
Betadine solution. A longitudinal incision of approximately 15mm in length was made using a 
disposable scalpel through the skin over the vertex of the skull and the pericranium removed from 
the underlying bone to expose bregma. The anaesthetic level was reduced at this point to 2L/minute 
O2 and 2% isofluorane. A midline hole 0.8mm posterior to bregma was made through the skull using 
an electric drill to accommodate the cannula. A permanent 22-gauge stainless steel cannula was 
then stereotactically implanted through this hole, 6.5mm below the surface of the skull, into the 
third cerebral ventricle. The cannula was secured and the wound sealed using dental cement 
anchored to three stainless steel jeweller’s screws secured into the cranium. The coordinates of the 
cannula position were calculated using “The Rat Brain in Stereotaxic Coordinates” (Paxinos and 
Watson, 1998). 
Following surgery, the cannula was ‘capped’ using a plastic-topped wire stylet to prevent occlusion 
of the cannula and minimise the potential route for infections. Rats were given an i.p. injection of 
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5ml of 0.9% NaCl (saline) for circulatory support and given subcutaneous (s.c.) buprenorphine 
(45μg/kg) for postoperative analgesia. The animals were left for a seven day recovery period before 
any experimental manipulation but were handled and weighed daily to familiarise them to the 
partial restraint experienced during injections. Only animals with correct cannula placement, as 
confirmed by a sustained drinking response being observed following ICV administration of 
angiotensin-II (50pmol per rat), were included in the studies. Animals were further acclimatised to 
the ICV injection procedure by a subsequent injection of 5μl of saline. Treatments were dissolved in 
saline to the appropriate concentrations and 5μl volumes injected. Injections were administered via 
a 27-gauge stainless steel injector which projected 1mm beyond the guide cannula. The injector was 
connected by polyethylene tubing (inner diameter, 0.5mm; outer diameter, 1mm) to a Hamilton 
syringe (Hamilton Company, Reno, Nevada, U.S.A.) in a Harvard infusion pump (Harvard Apparatus 
Ltd., Edenbridge, Kent, U.K.) set to dispense 5μl solution per minute. The volume of all ICV injections 
administered was 5μl.  
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3.4.5.2. The effect of ICV administration of 100nmol and 1000nmol L-cysteine on food intake in the 
early light phase following an overnight fast in rats.  
Rats were ICV cannulated as described in section 3.4.5.1. Rats were fasted overnight and were ICV 
injected with saline or 100nmol or 1000nmol L-cysteine or 3nmol NDP-MSH per rat (n = 5-9) in the 
early light phase. Following injection, rats were returned to their home cages and given a pre-
weighed amount of chow and free access to water. The food was reweighed at 1, 2, 4, 8 and 24 
hours post-injection.  
3.4.5.3. The effect of ICV administration of 100nmol and 1000nmol L-lysine on food intake in the 
early light phase following an overnight fast in rats.  
Cannulated rats were fasted overnight and were ICV injected with saline or 100nmol or 1000nmol L-
lysine or 3nmol NDP-MSH per rat (n = 5-8) in the early light phase. Following injection, rats were 
returned to their home cages and given a pre-weighed amount of chow and free access to water. 
The food was reweighed at 1, 2, 4, 8 and 24 hours post-injection.  
3.4.5.4. The effect of ICV administration of 100nmol and 1000nmol L-arginine on food intake in the 
early light phase following an overnight fast in rats. 
Cannulated rats were fasted overnight and were ICV injected with saline or 100nmol or 1000nmol L-
arginine or 3nmol NDP-MSH per rat (n = 5-8) in the early light phase. Following injection, rats were 
returned to their home cages and given a pre-weighed amount of chow and free access to water. 
The food was reweighed at 1, 2, 4, 8 and 24 hours post-injection.  
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3.4.6. The effect of oral administration of L-arginine, L-cysteine and L-lysine on plasma levels of gut 
hormones in rats. 
3.4.6.1. The effect of oral administration of L-arginine, L-lysine and L-cysteine on release of gut 
hormones in rats 30 minutes post-administration. 
Male Wistar rats (randomised according to body weight) were fasted overnight and then received an 
oral gavage of 2ml water, 4000umol/kg L-arginine, 4000umol/kg L-lysine or 4000umol/kg L-cysteine 
(n = 8 per group). Animals were returned to their home cages. Thirty minutes post-gavage, animals 
were killed by decapitation for the collection of trunk blood in plastic lithium heparin tubes 
containing 0.6mg aprotinin. Plasma was separated by centrifugation, frozen and stored at -20°C until 
radioimmunoassay for GLP-1, PYY and total ghrelin. Following centrifugation, a sample of plasma 
was acidified with HCl to a final concentration of 1N. This acidified plasma was used for analysis of 
acylated-ghrelin by ELISA. 
The principles of radioimmunoassay (RIA) 
The principle of a RIA is the competition between a radioactive and non-radioactive antigen (the 
peptide to be assayed) for a fixed number of antibody binding sites. Specificity is dependent upon 
the ability of the antibody to recognise structural features of the antigen molecule. When unlabelled 
antigen from standards or samples and a fixed amount of labelled antigen are incubated with a 
constant and limiting amount of antibody, decreasing amounts of labelled antigen are bound to the 
antibody as the amount of unlabelled antigen is increased. Once equilibrium has been reached, 
separation of the bound antigen from the free antigen can be achieved by two methods. The first is 
using a secondary antibody against the primary antibody. Following centrifugation, the complex of 
antigen and the two antibodies form a pellet that can be separated from the supernatant which 
contains unbound antigen. The second method is charcoal adsorption of the unbound antigen. 
Dextran coated charcoal is added to the tubes before centrifugation. The unbound-antigen is 
adsorbed into the porous charcoal, while the larger antibody-antigen complex remains in the 
supernatant. Following separation, the activity in the bound and free components is measured in a 
-counter. The resulting data are used to construct a standard curve from which the values of the 
unknown samples can be calculated. 
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Gut hormone RIAs 
Professor M. Ghatei iodinated the peptides GLP-1, PYY, insulin and ghrelin, using the iodogen 
method. Reaction products were purified by high performance liquid chromatography (HPLC) using a 
C18 column (Waters Corporation, Milford, Connecticut, U.S.A.) (Wood et al., 1981). The solvents 
were acetonitrile and water containing 0.05% (v/v) trifluoroacetic acid (TFA). Solvents were passed 
through a 0.2µm disc filter prior to use. The flow rate was maintained at 1ml/min. The column was 
equilibrated with 15% (v/v) acetonitrile before addition of the iodinated reaction mixture. The 
acetonitrile concentration was maintained at 20% (v/v) for the first ten minutes before being 
gradually increased to 20-45% (v/v) over the following 90 minutes. Fractions of 1.5ml were collected 
into a 1ml solution of 20mM Hepes buffer (pH 11) (to neutralise the acidity of the collected 
fractions) and 0.3% (v/v) bovine serum albumin (BSA). The fractions were tested by RIA and used at 
1,200 counts per minute (cpm) per tube. Antisera were raised in rabbits immunised with each 
peptide conjugated to Freund’s adjuvant. All assays were performed in 0.06M phosphate buffer (pH 
7.4) (0.05M Na2HPO4.2H2O, 0.006M KH2PO4, 0.01M disodium-EDTA.2H2O, 0.008M NaN3) with 0.3% 
BSA, unless otherwise stated. 
All samples were assayed in duplicate. The standard curves for each assay were prepared using 
synthetic peptide (specific to each assay) made up to varying concentrations in assay buffer and 
added in duplicate at volumes of 1, 2, 3, 5, 10, 15, 20, 30, 50 and 100µl. The assays were incubated 
for 72 hours at 4oC. Free and bound peptides were separated using secondary antibody or charcoal 
adsorption. For charcoal adsorption, the free fraction was separated using 4mg of charcoal per tube 
suspended in 0.06M phosphate buffer with gelatine (appendix III), added immediately prior to 
centrifugation. For secondary antibody separation, samples were pre-incubated for at least 60 
minutes with 100µl of goat anti-rabbit solid-phase secondary antibody (Pharmacia Diagnostics AB, 
Uppsala, Sweden). Immediately prior to centrifugation, 500µl of 0.01% Triton-X-100 solution and 
100µl PEG (1:1) was added to each tube. For both charcoal and 2° antibody separation, the samples 
were then centrifuged at 1,500g at 4oC for 20 minutes. Bound and free label were separated and 
both the pellet and supernatant counted for 180 seconds in a γ-counter (model NE1600 (Thermo 
Electron Corporation, San Jose, California, U.S.A.)). Peptide concentrations in the samples were 
calculated using a non-linear plot (RIA software, Thermo Electron Corporation) and the results 
calculated with reference to the standard. 
GLP-1 RIA 
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A sample volume of 100µl of plasma was used and all tubes were buffered in Veronal buffer 
(appendix III) containing 0.3% BSA. A standard concentration of 0.5pmol/ml was used and the 
antiserum was used at a final concentration of 1:50,000. Separation was performed with charcoal. 
The volumes required for all components in the RIA are shown in appendix II. 
PYY RIA 
A sample volume of 200µl of plasma was used and all tubes were buffered in 0.06M phosphate 
buffer (appendix III) containing 0.3% BSA. A standard concentration of 1pmol/ml was used and the 
antiserum was used at a final concentration of 1:50,000. Separation was performed using a goat 
anti-rabbit antibody. The volumes required for all components in the RIA are shown in appendix II. 
Total ghrelin RIA 
A sample volume of 25µl of plasma was used and all tubes were buffered in 0.06M phosphate buffer 
(appendix III) containing 0.3% BSA. A standard concentration of 2pmol/ml was used and the 
antiserum was used at a final concentration of 1:50,000. Separation was performed with charcoal. 
The volumes required for all components in the RIA are shown in appendix II. 
Rat Acylated Ghrelin Enzyme Immunoassay 
Acidified rat plasma samples were used for this assay (1N HCl). A rat acylated ghrelin enzyme 
immunoassay kit was used as was carried out as per manufacturer’s instructions (SPI bio bertin, 
Bertin Pharma, Montigny le Bretonneux, France.) 
3.4.6.2. The effect of oral administration of L-arginine, L-lysine and L-cysteine on release of gut 
hormones in rats 60 minutes post-administration 
Male Wistar rats (randomised according to body weight) were fasted overnight and then received an 
oral gavage of 2ml water, 4000umol/kg L-arginine, 4000umol/kg L-cysteine or 4000umol/kg L-lysine 
(n = 9-10 per group). Animals were returned to their home cages. Sixty minutes post-gavage, animals 
were killed by decapitation and blood was collected and prepared as described in section 3.4.6.1. 
Radioimmunoassays for GLP-1, PYY and total ghrelin were performed as described in section 3.4.6.1. 
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3.4.7. The effect of i.p. administration of L-arginine, L-cysteine and L-lysine on plasma levels of gut 
hormones in rats 30 minutes post-administration 
Male Wistar rats (randomised according to body weight) were fasted overnight and then received an 
i.p. injection of 2ml saline, 2000umol/kg L-arginine, 2000umol/kg L-lysine or 2000umol/kg L-cysteine 
(n = 6-8 per group). Animals were returned to their home cages. Thirty minutes post-injection, 
animals were killed by decapitation and blood was collected and prepared as described in section 
3.4.6.1. Radioimmunoassays for GLP-1, PYY and total ghrelin were performed as described in section 
3.4.6.1. An ELISA was carried out as described in section 3.4.6.1. to determine plasma levels of acyl-
ghrelin. 
3.4.8. The effect of peripheral administration of L-arginine, L-cysteine and L-lysine on plasma levels 
of insulin 
Plasma samples collected in sections 3.4.6. – 3.4.7. were also examined for insulin content using RIA. 
Insulin RIA 
A sample volume of 100µl of plasma was used and all tubes were buffered in 0.06M phosphate 
buffer containing 0.3% BSA and 0.02% Tween. A standard concentration of 1pmol/ml was used and 
the antiserum was used at a final concentration of 1:250,000. Separation was performed with 
charcoal. The volumes required for all components in the RIA are shown in appendix II. 
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3.4.9. The effect of amino acid administration on GLP-1 release from the NCI-H716 cell line. 
The NCI-H716 cell line was derived from cells present in ascites fluid obtained from a patient with 
colorectal carcinoma after treatment with 5-fluorouracil (Park et al., 1987). The cells contain Dopa 
decarboxylase and, unlike other colorectal lines, contain cytoplasmic dense core granules 
characteristic of endocrine secretion (Park et al., 1987). Several groups have confirmed the release 
of GLP-1 from this cell line (Reimer et al., 2001, Lauffer et al., 2009, Yu et al., 2010). 
Cell culture reagents 
Cell culture materials were from GIBCO BRL (Life Technologies, Paisley, Renfrewshire, U.K.). Krebs-
Ringer Bicarbonate buffer (KRB) was purchased from Sigma and was made up as per manufacturer’s 
instructions. 
Cell culture 
NCI-H716 human L-cells were purchased from ATCC (LGC Standards, Teddington, Middlesex, U.K.). 
Cells were cultured in RPMI-1640 medium containing 2 mM L-glutamine, 10 mM HEPES, 1 mM 
sodium pyruvate, 4500 mg/L glucose, and 1500 mg/L sodium bicarbonate, supplemented with 10% 
(v/v) foetal calf serum (FCS) (Invitrogen Ltd), and were maintained at 37°C in a humidified 
atmosphere of 95% air/5% CO2. 
Cell seeding 
Cells were seeded onto 12-well culture plates. Basement membranes are thin extracellular matrices 
underlying cells in vivo. BD MatrigelTM Basement Membrane Matrix is a solubilised basement 
membrane preparation extracted from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma, a tumour 
rich in extracellular matrix proteins. BD MatrigelTM Basement Membrane Matrix aids cell 
attachment. In order to prepare the plates for the cells, each well was coated with 350µl of a 1:100 
dilution of BD MatrigelTM Basement Membrane Matrix for one hour at room temperature. The 
diluent was high glucose Dulbecco’s modified Eagle’s medium (DMEM) containing 10% FCS and 2mM 
L-glutamine. After one hour, unbound material was aspirated and each well was rinsed with 1ml 
DMEM. Cells were centrifuged at 100g for 5 minutes, the media removed and the cells resuspended 
in DMEM. Cells were then seeded into poly-L-lysine coated 12-well plates, with 1ml of cell 
suspension per well at a density of 1 x 106 cells per well. Plates were then left at 37°C in a humidified 
atmosphere of 95% air/5% CO2 for 48 hours before treatment. 
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GLP-1 secretion experiments 
Media was aspirated and each well was washed with 1ml of filtered KRB (pH 7.2) (Sigma), warmed to 
37°C. Cells were then pre-incubated for 120 minutes with KRB to stabilise the cells in their new 
environment. This buffer was then discarded and wells were again washed with 1ml of KRB. Cells 
were then treated as described in sections 3.4.9.1. – 3.4.9.3. 
3.4.9.1. The effect of L-arginine on GLP-1 secretion from NCI-H716 cells 
Following pre-incubation, cells were incubated for 120 minutes at 37°C in a humidified atmosphere 
of 95% air/5% CO2 in 1ml KRB (basal) or 1ml KRB containing L-arginine (1, 10 or 100mM) (n = 12). 
Following the treatment incubation, the supernatant was collected and stored at -20°C for 
subsequent by RIA. 
3.4.9.2. The effect of L-cysteine on GLP-1 secretion from NCI-H716 cells 
The protocol was as per study 3.4.9.1. except that cells were incubated with 1ml KRB (basal) or 1ml 
KRB containing L-cysteine (1, 10 or 100mM) (n = 10). 
3.4.9.3. The effect of L-lysine on GLP-1 secretion from NCI-H716 cells 
The protocol was as per study 3.4.9.1. except that cells were incubated with 1ml KRB (basal) or 1ml 
KRB containing L-lysine (1, 10 or 100mM) (n = 12). 
3.4.10. Confirmation of the anorectic effect of L-arginine, L-cysteine and L-lysine in mice 
3.4.10.1. The effect of oral administration of L-arginine on food intake in the early light phase 
following an overnight fast in mice. 
Male C57BL/6 mice were fasted overnight and then received an oral gavage of 200µl water or L-
arginine at a dose of 4000µmol/kg or 8000µmol/kg (n = 9-10). Following oral gavage, animals were 
returned to their home cages and given a pre-weighed amount of chow and free access to water. 
The food was reweighed at 1, 2, 4, 8 and 24 hours post-gavage. 
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3.4.10.2. The effect of oral administration of L-cysteine on food intake in the early light phase 
following an overnight fast in mice. 
Male C57BL/6 mice were fasted overnight and then received an oral gavage of 100µl water or L-
cysteine at a dose of 4000µmol/kg or 8000µmol/kg (n = 9). Following oral gavage, animals were 
returned to their home cages and given a pre-weighed amount of chow and free access to water. 
The food was reweighed at 1, 2, 4, 8 and 24 hours post-gavage. 
3.4.10.3. The effect of oral administration of L-lysine on food intake in the early light phase 
following an overnight fast in mice. 
Male C57BL/6 mice were fasted overnight and then received an oral gavage of 100µl water or L-
lysine at a dose of 4000µmol/kg or 8000µmol/kg (n = 10). Following oral gavage, animals were 
returned to their home cages and given a pre-weighed amount of chow and free access to water. 
The food was reweighed at 1, 2, 4, 8 and 24 hours post-gavage. 
3.4.10.4. The effect of i.p. administration of L-arginine on food intake in the early light phase 
following an overnight fast in mice. 
Male C57BL/6 mice were fasted overnight and then received an i.p. injection of 150µl saline or L-
arginine at a dose of 1000µmol/kg, 2000µmol/kg or 4000µmol/kg (n = 8-9). Following injection, 
animals were returned to their home cages and given a pre-weighed amount of chow and free 
access to water. The food was reweighed at 1, 2, 4, 8 and 24 hours post-injection. 
3.4.10.5. The effect of i.p. administration of L-cysteine on food intake in the early light phase 
following an overnight fast in mice. 
Male C57BL/6 mice were fasted overnight and then received an i.p. injection of 100µl saline or L-
cysteine at a dose of 1000µmol/kg, 2000µmol/kg or 4000µmol/kg (n = 8-9 per group). Following 
injection, animals were returned to their home cages and given a pre-weighed amount of chow and 
free access to water. The food was reweighed at 1, 2, 4, 8 and 24 hours post-injection. 
3.4.10.6. The effect of i.p. administration of L-lysine on food intake in the early light phase 
following an overnight fast in mice. 
Male C57BL/6 mice were fasted overnight and then received an i.p. injection of 100µl saline or L-
lysine at a dose of 1000µmol/kg, 2000µmol/kg or 4000µmol/kg (n = 8-9). Following injection, 
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animals were returned to their home cages and given a pre-weighed amount of chow and free 
access to water. The food was reweighed at 1, 2, 4, 8 and 24 hours post-injection. 
3.4.11. The effect of oral administration of L-arginine monohydrochloride and L-lysine 
monohydrochloride on food intake in the early light phase following an overnight fast in rats and 
mice. 
L-Arginine and L-lysine are basic amino acids. At the oral doses administered (4000µmol/kg) the pH 
would be approximately 11.7 for L-arginine and approximately 10.3 for L-lysine (for a 250g rat). To 
determine whether the anorectic effects of these amino acids might be secondary to pH, I 
investigated whether the hydrochloride salts of these amino acids, which have a neutral pH in 
solution, also induced a reduction in food intake. The hydrochloride salt of L-Cysteine was not 
tested, as L-cysteine has a relatively neutral pH (the 4000µmol/kg oral dose for a 250g rat would be 
approximately pH 5.2), whilst the salt is very acidic. 
3.4.11.1. The effects of oral administration of L-arginine monohydrochloride, L-lysine 
monohydrochloride and L-cysteine on food intake in the early light phase following an overnight 
fast in rats. 
Male Wistar rats were fasted overnight and then received an oral gavage of 1ml water or L-arginine 
monohydrochloride, L-lysine monohydrochloride or L-cysteine at a dose of 4000μmol/kg (n = 6-12 
per group). Following injection, animals were returned to their home cages and given a pre-weighed 
amount of chow and free access to water. The food was reweighed at 1, 2, 4, 8 and 24 hours post-
injection. 
3.4.11.2. The effects of oral administration of L-arginine monohydrochloride, L-lysine 
monohydrochloride and L-cysteine on food intake in the early light phase following an overnight 
fast in mice. 
Male C57BL/6 mice were fasted overnight and then received an oral gavage of 100μl water or L-
arginine monohydrochloride, L-lysine monohydrochloride or L-cysteine at a dose of 8000μmol/kg (n 
= 4-8 per group). Following injection, animals were returned to their home cages and given a pre-
weighed amount of chow and free access to water. The food was reweighed at 1, 2, 4, 8 and 24 
hours post-injection. 
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3.4.12. Statistical analysis 
C-fos data are shown as median values ± interquartile range. Food intake data are shown as mean 
values ± standard error of the mean (S.E.M.). Hormone levels from both plasma and cell 
supernatants are shown as mean values ± S.E.M. 
For the c-fos studies, differences between the treatment groups were determined using the Kruskal-
Wallis one-way ANOVA on ranks, followed by a post hoc Dunn’s test (Stata 9, Statacorp, College 
Station, Texas, U.S.A.). Data from the food intake studies were analysed using a one-way analysis of 
variance (ANOVA) test, followed by a post hoc Dunnett’s test (GraphPad Prism 5 software). For 
studies involving hormone levels, data were analysed using a one-way analysis of variance (ANOVA) 
test, followed by a post hoc Dunnett’s test (GraphPad Prism 5 software). In all cases, p < 0.05 was 
considered to be statistically significant. 
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3.5. Results 
3.5.1. The effect of oral administration of 4000µmol/kg L-arginine, L-cysteine, glycine and L-lysine 
on hypothalamic c-fos-like immunoreactivity in rats. 
Oral administration of 4000µmol/kg Glycine significantly increased cFLI in the VMN compared to 
water-treated controls (Table 3.1.). Oral administration of 4000µmol/kg L-arginine, L-cysteine, L-
lysine or glycine did not induce a significant increase in cFLI in any other hypothalamic nuclei 
measured (Table 3.1.). L-Cysteine increased cFLI in the SON but the n-numbers for this group were 
too few to statistically analyse due to insufficient matched sections for this nucleus.   
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Hypothalamic 
nucleus 
cFLI positive counts 
Water L-Arginine L-Cysteine Glycine L-Lysine 
SON 6 7 (7-11) 59 (43-68) 3.5 (3-8) 5 (4.50-5.50) 
ARC 3 (2.50-4.75) 11 (10-12) 11.75 (10.38-15.50) 9 (7.50-14) 11 (6.50-11.50) 
PVN 13.75 (8.63-18.88) 24.50 (16-31) 23 (17.50-25.50) 24.5 (19-27) 25 (18-27) 
AHA 27.75 (16.13-39.38) 27 (22-30) 12.5 (12.25-18.75) 24 (21.50-51.500) 39.50 (37.75-45.75) 
VMN 8 14 (12-21) 10 (9.50-10.38) 28 (23-29)* 12 (11-14) 
DMN 24.50 (22-28.75) 38.50 (33-42) 21.25 (20.38-24.25) 30 (29.50-37.75) 25 (23.50-29) 
LHA 12 (8-18.50) 16 (11-33) 13 (12-13.50) 12 (10.50-21.50) 30 (26-33.50) 
Table 3.1. The effect of oral administration of water or 4000µmol/kg L-arginine, L-cysteine, glycine or L-lysine on cFLI-positive cell counts in 
hypothalamic nuclei in rats. 
Table summarising cFLI-positive cell counts observed in hypothalamic nuclei following oral administration of water or 4000µmol/kg L-arginine, L-Cysteine, 
glycine or L-lysine. Data are presented as median (interquartile range), except where group had an n of one, in which case the actual value is shown. 
* = p < 0.05 vs. water; n = 1-4 per group. 
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2.5.2. The effect of oral administration of 4000µmol/kg L-arginine, L-cysteine, glycine and L-lysine 
on brainstem c-fos-like immunoreactivity in rats. 
Oral administration of 4000µmol/kg L-cysteine induced a significant increase in cFLI in the NTS 
compared to water-treated controls. Oral administration of 4000µmol/kg L-cysteine also increased 
cFLI in the AP but the n-numbers for this group were too few to statistically analyse. No other 
treatment induced changes in cFLI in the NTS or the AP of the brainstem (Table 3.2 and Figures 3.3 
and 3.4). 
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Hypothalamic 
nucleus 
cFLI positive counts 
Water L-Arginine L-Cysteine Glycine L-Lysine 
NTS 15 (14-16) 25.25 (16.50-33.88) 36 (21.50-36.50)* 16 (15-17.50) 17.50 (14-23) 
AP 8 (7.50-10.75) 19 (13.63-25.25) 51.75 (50.13-53.38) 6.50 (6.25-6.75) 14 (12.50-18) 
               
               
Table 3.2. The effect of oral administration of water or 4000µmol/kg L-arginine, L-cysteine, Glycine or L-lysine on cFLI-positive cell counts in brainstem 
areas in rats. 
Table summarising cFLI-positive cell counts observed in brainstem areas following oral administration of water or 4000µmol/kg L-arginine, L-cysteine, 
glycine or L-lysine. Data are presented as median (interquartile range). 
* = p < 0.05 vs. water; n = 2-5 per group. 
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Figure 3.3. Effect of oral administration of water or 4000µmol/kg L-arginine, L-cysteine, glycine or 
L-lysine  on cFLI-positive neurone counts in brainstem areas in rats. 
(A) cFLI-positive counts in the nucleus tractus solitarius, (B) cFLI-positive counts in the area 
postrema. Open bars represent the first to third quartiles with median values represented by the 
horizontal lines within the open bars. Whisker bars indicate the minimum and maximum values 
counted for that nucleus from rats within that group. * = p < 0.05 vs. water; n = 2-5 per group. 
L-Arg, L-arginine; L-Cys, L-cysteine, Gly, glycine, L-Lys, L-lysine. 
  
A 
B 
 
 
 188 
 
  
  
  
Figure 3.4. Representative light-field photomicrographs of the effect of oral administration of 
water or 4000µmol/kg L-cysteine or glycine on nucleus tractus solitarius and area postrema cFLI in 
rats. 
100x magnification in the nucleus tractus solitarius of (A) water-treated, (B) L-cysteine treated and 
(C) glycine-treated animals; and area postrema of water-treated (D), L-cysteine treated (E) and 
glycine-treated (F) animals. Scale bars = 100µm.  
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3.5.3. The effect of ICV injection of specific amino acids on food intake in the early light phase 
following an overnight fast in rats. 
3.5.3.1. The effect of ICV administration of 100nmol and 1000nmol L-cysteine on food intake in the 
early light phase following an overnight fast in rats. 
Intracerebroventricular administration of 100nmol L-cysteine significantly increased food intake 1-2 
hours post-administration compared to saline-injected controls (1-2 hour food intake, saline: 0.4 ± 
0.1g vs. 100nmol L-cysteine: 2.8 ± 0.8g, p < 0.005 vs. saline, n = 8-9 per group) (Figure 3.5. B). No 
dose of L-cysteine significantly altered food intake at any other time point measured. As expected, 
ICV administration of 3nmol NDP-MSH significantly reduced 0-1 hour food intake compared to 
saline-injected controls (0-1 hour food intake, saline: 4.8 ± 0.5g vs. 3nmol NDP-MSH: 0.6 ± 0.2g, p < 
0.001 vs. saline, n = 5-9 per group) (Figure 3.5. A). This reduction in food intake was sufficient to 
make longer cumulative time points statistically significant i.e. the 0-2 hour time point (0-2 hour 
food intake, saline: 5.1 ± 0.5g vs. 3nmol NDP-MSH: 3.4 ± 1.0g, p < 0.05 vs. saline, n = 5-9 per group) 
and the 0-4 hour time point (0-4 hour food intake, saline: 7.8 ± 1.2g vs. 3nmol NDP-MSH: 5.8 ± 1.0g, 
p < 0.05 vs. saline, n = 5-9 per group) (Figure 3.6.).  
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Figure 3.5. The effect of ICV administration of 100nmol and 1000nmol L-cysteine on food intake in 
the early light phase following an overnight fast in rats. 
Rats were ICV injected with (i) saline, (ii) 100nmol, (iii) 1000nmol L-cysteine or (iv) 3nmol NDP-MSH. 
(A) 0-1 hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 hour; (E) 8-24 hour; (F) 0-24 hour food intake post 
injection. Data are expressed as mean ± S.E.M. ** = p < 0.005 vs. saline; *** = p < 0.001 vs. saline; n 
= 5-9 per group.  
A B 
C D 
F E 
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Figure 3.6. The effect of ICV administration of 100nmol and 1000nmol L-cysteine on cumulative 
food intake in the early light phase following an overnight fast in rats. 
Rats were ICV injected with (i) saline, (ii) 100nmol, (iii) 1000nmol L-cysteine or (iv) 3nmol NDP-MSH. 
(A) 0-2 hour; (B) 0-4 hour food intake post injection. Data are expressed as mean ± S.E.M. * = p < 
0.05 vs. saline; n = 5-9 per group.  
A B 
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3.5.3.2. The effect of ICV administration of 100nmol and 1000nmol L-lysine on food intake in the 
early light phase following an overnight fast in rats. 
Intracerebroventricular administration of 100nmol or 1000nmol L-lysine did not significantly alter 
food intake at any time point measured. As expected, ICV administration of 3nmol NDP-MSH 
significantly reduced 0-1 hour food intake compared to saline-injected controls (0-1 hour food 
intake, saline: 5.1 ± 0.6g vs. 3nmol NDP-MSH: 1.9 ± 0.2g, p < 0.005 vs. saline, n = 5-8 per group) 
(Figure 3.7. A). This reduction in food intake was sufficient to make the reduction in longer 
cumulative time periods statistically significant i.e. the 0-2 hour time point (0-2 hour food intake, 
saline: 6.7 ± 0.4g vs. 3nmol NDP-MSH: 3.6 ± 0.6g, p < 0.005 vs. saline, n = 5-8 per group), the 0-4 
hour time point (0-4 hour food intake, saline: 9.0 ± 0.5g vs. 3nmol NDP-MSH: 4.2 ± 0.9g, p < 0.001 vs. 
saline, n = 5-8 per group) and the 0-8 hour time point (0-8 hour food intake, saline: 15.7 ± 0.6g vs. 
3nmol NDP-MSH: 9.8 ± 1.5g, p < 0.005 vs. saline, n = 5-8 per group) (Figure 3.8.).  
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Figure 3.7. The effect of ICV administration of 100nmol and 1000nmol L-lysine on food intake in 
the early light phase following an overnight fast in rats. 
Rats were ICV injected with (i) saline, (ii) 100nmol, (iii) 1000nmol L-lysine or (iv) 3nmol NDP-MSH. (A) 
0-1 hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 hour; (E) 8-24 hour; (F) 0-24 hour food intake post 
injection. Data are expressed as mean ± S.E.M. ** = p < 0.005 vs. saline; n = 5-8 per group. 
A 
F E 
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Figure 3.8. The effect of ICV administration of 100nmol and 1000nmol L-lysine on cumulative food 
intake in the early light phase following an overnight fast in rats. 
Rats were ICV injected with (i) saline, (ii) 100nmol, (iii) 1000nmol L-lysine or (iv) 3nmol NDP-MSH. (A) 
0-2 hour; (B) 0-4 hour; (C) 0-8 hour food intake post injection. Data are expressed as mean ± S.E.M. 
** = p < 0.005 vs. saline;*** = p < 0.001 vs. saline;  n = 5-8 per group.  
A B 
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3.5.3.3. The effect of ICV administration of 100nmol and 1000nmol L-arginine on food intake in the 
early light phase following an overnight fast in rats. 
Intracerebroventricular administration of 100nmol or 1000nmol L-arginine did not significantly alter 
food intake at any time point measured. As expected, ICV administration of 3nmol NDP-MSH 
significantly reduced 0-1 hour food intake compared to saline-injected controls (0-1 hour food 
intake, saline: 5.9 ± 0.6g vs. 3nmol NDP-MSH: 1.0 ± 0.3g, p < 0.001 vs. saline, n = 5-8 per group) 
(Figure 3.9. A). Administration of 3nmol NDP-MSH also significantly reduced 4-8 hour food intake 
compared to saline-injected controls (4-8 hour food intake, saline: 6.7 ± 1.0g vs. 3nmol NDP-MSH: 
3.3 ± 1.0g, p < 0.05 vs. saline, n = 5-8 per group) (Figure 3.9. D). The reduction in food intake induced 
by 3nmol NDP-MSH was sufficient to make longer cumulative time points statistically significant i.e. 
the 0-2 hour time point (0-2 hour food intake, saline: 7.9 ± 0.9g vs. 3nmol NDP-MSH: 3.4 ± 1.2g, p < 
0.005 vs. saline, n = 5-8 per group), the 0-4 hour time point (0-4 hour food intake, saline: 10.2 ± 0.6g 
vs. 3nmol NDP-MSH: 4.7 ± 1.6g, p < 0.005 vs. saline, n = 5-8 per group), the 0-8 hour time point (0-8 
hour food intake, saline: 16.9± 0.9g vs. 3nmol NDP-MSH: 8.0± 1.7g, p < 0.001 vs. saline, n = 5-8 per 
group) and the 0-24 hour time point (0-24 hour food intake, saline: 39.3 ± 1.1g vs. 3nmol NDP-MSH: 
31.4 ± 2.2g, p < 0.05 vs. saline, n = 5-8 per group) (Figure 3.10.). 
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Figure 3.9. The effect of ICV administration of 100nmol and 1000nmol L-arginine on food intake in 
the early light phase following an overnight fast in rats. 
Rats were ICV injected with (i) saline, (ii) 100nmol, (iii) 1000nmol L-arginine or (iv) 3nmol NDP-MSH. 
(A) 0-1 hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 hour; (E) 8-24 hour; (F) 0-24 hour food intake post 
injection. Data are expressed as mean ± S.E.M. * = p < 0.05 vs. saline; *** = p < 0.001 vs. saline; n = 
5-8 per group. 
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Figure 3.10. The effect of ICV administration of 100nmol and 1000nmol L-arginine on cumulative 
food intake in the early light phase following an overnight fast in rats. 
Rats were ICV injected with (i) saline, (ii) 100nmol, (iii) 1000nmol L-arginine or (iv) 3nmol NDP-MSH. 
(A) 0-2 hour; (B) 0-4 hour; (C) 0-8 hour food intake post injection. Data are expressed as mean ± 
S.E.M. ** = p < 0.005 vs. saline;*** = p < 0.001 vs. saline;  n = 5-8 per group.  
A 
C 
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3.5.4. The effect of oral administration of L-arginine, L-cysteine and L-lysine on plasma levels of gut 
hormones in rats 
3.5.4.1. The effect of oral administration of L-arginine, L-lysine and L-cysteine on release of gut 
hormones in rats 30 minutes post-administration 
Oral administration of 4000µmol/kg L-lysine significantly increased plasma levels of GLP-1 
immunoreactivity 30 minutes later compared to levels in water-treated animals (GLP-1, water: 62.5 
± 7.8pmol/l vs. L-lysine: 129.7 ± 10.6pmol/l, p < 0.001 vs. water, n = 7-8 per group) (Figure 3.11. A). 
L-Cysteine did not affect plasma levels of GLP-1 immunoreactivity whilst L-arginine tended to 
increase plasma levels of GLP-1 immunoreactivity (Figure 3.11. A). 
Oral administration of 4000µmol/kg L-arginine significantly increased plasma levels of PYY 
immunoreactivity 30 minutes later compared to levels in water-treated animals (PYY, water: 25.8 ± 
5.7pmol/l vs. L-arginine: 39.1 ± 11.1pmol/l, p < 0.005, n = 8 per group) (Figure 3.11. C). L-Cysteine did 
not significantly affect plasma levels of PYY immunoreactivity whilst L-lysine tended to increase 
plasma levels of PYY immunoreactivity (Figure 3.11. C). 
No treatment given significantly affected plasma levels of total ghrelin immunoreactivity (Figure 
3.12. A) or acylated ghrelin immunoreactivity (Figure 3.12. C) 30 minutes after administration. 
However, L-cysteine tended to reduce plasma levels of acylated ghrelin immunoreactivity (Figure 
3.12. C). Oral administration of 4000µmol/kg L-cysteine reduced acylated ghrelin immunoreactivity 
as a percentage of total ghrelin by around 40%, but this effect was not statistically significant (Figure 
3.12. D). 
3.5.4.2. The effect of oral administration of L-arginine, L-lysine and L-cysteine on release of gut 
hormones in rats 60 minutes post-administration. 
Oral administration of 4000µmol/kg L-arginine and L-lysine significantly increased plasma levels of 
GLP-1 immunoreactivity 60 minutes later compared to levels in water-treated animals (GLP-1, water: 
64.8 ± 5.5pmol/l vs. L-arginine: 101.6 ± 16.4pmol/l, p < 0.05 vs. water; L-lysine: 126.5 ± 7.3pmol/l, p 
< 0.001 vs. water, n = 8-9 per group) (Figure 3.11. B). L-Cysteine did not affect plasma levels of GLP-1 
immunoreactivity (Figure 3.11. B). 
Oral administration of 4000µmol/kg L-lysine significantly increased plasma levels of PYY 
immunoreactivity 60 minutes later compared to levels in water-treated animals (PYY, water: 48.1 ± 
2.6pmol/l vs. L-lysine: 77.4 ± 2.6pmol/l, p < 0.001 vs. water, n = 9 per group) (Figure 3.11. D). Oral 
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administration of L-arginine or L-cysteine did not affect plasma levels of PYY immunoreactivity 
(Figure 3.11. D). 
No treatment affected plasma levels of total ghrelin immunoreactivity however oral administration 
of L-cysteine tended to reduce plasma levels of total ghrelin immunoreactivity (Figure 3.12. B). 
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Figure 3.11. The effect of oral administration of L-arginine, L-lysine and L-cysteine on plasma levels 
of GLP-1 and PYY immunoreactivity. 
Animals received an oral gavage of water or 4000µmol/kg L-arginine, L-lysine or L-cysteine and were 
decapitated 30 minutes (A and C) or 60 minutes (B and D) later. Plasma levels of GLP-1 
immunoreactivity (A and B) and PYY immunoreactivity (C and D) were measured. Data are expressed 
as mean ± S.E.M. * = p < 0.05 vs. water; ** = p < 0.005 vs. water; *** = p < 0.001 vs. water; n = 7-8 
per group (A and C) or 8-10 per group (B and D). 
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Figure 3.12. The effect of oral administration of L-arginine, L-lysine and L-cysteine on plasma levels 
of ghrelin immunoreactivity. 
Animals received an oral gavage of water or 4000µmol/kg L-arginine, L-lysine or L-cysteine and were 
decapitated 30 minutes (A, C and D) or 60 minutes (B) later. Plasma levels of total ghrelin 
immunoreactivity (A and B) and acylated ghrelin immunoreactivity (C) were measured. (D) shows 
plasma levels of acylated ghrelin immunoreactivity as a percentage of total ghrelin immunoreactivity 
in the 60 minute study. Data are expressed as mean ± S.E.M. n = 7-8 per group (A, C and D) or 8-10 
per group (B). 
 
  
A 
C 
B 
D 
 
 
 202 
3.5.5. The effect of i.p. administration of L-arginine, L-cysteine and L-lysine on plasma levels of gut 
hormones in rats 30 minutes post-administration. 
No treatment given affected plasma levels of GLP-1 or PYY (Figure 3.13. A and B). 
Intraperitoneal administration of 2000µmol/kg L-cysteine significantly reduced plasma levels of total 
ghrelin immunoreactivity 30 minutes later compared to levels in saline-treated animals (total 
ghrelin, saline: 886.5 ± 81.0pmol/l vs. L-cysteine: 461.6 ± 31.8pmol/l, p < 0.005 vs. saline, n = 6-8 per 
group) (Figure 3.11. C). L-Arginine or L-lysine did not affect plasma levels of total ghrelin 
immunoreactivity (Figure 3.13. C). 
Intraperitoneal administration of 2000µmol/kg L-cysteine also significantly reduced plasma levels of 
acylated ghrelin immunoreactivity 30 minutes later compared to levels in saline-treated animals 
(acyl-ghrelin, saline: 22.3 ± 1.2pmol/l vs. L-cysteine: 9.2 ± 2.4pmol/l, p < 0.05 vs. saline, n = 6-7 per 
group) (Figure 3.13. D). L-Arginine or L-lysine did not affect plasma levels of acylated ghrelin 
immunoreactivity (Figure 3.13. D). 
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Figure 3.13. The effect of i.p. administration of L-arginine, L-lysine and L-cysteine on plasma levels 
of gut hormones. 
Animals received an i.p. injection of saline or 2000µmol/kg L-arginine, L-lysine or L-cysteine and 
were decapitated 30 minutes later. Plasma levels of GLP-1 immunoreactivity (A), PYY 
immunoreactivity (B), total ghrelin immunoreactivity (C) and acylated ghrelin (D) were measured. (E) 
shows plasma levels of acylated ghrelin immunoreactivity as a percentage of total ghrelin 
immunoreactivity. Data are expressed as mean ± S.E.M. * = p < 0.05 vs. saline; ** = p < 0.005 vs. 
saline; n = 6-8 per group.  
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3.4.6. The effect of peripheral administration of L-arginine, L-cysteine and L-lysine on plasma levels 
of insulin. 
Oral administration of 4000µmol/kg L-cysteine significantly increased plasma levels of insulin 30 
minutes later compared to levels in water-treated animals (insulin, water: 68.0 ± 7.7pmol/l vs. L-
cysteine: 125.7 ± 20.7pmol/l, p < 0.005, n = 8 per group) (Figure 3.14. A). Oral administration of L-
arginine and L-lysine did not significantly affect plasma levels of insulin 30 minutes later (Figure 3.14. 
A). No treatment affected plasma levels of insulin 60 minutes post-administration (Figure 3.14. B). 
Intraperitoneal administration of 2000µmol/kg L-lysine significantly increased plasma levels of 
insulin 30 minutes later compared to levels in saline-treated animals (insulin, saline: 94.9 ± 
15.1pmol/l vs. L-lysine: 160.2 ± 16.1pmol/l, p < 0.05 vs. saline, n = 8 per group) (Figure 3.14. C). L-
Arginine or L-cysteine did not affect plasma levels of insulin (Figure 3.14. C). 
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Figure 3.14. The effect of peripheral administration of L-arginine, L-lysine and L-cysteine on plasma 
levels of insulin. 
Animals received an oral gavage (A and B) of water or 4000µmol/kg L-arginine, L-lysine or L-cysteine 
and were decapitated 30 minutes (A) or 60 minutes (B) later. Plasma levels of insulin were 
measured. A separate batch of animals received an i.p. injection of saline or 4000µmol/kg L-arginine, 
L-lysine or L-cysteine and were decapitated 30 minutes later (C). Data are expressed as mean ± 
S.E.M. * = p < 0.05 vs. control; ** = p < 0.005 vs. control; n = 6-10 per group. 
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3.5.7. The effect of amino acid administration on GLP-1 secretion from the NCI-H716 cell line. 
3.5.7.1. The effect of 1mM, 10mM and 100mM L-arginine on GLP-1 secretion from NCI-H716 cells. 
Incubation with 100mM L-arginine for 120 minutes significantly increased GLP-1 secretion compared 
to basal release (GLP-1, KRB: 0.03 ± 0.00µmol/l vs. 100mM L-arginine: 1.59 ± 0.29µmol/l, p < 0.001, n 
= 11-12 per group) (Figure 3.15. A). No other dose of L-arginine significantly affected GLP-1 secretion 
(Figure 3.15. A). 
3.5.7.2. The effect of 1mM, 10mM and 100mM L-cysteine on GLP-1 release from NCI-H716 cells. 
No dose of L-cysteine significantly affected GLP-1 secretion (Figure 3.15. B). 
3.5.7.3. The effect of 1mM, 10mM and 100mM L-lysine on GLP-1 release from NCI-H716 cells. 
Incubation with 100mM L-lysine for 120 minutes significantly increased GLP-1 secretion compared to 
basal release (GLP-1, KRB: 0.22 ± 0.05µmol/l vs. 100mM L-lysine: 1.55 ± 0.21µmol/l, p < 0.001, n = 12 
per group) (Figure 3.15. C). No other dose of L-lysine significantly affected GLP-1 secretion (Figure 
3.15. C). 
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Figure 3.15. The effect of (A) L-arginine, (B) L-cysteine and (C) L-lysine on GLP-1 release from NCI-
H716 cells. 
Cells were incubated for 120 minutes with (i) KRB or (A) L-arginine, (B) L-cysteine or (C) L-lysine 
(conducted separately) at concentrations of (ii) 1mM, (iii) 10mM or (iv) 100mM. Data are expressed 
as mean ± S.E.M. *** = p < 0.001 vs. KRB; n = 11-12 per group for (A); n = 9-10 per group for (B); n = 
10-12 per group for (C). 
A 
 
B 
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3.5.8. Confirmation of the anorectic effect of L-arginine, L-cysteine and L-lysine in mice 
3.5.8.1. The effect of oral administration of L-arginine on food intake in the early light phase 
following an overnight fast in mice. 
Oral administration of 4000µmol/kg and 8000µmol/kg L-arginine failed to significantly reduce food 
intake at any of the time points measured (Figure 3.16.).  
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Figure 3.16. The effect of oral administration of 4000µmol/kg and 8000µmol/kg L-arginine on food 
intake in the early light phase following an overnight fast in mice. 
Mice were orally gavaged with (i) water, (ii) 4000µmol/kg or (iii) 8000µmol/kg L-arginine. (A) 0-1 
hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 hour; (E) 8-24 hour; (F) 0-24 hour food intake post injection. 
Data are expressed as mean ± S.E.M.; n = 7-10 per group. 
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3.5.8.2. The effect of oral administration of L-cysteine on food intake in the early light phase 
following an overnight fast in mice. 
Oral administration of 4000µmol/kg and 8000µmol/kg L-cysteine significantly reduced food intake 0-
1 hours post-administration compared to water-treated controls (0-1 hour food intake, water: 0.7 ± 
0.1g vs. 4000µmol/kg L-cysteine: 0.3 ± 0.1g, p < 0.005 vs. water; 8000µmol L-cysteine: 0.2 ± 0.1g, p < 
0.001 vs. water,  n = 8-9 per group) (Figure 3.17. A). The reduction in food intake induced by 
8000µmol/kg L-cysteine was sufficient to make reductions over longer cumulative time periods 
statistically significant i.e. the 0-2 hour time point (0-2 hour food intake, water: 0.8 ± 0.1g 
vs.8000µmol/kg L-cysteine: 0.3 ± 0.1g, p < 0.05 vs. water, n = 9 per group) (Figure 3.18. A), the 0-8 
hour time point (0-8 hour food intake, water: 2.5 ± 0.1g vs.8000µmol/kg L-cysteine: 1.4 ± 0.4g, p < 
0.05 vs. water, n = 9 per group) (Figure 3.18. B)  and the 0-24 hour time point (0-24 hour food intake, 
water: 5.9 ± 0.2g vs. 8000µmol/kg L-cysteine: 4.1 ± 0.8g, p < 0.05 vs. water, n = 9 per group) (Figure 
3.18. F). No dose of L-cysteine significantly altered food intake at any other time point measured.  
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Figure 3.17. The effect of oral administration of 4000µmol/kg and 8000µmol/kg L-cysteine on food 
intake in the early light phase following an overnight fast in mice. 
Mice were orally gavaged with (i) water, (ii) 4000µmol/kg or (iii) 8000µmol/kg L-cysteine. (A) 0-1 
hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 hour; (E) 8-24 hour; (F) 0-24 hour food intake post injection. 
Data are expressed as mean ± S.E.M. * = p < 0.05 vs. water; ** = p < 0.005 vs. water; *** = p < 0.001 
vs. water; n = 8-9 per group. 
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Figure 3.18. The effect of oral administration of 4000µmol/kg and 8000µmol/kg L-cysteine on 
cumulative food intake in the early light phase following an overnight fast in mice. 
Mice were orally gavaged with (i) water, (ii) 4000µmol/kg or (iii) 8000µmol/kg L-cysteine. (A) 0-2 
hour; (B) 0-8 hour food intake post injection. Data are expressed as mean ± S.E.M. * = p < 0.05 vs. 
water; n = 8-9 per group. 
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3.5.8.3. The effect of oral administration of L-lysine on food intake in the early light phase 
following an overnight fast in mice. 
Oral administration of 8000µmol/kg L-lysine significantly reduced food intake 0-1 hours post-
administration compared to water-treated controls (0-1 hour food intake, water: 0.6 ± 0.0g vs. 
8000µmol/kg L-lysine: 0.4 ± 0.1g, p < 0.001 vs. water, n = 10 per group) (Figure 3.19. A). This 
reduction in food intake was sufficient to make the longer cumulative 0-2 hour time point 
statistically significant (0-2 hour food intake, water: 0.9 ± 0.0g vs. 8000µmol/kg L-lysine: 0.6 ± 0.1g, p 
< 0.005 vs. water, n = 10 per group) (Figure 3.20. A). No dose of L-lysine significantly altered food 
intake at any other time point measured.  
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Figure 3.19. The effect of oral administration of 4000µmol/kg and 8000µmol/kg L-lysine on food 
intake in the early light phase following an overnight fast in mice. 
Mice were orally gavaged with (i) water, (ii) 4000µmol/kg or (iii) 8000µmol/kg L-lysine. (A) 0-1 hour; 
(B) 1-2 hour; (C) 2-4 hour; (D) 4-8 hour; (E) 8-24 hour; (F) 0-24 hour food intake post injection. Data 
are expressed as mean ± S.E.M. *** = p < 0.001 vs. water; n = 10 per group.  
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Figure 3.20. The effect of oral administration of 4000µmol/kg and 8000µmol/kg L-lysine on 
cumulative food intake in the early light phase following an overnight fast in mice. 
Mice were orally gavaged with (i) water, (ii) 4000µmol/kg or (iii) 8000µmol/kg L-lysine. (A) 0-2 hour; 
(B) 0-8 hour food intake post injection. Data are expressed as mean ± S.E.M. ** = p < 0.005 vs. water; 
n = 10 per group. 
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3.5.8.4. The effect of i.p. administration of L-arginine on food intake in the early light phase 
following an overnight fast in mice. 
Intraperitoneal administration of 4000µmol/kg L-arginine significantly reduced food intake 0-1 hours 
post-injection (0-1 hour food intake, saline: 0.6 ± 0.0g vs. 4000µmol/kg L-arginine: 0.2 ± 0.1g, p < 
0.001 vs. saline, n = 7-8 per group) (Figure 3.21. A). This reduction in food intake was sufficient to 
make longer cumulative time points statistically significant i.e. the 0-2 hour time point (0-2 hour 
food intake, saline: 1.0 ± 0.1g vs. 4000µmol/kg L-arginine: 0.5 ± 0.1g, p < 0.001 vs. saline, n = 7-8 per 
group) (Figure 3.22. A), the 0-4 hour time point (0-4 hour food intake, saline: 1.3 ± 0.1g vs. 
4000µmol/kg L-arginine: 0.6 ± 0.2g, p < 0.001 vs. saline, n = 7-8 per group) (Figure 3.22. B) and the 0-
8 hour time point (0-8 hour food intake, saline: 2.2 ± 0.1g vs. 4000µmol/kg L-arginine: 1.4 ± 0.3g, p < 
0.005 vs. saline, n = 7-8 per group) (Figure 3.22. C). No treatment significantly altered food intake at 
any other time point measured (Figure 3.20. B-F). 
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Figure 3.21. The effect of i.p. administration of L-arginine on food intake in the early light phase 
following an overnight fast in mice. 
Mice received an i.p. injection of (i) saline, (ii) 1000µmol/kg, (iii) 2000µmol/kg or (iv) 4000µmol/kg L-
arginine. (A) 0-1 hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 hour; (E) 8-24 hour; (F) 0-24 hour food 
intake post injection. Data are expressed as mean ± S.E.M. *** = p < 0.001 vs. saline; n = 7-9 per 
group. 
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Figure 3.22. The effect of i.p. administration of L-arginine on cumulative food intake in the early 
light phase following an overnight fast in mice. 
Mice received an i.p. injection of (i) saline, (ii) 1000µmol/kg, (iii) 2000µmol/kg or (iv) 4000µmol/kg L-
arginine. (A) 0-2 hour; (B) 0-4 hour; (C) 0-8 hour food intake post injection. Data are expressed as 
mean ± S.E.M. ** = p < 0.005 vs. saline; *** = p < 0.001 vs. saline; n = 7-9 per group.   
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3.5.8.5. The effect of i.p. administration of L-cysteine on food intake in the early light phase 
following an overnight fast in mice. 
Intraperitoneal administration of 4000µmol/kg L-cysteine significantly reduced food intake 0-1 hour 
post-injection compared to saline-treated animals (0-1 hour food intake, saline: 0.55± 0.06g vs. 
4000µmol/kg L-cysteine: 0.16 ± 0 03g, p < 0.005 vs. saline, n = 7-9 per group) (Figure 3.23. A). No 
treatment significantly affected food intake at any other time point measured. (Figure 3.23. B-F). 
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Figure 3.23. The effect of i.p. administration of L-cysteine on food intake in the early light phase 
following an overnight fast in mice. 
Mice received an i.p. injection of (i) saline, (ii) 1000µmol/kg, (iii) 2000µmol/kg or (iv) 4000µmol/kg L-
cysteine. (A) 0-1 hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 hour; (E) 8-24 hour; (F) 0-24 hour food 
intake post injection. Data are expressed as mean ± S.E.M. ** = p < 0.005 vs. saline; n = 8-9 per 
group.   
A B 
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3.5.8.6. The effect of i.p. administration of L-lysine on food intake in the early light phase following 
an overnight fast in mice. 
Intraperitoneal administration of 2000µmol/kg and 4000µmol/kg L-lysine significantly reduced food 
intake 0-1 hour post administration compared to saline-injected controls (0-1 hour food intake, 
saline: 1.2 ± 0.1g vs. 2000µmol/kg L-lysine: 0.9 ± 0.1g, p < 0.005 vs. saline; 4000µmol/kg L-lysine: 0.9 
± 0.1g, p < 0.001 vs. saline, n = 8-9 per group) (Figure 3.24 A). Intraperitoneal administration of 
4000µmol/kg L-lysine significantly increased food intake 4-8 hours post-injection compared to 
saline-injected controls (4-8 hour food intake, saline: 0.1 ± 0.1g vs. 4000µmol/kg L-lysine: 0.2 ± 0.0g, 
p < 0.05 vs. saline, n = 8-9 per group) (Figure 3.24. B). The initial reduction in food intake induced by 
2000µmol/kg and 4000µmol/kg L-lysine was sufficient to make the reductions in food intake over 
the longer cumulative 0-2 hour time point statistically significant (0-2 hour food intake, saline: 1.7 ± 
0.1g vs. 2000µmol/kg L-lysine: 1.3 ± 0.1g, p < 0.005 vs. saline; 4000µmol/kg L-lysine: 1.3 ± 0.1g, p < 
0.005 vs. saline, n = 8-9 per group) (Figure 3.25. A) and the reduction in food intake induced by 
2000µmol/kg L-lysine was sufficient to make the longer cumulative 0-4 hour time point statistically 
significant (0-4 hour food intake, saline: 2.0 ± 0.1g vs. 2000µmol/kg L-lysine: 1.6 ± 0.1g, p < 0.05 vs. 
saline, n = 9 per group) (Figure 3.25. B). No treatment significantly altered food intake at any other 
time point measured. 
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Figure 3.24. The effect of i.p. administration of L-lysine on food intake in the early light phase 
following an overnight fast in mice. 
Mice received an i.p. injection of (i) saline, (ii) 1000µmol/kg, (iii) 2000µmol/kg or (iv) 4000µmol/kg L-
lysine. (A) 0-1 hour; (B) 1-2 hour; (C) 2-4 hour; (D) 4-8 hour; (E) 8-24 hour; (F) 0-24 hour food intake 
post injection. Data are expressed as mean ± S.E.M. * = p < 0.05 vs. saline; ** = p < 0.005 vs. saline; n 
= 8-9 per group. 
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Figure 3.25. The effect of i.p. administration of L-lysine on cumulative food intake in the early light 
phase following an overnight fast in mice. 
Mice received an i.p. injection of (i) saline, (ii) 1000µmol/kg, (iii) 2000µmol/kg or (iv) 4000µmol/kg L-
lysine. (A) 0-2 hour; (B) 0-4 hour food intake post injection. Data are expressed as mean ± S.E.M. * = 
p < 0.05 vs. saline; ** = p < 0.005 vs. saline; n = 8-9 per group. 
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3.5.9. The effect of oral administration of L-arginine monohydrochloride and L-lysine 
monohydrochloride on food intake in the early light phase following an overnight fast in rats and 
mice. 
3.5.9.1. The effects of oral administration of L-arginine monohydrochloride, L-lysine 
monohydrochloride and L-cysteine on food intake in the early light phase following an overnight 
fast in rats. 
Oral administration of 4000μmol/kg L-Cysteine significantly reduced food intake compared to water 
one hour post administration (0-1 hour food intake, water: 6.9 ± 0.6g vs. L-Cysteine: 1.9 ± 0.3g; p < 
0.001 vs. water; n = 6-12 per group) (Figure 3.26. A). L-Arginine monohydrochloride and L-lysine 
monohydrochloride failed to significantly reduce food intake one hour post administration although 
both tended to reduce food intake (Figure 3.26. A).  
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Figure 3.26. The effect of oral administration of L-arginine monohydrochloride, L-lysine 
monohydrochloride and L-cysteine on food intake in the early light phase following an overnight 
fast in rats. 
Rats were orally gavaged with (i) water, (ii) 4000µmol/kg L-arginine monohydrochloride, (iii) 
4000µmol/kg L-lysine monohydrochloride or (iv) 4000µmol/kg L-cysteine. (A) 0-1 hour; (B) 1-2 hour; 
(C) 2-4 hour; (D) 4-8 hour; (E) 8-24 hour; (F) 0-24 hour food intake post injection. Data are expressed 
as mean ± S.E.M. *** = p < 0.001 vs. water; n = 6-12 per group. 
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3.5.9.2. The effects of oral administration of L-arginine monohydrochloride, L-lysine 
monohydrochloride and L-cysteine on food intake in the early light phase following an overnight 
fast in mice. 
Oral administration of 8000μmol/kg L-cysteine significantly reduced food intake compared to water 
one hour post administration (0-1 hour food intake, water: 0.7 ± 0.0g vs. 8000μmol/kg L-cysteine: 
0.3 ± 0.1g; p < 0.01 vs. water, n = 4-8 per group) (Figure 3.27. A). Oral administration of 8000μmol/kg 
L-cysteine significantly increased food intake compared to water 2-4 hours post administration (2-4 
hour food intake, water: 0.6 ± 0.1g vs. 8000μmol/kg L-cysteine: 0.8 ± 0.0g; p < 0.05 vs. water, n = 4-8 
per group) and 8-24 hours post administration (8-24 hour food intake, water: 2.9 ± 0.1g vs. 
8000μmol/kg L-cysteine: 3.4 ± 0.1g; p < 0.05 vs. water, n = 4-8 per group) (Figure 3.27. C and E). The 
acute reduction in food intake induced by L-cysteine was sufficient to make reductions in the longer 
0-2 hour time period statistically significant (0-2 hour food intake, water: 0.9 ± 0.0g vs. 8000μmol/kg 
L-cysteine: 0.6 ± 0.1g; p < 0.01 vs. water; n = 4-8 per group) (Figure 3.28. A). Oral administration of 
8000μmol/kg L-lysine monohydrochloride significantly reduced food intake compared to water 0-2 
hours post administration (0-2 hour food intake, water: 0.9 ± 0.0g vs. 8000μmol/kg L-lysine 
monohydrochloride: 0.7 ± 0.1g; p < 0.05 vs. water, n = 8 per group), 0-4 hours post administration 
(0-4 hour food intake, water: 1.5 ± 0.1g vs. 8000μmol/kg L-lysine monohydrochloride: 1.2 ± 0.1g; p < 
0.05 vs. water; n = 8 per group) and 0-8 hours post administration (0-8 hour food intake, water: 2.6 ± 
0.1g vs. 8000μmol/kg L-lysine monohydrochloride: 2.2 ± 0.1g; p < 0.05 vs. water; n = 8 per group) 
(Figure 3.28. A, B and C). 
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Figure 3.27. The effect of oral administration of L-arginine monohydrochloride, L-lysine 
monohydrochloride and L-cysteine on food intake in the early light phase following an overnight 
fast in mice. 
Mice were orally gavaged with (i) water, (ii) 8000µmol/kg L-arginine monohydrochloride, (iii) 
8000µmol/kg L-lysine monohydrochloride or (iv) 8000µmol/kg L-cysteine. (A) 0-1 hour; (B) 1-2 hour; 
(C) 2-4 hour; (D) 4-8 hour; (E) 8-24 hour; (F) 0-24 hour food intake post injection. Data are expressed 
as mean ± S.E.M. * = p < 0.05 vs. water; ** = p < 0.01 vs. water; n = 4-8 per group. 
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Figure 3.28. The effect of oral administration of L-arginine monohydrochloride, L-lysine 
monohydrochloride and L-cysteine on cumulative food intake in the early light phase following an 
overnight fast in mice. 
Mice were orally gavaged with (i) water, (ii) 8000µmol/kg L-arginine monohydrochloride, (iii) 
8000µmol/kg L-lysine monohydrochloride or (iv) 8000µmol/kg L-cysteine. (A) 0-2 hour; (B) 0-4 hour; 
(C) 0-8 hour food intake post injection. Data are expressed as mean ± S.E.M. * = p < 0.05 vs. water; 
** = p < 0.01 vs. water; n = 4-8 per group. 
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3.6. Discussion 
The results described in this chapter suggest that specific amino acids may alter food intake by 
modulating the release of gut hormones. Investigation of the mechanisms which might mediate the 
anorectic effects of L-arginine, L-cysteine and L-lysine have shown that L-arginine and L-lysine induce 
an increase in GLP-1 and PYY release whilst L-cysteine suppresses ghrelin release in vivo. The effects 
of L-arginine and L-lysine on GLP-1 release were confirmed in vitro. I have also confirmed that i.p. 
administration of L-arginine, L-cysteine and L-lysine significantly reduce acute food intake in mice. 
When administered orally, L-cysteine and L-lysine reduced acute food intake in mice whilst L-
arginine had no effect. Neuronal activation studies suggest that L-cysteine may mediate its effects 
on food intake directly or indirectly via the brainstem. The investigations in this chapter suggest that 
the anorectic effect of L-cysteine might be mediated by a separate mechanism to that of L-arginine 
and L-lysine. 
Hypothalamic staining for c-fos following oral administration of L-arginine, L-cysteine, L-lysine and 
glycine suggested that glycine and L-cysteine might activate hypothalamic areas involved in energy 
homeostasis. Glycine administration resulted in an increase in cFLI in the hypothalamic VMN. Since 
oral administration of glycine did not affect food intake in chapter 2, the activated neurones are 
presumably not involved in regulating food intake. Although the n numbers were too low to 
compute the statistics, it appeared that oral administration of L-cysteine activated neurones in the 
SON. The SON comprises magnocellular neurosecretory cells which secrete vasopressin, but has also 
been shown to have a role in the regulation of food intake. It is possible that L-cysteine is influencing 
SON neurones involved in energy homeostasis. Alternatively, the amino acids could be activating the 
well characterised water balance pathways within the SON. 
ICV injection of L-cysteine, L-arginine or L-lysine at doses up to 1000nmol did not significantly affect 
food intake in fasted rats. This suggests that the effects on food intake observed following peripheral 
administration are not mediated by subsequent changes in ICV concentrations of these amino acids. 
This is consistent with the relatively low levels of activation of hypothalamic neurones following oral 
administration. The promiscuous L-amino acid receptors are activated in the mM range in vitro and 
the doses given here are at a concentration of up to 200mM, suggesting that receptor activation 
would likely occur. These results contrast with a recent paper demonstrating that central 
administration of L-leucine to rats at a dose of 840pmol significantly reduces food intake in fasted 
rats (Blouet et al., 2009). It is suggested that the effects of L-leucine may be mediated by activation 
of hypothalamic mTOR. Disparate satiety pathways may be activated by different amino acids. 
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I also investigated activation of brainstem areas following oral administration of L-arginine, L-
cysteine, glycine and L-lysine by determining levels of cFLI. The results of this study suggested that 
the NTS and AP were activated by L-cysteine, although activation in the AP was not statistically 
significant. No other amino acid tested induced any changes in brainstem cFLI. This suggests that the 
anorectic effects of L-cysteine may be mediated, at least in part, by activation of the brainstem. The 
AP is involved in chemosensing and is often thought to mediate nausea pathways. However, it has 
also been shown to be activated following administration of anorectic hormones which are known 
not to cause nausea, for example OXM (Baggio et al., 2004a, Parkinson et al., 2009). The NTS 
receives meal-related signals from the GI tract which are transmitted by the vagus nerve (Schwartz, 
2006). It is possible that vagal signalling is mediating the anorectic effect of L-cysteine. Vagal 
signalling is also stimulated by factors such as osmolarity (Schwartz, 2006), so it is possible that the 
cFLI in the NTS is due to osmotic effects, which is also suggested by the SON activation. 
Brainstem c-fos staining indicated that the AP and NTS were highly activated following amino acid 
administration. Several gut hormones are known to activate these areas (Bonaz et al., 1993, 
Nakazato et al., 2001, Baggio et al., 2004b) and so I investigated the effects of peripheral 
administration of L-arginine, L-cysteine and L-lysine on gut hormone levels. As the release of gut 
hormones might be different depending on the route of amino acid administration, I looked at gut 
hormone levels following both oral and i.p. administration. The effects observed with oral 
administration of amino acids could be mediated by receptors expressed on the inner surface of the 
gastrointestinal lumen before absorption occurs. This would not, however, explain the reduction in 
food intake induced by i.p. administration, as substances are not generally transported across cell 
membranes into the gastrointestinal lumen. Equally, although peripherally expressed receptors 
could be activated by i.p. administered amino acids, it would not explain the effects of the orally 
administered amino acids as both anorectic responses occur within a similar time frame and orally 
administered amino acids are unlikely to have been fully absorbed from the gut lumen in this time. 
However, the gut hormone profile following oral amino acid administration suggests that the 
anorectic gut hormone response to orally administered amino acids is greater at 60 than at 30 
minutes. Thirty minutes following oral administration, L-lysine only produced an increase in GLP-1 
levels. However, 60 minutes following oral administration, both L-arginine and L-lysine increased 
levels of GLP-1, suggesting that the timing of the effects of different amino acids on gut hormone 
release might differ, possibly due to the time taken for them to be absorbed. A similar observation 
was made regarding PYY release. Thirty minutes after amino acid administration, only L-arginine 
increased plasma PYY. By 60 minutes, this effect had disappeared, but L-lysine potently increased 
plasma PYY at this time point. L-Arginine and l-lysine, therefore have similar effects on gut hormone 
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release, but cause different temporal release profiles. If this is secondary to differences in absorption 
rate, it is likely that the receptor responsible for mediating these effects does not face the intestinal 
lumen. However, none of the  amino acids tested resulted in an increase of the anorectic hormones 
GLP-1 and PYY following i.p. administration, which suggests the effect is mediated in the lumen of 
the intestine, which i.p. administered amino acids would not have access to. Amino acids 
(particularly lysine) are absorbed quickly from the upper small intestine (Buraczewska et al., 1980). 
This makes it unlikely that the temporal pattern in gut hormone release following oral administration 
of L-arginine and L-lysine is secondary to rates of absorption. L-Cysteine had no effect on GLP-1 or 
PYY levels following either route of administration. This suggests that the brainstem activation seen 
following oral administration of L-cysteine is not due to secondary activation by PYY or GLP-1. In 
addition, i.p. administration of L-arginine or L-lysine reduced food intake but did not increase levels 
of anorectic gut hormones, suggesting that another mechanism mediates these effects. 
Following i.p. administration, L-cysteine reduced the levels of plasma total ghrelin and active acyl-
ghrelin. L-Arginine and L-lysine had no significant effect on ghrelin. None of the amino acids tested 
significantly reduced ghrelin following oral administration, although L-cysteine tended to reduce 
active acyl-ghrelin 30 minutes after administration. If cysteine does influence ghrelin levels, this is 
further evidence that the mechanisms mediating the satiating effects of L-cysteine are different to 
those mediating the satiating effects of L-arginine and L-lysine. 
Oral administration of L-cysteine increased plasma insulin 30 minutes post administration. This 
effect had disappeared by 60 minutes post administration. Following i.p. administration of L-lysine, 
plasma insulin was increased 30 minutes post administration. L-Cysteine also tended to increase 
plasma insulin levels following i.p. administration, but this effect was not statistically significant. 
Amino acids have previously been shown to increase plasma insulin levels (Thams and Capito, 1999). 
These results suggest that these amino acids might modulate glucose homeostasis. Insulin can 
reduce food intake (Woods et al., 1979, Air et al., 2002), but whether changes in insulin or glucose 
are mediating the anorectic effects of these amino acids requires further investigation. 
L-Arginine salt did not reduce food intake in mice and L-lysine salt reduced food intake only 
cumulatively after 2 hours. As discussed in chapter 2, the anorectic effects of these amino acids 
might therefore be due to pH, as in the neutral salt form their effects were markedly 
reduced/abolished. However, these amino acids induced a potent increase in the anorectic gut 
hormones GLP-1 and PYY, which are unlikely to be driven by changes in pH. As GLP-1 and PYY3-36 are 
synthesised and released from the enteroendocrine L-cells, I investigated the secretion of GLP-1 
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from an in vitro L-cell model following amino acid administration. The NCI-H716 cell line is derived 
from cells present in ascites fluid obtained from a patient with colorectal adenocarcinoma. The cells 
contain dopa decarboxylase and, unlike other colorectal lines, contain cytoplasmic dense core 
granules characteristic of endocrine secretion. These studies demonstrated that L-arginine and L-
lysine increase GLP-1 release from L-cells in vitro, corroborating the in vivo studies. The effect of L-
cysteine on GLP-1 secretion from these cells was also investigated. L-cysteine had no significant 
effect on GLP-1 release, again in agreement with the in vivo studies. 
Feeding studies were also performed in mice to confirm the anorectic effect of L-arginine, L-cysteine 
and L-lysine in the mouse. This was with a view to conducting future feeding studies on genetically 
altered mice. Intraperitoneal administration of L-arginine, L-cysteine and L-lysine all significantly 
reduced food intake 0-1 hours post injection, consistent with the effects in rats. Oral administration 
of L-cysteine and l-lysine significantly reduced food intake 0-1 hours post-administration. However, 
oral administration of L-arginine failed to significantly reduce food intake 0-1 hours post-
administration. This might be because the receptor that mediates the anorectic effects of L-arginine 
does not lie within the GI lumen in mice. Alternatively, the mouse orthologue of the receptor which 
mediates the effects of L-arginine within the GI lumen in rats may not be as potently activated by L-
arginine as the rat orthologue. These results also suggest that it is not the pH of the amino acid 
solutions that drive the changes in food intake, as this would have also been expected to occur in the 
mouse. 
The investigations presented in this chapter have demonstrated that L-arginine, L-cysteine and L-
lysine reduce acute food intake via mechanisms that perhaps involve modulation of gut hormone 
release. For dietary supplementation with these amino acids to be useful for obesity treatment, they 
would need to effective following chronic administration. I therefore carried out further studies to 
investigate the possible therapeutic utility of these amino acids. 
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CHAPTER 4: THE UTILITY 
OF SPECIFIC AMINO ACIDS 
TO CHRONICALLY REDUCE 
FOOD INTAKE  
 
 
 234 
4.1. Introduction 
4.1.1. The effects of a high protein diet on body weight and composition 
Evidence suggests that diets high in protein can reduce food intake and body weight as well as 
improve body composition. However the precise effects of a high protein diet depend on the 
percentage of protein and the absolute amount of protein, as well as the conditions under which the 
diet is administered. 
When high protein (around 30% of energy) and high carbohydrate diets are administered to 
volunteers whereby actual calorie intake is low and equal in both groups, the volunteers 
administered the high protein diet do not show a statistically different body weight loss compared to 
volunteers fed a high carbohydrate diet. However, volunteers given a high protein diet do show an 
improved body composition, i.e. an increased fat free mass/fat mass ratio, and an improved 
metabolic profile (Johnston et al., 2004, Layman et al., 2003). In addition, a high protein diet has a 
greater satiating effect than a normal protein diet, where total calorie intake is the same in both 
groups, when fed for 2 weeks (Weigle et al., 2005). 
In contrast, studies which provide ad libitum access to a particular diet have shown that a high 
protein diet aids weight loss. This suggests that protein promotes satiety; when volunteers are fed a 
high protein diet ad libitum, they consume less calories compared to subjects fed a low protein diet 
(Dumesnil et al., 2001, Skov et al., 1999, Weigle et al., 2005). Such diets contain a sufficient absolute 
amount of protein but lead to decreased energy intake, suggesting that in addition to metabolic 
effects of protein on body weight loss, energy intake plays an important role. 
A relatively high protein diet can also promote weight maintenance following weight loss. For 
example, overweight to moderately obese subjects who had recently lost weight who consumed 
18% of their energy intake as protein regained less weight after three months, compared to those 
consuming 15% of their energy intake as protein (Westerterp-Plantenga et al., 2004). Furthermore, 
the composition of the body mass regained was more favourable in the higher protein group; only 
fat free mass was regained, resulting in a lower percentage body fat. Concurrently, fasting plasma 
leptin concentrations increased significantly slower in the higher protein group than in the lower 
protein group during weight gain. 
In the previous chapters I have shown that administration of L-arginine, L-cysteine and L-lysine 
reduce acute food intake. These effects are manifest following oral administration of these amino 
acids, and it is therefore possible that dietary supplementation with these amino acids could 
chronically increase satiety and therefore chronically reduce food intake and body weight. The aim 
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of this chapter is to investigate the utility of specific amino acids in the modulation of energy 
homeostasis.   
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4.2. Hypotheses 
The reduction in acute food intake induced by L-arginine, L-cysteine and L-lysine is not due to 
visceral illness. Chronic oral administration of specific amino acids will reduce cumulative food intake 
and body weight gain.  
4.3. Aims 
I aim to investigate whether the effects of L-arginine, L-cysteine and L-lysine on food intake are due 
to visceral illness and whether chronic administration of these amino acids might reduce cumulative 
food intake. In order to do this I will investigate: 
- Whether intraperitoneal administration of L-cysteine, L-arginine, L-lysine or glycine induces 
conditioned taste aversion in male rats. 
- The effects of oral administration of L-arginine, L-cysteine, L-lysine and glycine on acute food 
intake in the early dark phase in male rats. 
- The effect of chronic oral administration of L-cysteine and glycine on cumulative food intake 
and body weight gain in male rats. 
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4.4. Materials and Methods 
4.4.1. Materials 
All amino acids were purchased from Sigma Aldrich (Poole, Dorset, U.K.) 
4.4.2. Animals 
Male Wistar rats were maintained in individual cages under controlled conditions of temperature 
(21-23°C) and light (12 hours light, 12 hours dark; lights on at 07.00). Unless otherwise specified, 
animals were given ad libitum access to food (RM1 diet, Special Diet Services Ltd, Witham, UK) and 
water. Animals were acclimatised to laboratory conditions and handled daily for one week prior to 
experimental manipulation. Two sham injections / gavages were given in during this time to 
minimise the stress of subsequent study injections / gavages. Intraperitoneal injections were 
administered via a 1ml syringe with a 29-guage needle. All animal procedures conducted were 
approved by the British Home Office under the Animals (Scientific Procedures) Act 1986 (Project 
Licence number 70/6402). 
4.4.3. The effect of intraperitoneal administration of L-arginine, L-cysteine, glycine and L-lysine on 
conditioned taste aversion (CTA) in male rats 
Rodents lack the required anatomy for emesis and it is difficult to determine whether the 
administration of a specific substance induces feelings of nausea. Therefore, to investigate whether 
the amino acids induce feelings of visceral illness I employed the conditioned taste aversion (CTA) 
technique. CTA is an example of ‘classical conditioning.’ It occurs when an animal associates the 
taste of a certain food or drink with symptoms, particularly nausea or sickness, caused by a harmful 
substance. CTA is an evolutionary adaptation to prevent consumption of the same substance in the 
future. To determine whether the administration of amino acids was causing visceral ill-effects in 
rats, they were administered shortly after the rats were exposed to a novel flavour, Kool Aid. If the 
animals subsequently avoid the Kool Aid when exposed to it without the amino acid injection, it 
suggests that there are ill effects associated with amino acid administration. 
Lithium chloride was used as a positive control for illness / aversive symptoms. This was given at a 
dose of 127mg/kg by i.p. injection, a dose previously shown to produce a sensation of visceral illness 
(Thiele et al., 1997). All amino acids and the LiCl were dissolved in 1ml 0.9% saline for injection. The 
control injection was 1ml 0.9% saline. Novel flavour was provided during the training week using 
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sweetened grape flavour Kool-Aid (Northfield, IL, USA) diluted according to the packet instructions 
(1 sachet grape flavour Kool-Aid and 190g sucrose made up to 1.9L with water). 
The experimental protocol was based on a modification of an established method for analysis of 
conditioned taste avoidance by single-bottle method (Lachey et al., 2005). Male Wistar rats weighing 
210-260g were used. Fluid intake, food intake and body weight were measured daily throughout the 
study. After acclimatising to laboratory conditions, the rats underwent a training week and a test 
week. During the training week, food was provided ad libitum but access to water was restricted to a 
single hour every 24 hours (10:00 – 11:00). The purpose of this was to train the rats to drink their full 
fluid requirement during that period. On days 2 and 4 of the training week, each rat received an 
intraperitoneal injection of saline at the end of the water access period, to acclimatise the rats to the 
procedure and to minimise stress during the subsequent study. 
At the start of the test week the rats were stratified for body weight and fluid intake and randomised 
into treatment groups (n = 5-9 per group). On day 1 of the test week, water for substituted by Kool-
Aid during the hour of access to fluid. This was followed by an i.p. injection of saline, 2000µmol/kg L-
arginine, 2000µmol/kg L-cysteine, 2000µmol/kg glycine, 2000µmol/kg L-lysine or 127mg/kg LiCl 
according to group allocation. Glycine was used as a negative control as it did not induce any 
changes in food intake in experiments described in chapter 2. On day 2, all rats received water for 1 
hour. On day 3, rats had access to Kool-Aid for 1 hour followed by an injection of the same substance 
they had received on day 1. On day 4 all rats received water for 1 hour. On day 5 (the test day) the 
rats received Kool-Aid for 1 hour without any subsequent injection. The fluid intake on this final day 
was compared between groups. Figure 4.1. is a schematic outlining the study protocol. 
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Figure 4.1. Schematic diagram outlining the conditioned taste aversion (CTA) protocol. 
Rats were handled daily during the acclimatisation week to acclimatise them to the experimental manipulation. In the training week, rats were trained to 
consume their daily water within one hour. They also received two sham injections of 1ml 0.9% saline after fluid consumption during this week. On the first 
and third days of the test week rats received Kool-Aid instead of water and an injection of either saline or 2000µmol/kg of L-arginine, L-cysteine, glycine or 
L-lysine or 127mg/kg LiCl. On the second and fourth days the animal received water. On the fifth and final day, the animals received Kool Aid only and the 
intake was measured and compared between groups. 
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4.4.4. The effect of oral administration of L-arginine, L-cysteine, L-lysine and glycine on acute food 
intake in the early dark phase in male rats. 
To determine whether chronic dark phase administration of specific amino acids was likely to 
chronically influence food intake and body weight, their acute effects on food intake in the early 
dark phase were investigated. Male Wistar rats weighing 290-300g (randomised according to body 
weight) were orally gavaged with water or 4000µmol/kg L-arginine, 4000µmol/kg L-cysteine,  
4000µmol/kg L-lysine or 4000µmol/kg glycine at the onset of the dark phase (n = 7-10 per group). 
Animals were returned to their cage with a pre-weighed amount of chow and food was reweighed 
one hour later. 
4.4.5. The effect of chronic oral administration of L-cysteine and glycine on cumulative food intake 
and body weight in male rats. 
The results of study 4.4.2 suggested that chronic administration of L-cysteine influence food intake 
and body weight. Male Wistar rats weighing 290-300g (randomised according to body weight) were 
orally gavaged with water or 4000µmol/kg L-cysteine or 4000µmol/kg glycine (used as a negative 
control) three times throughout the dark phase- once at the onset of the dark phase (19.00), then 
again at 00.00 and 04.00 (n = 7-10 per group) for 5 days. All gavage volumes were 1.5ml. Animals 
received the same amino acid throughout the study. Food intake and body weight was measured at 
the beginning of the dark phase. Food intake was also measured one hour after the first gavage of 
the dark phase.  
4.4.6. Statistical analysis 
For the CTA study, Kool Aid consumption is expressed as mean ± S.E.M. For feeding studies, food 
intake and body weight are expressed as mean ± S.E.M. 
For the CTA study and the acute feeding study, differences between groups were analysed using a 
one-way analysis of variance (ANOVA) (GraphPad Prism) and post hoc Dunnett’s test. For the chronic 
study, differences in cumulative food intake and body weight gain were analysed using a two-way 
ANOVA (GraphPad Prism) with a post hoc Bonferroni test. In all cases, p < 0.05 was considered to be 
statistically significant. 
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4.5. Results 
4.5.1. The effect of intraperitoneal administration of L-arginine, L-cysteine, L-lysine and glycine on 
Kool Aid intake as a measure of CTA in male rats 
Intraperitoneal administration of L-arginine, L-cysteine, glycine or L-lysine at a dose of 2000umol/kg 
did not significantly reduce intake of the novel flavour (Figure 4.2.). As anticipated, intraperitoneal 
administration of 127mg/kg LiCl significantly reduced intake of the novel flavour (1 hour Kool Aid 
intake, saline: 16.8 ± 1.3g vs. LiCl: 0.1 ± 0.1g, p < 0.001, n = 5-8 per group) (Figure 4.2.). 
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Figure 4.2. The effect of intraperitoneal administration of L-arginine, L-cysteine, L-lysine and 
glycine on Kool Aid intake as a measure of conditioned taste aversion in male rats. 
Following Kool Aid availability on two test days following an intraperitoneal injection of saline or 
2000µmol/kg L-arginine, L-cysteine, glycine, L-lysine or 127mg/kg LiCl, animals were given access to 
Kool Aid and fluid intake was measured and compared between groups. Data are expressed as mean 
± S.E.M. *** = p < 0.001 vs. saline; n = 5-9 per group.  
 
 
 243 
4.4.2. The effect of oral administration of L-arginine, L-cysteine, L-lysine and glycine on acute food 
intake in the early dark phase in male rats. 
Oral administration of 4000µmol/kg L-cysteine significantly reduced food intake one hour after oral 
gavage at the onset of the dark phase (0-1 hour food intake, water: 2.4 ± 0.4g vs. L-cysteine: 0.7 ± 
0.2 p < 0.01 vs. water, n = 6-9 per group) (Figure 4.3.). Oral administration of 4000µmol/kg L-
arginine, L-lysine or glycine did not significantly reduce food intake one hour following oral gavage 
(Figure 4.3.). 
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Figure 4.3. The effect of oral administration of 4000µmol/kg L-arginine, L-cysteine, L-lysine and 
glycine in the early dark phase on one hour food intake in rats. 
Rats were orally gavaged with (i) water, (ii) 4000µmol/kg L-arginine, (iii) 4000µmol/kg L-cysteine, (iv) 
L-lysine or (v) 4000µmol/kg glycine. Data are expressed as mean ± S.E.M. ** = p < 0.01 vs. water; n = 
6-9 per group. 
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4.4.3. The effect of chronic oral administration of L-cysteine and glycine on cumulative food intake 
and body weight in male rats. 
Chronic oral administration of L-cysteine significantly reduced food intake over a period of five 
nights (0-5 day food intake, water: 144.7 ± 3.5g vs. L-cysteine: 130.1 ± 2.5g, p < 0.001 vs. water, n = 
8-9 per group) (Figure 4.4 A). Chronic oral administration of glycine did not alter cumulative food 
intake compared to water control (Figure 4.4. A). The cumulative food intake in the L-cysteine group 
was also significantly lower than the glycine group (0-5 day food intake, glycine: 28.3 ± 0.9g vs. L-
cysteine: 24.5 ± 1.1g, p < 0.001 vs. water, n = 6-8 per group). 
Chronic oral administration of L-cysteine or glycine did not significantly alter body weight gain over a 
period of five days compared to water (Figure 4.4. B).  
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Figure 4.4. The effect of chronic oral administration of L-arginine, L-cysteine, L-lysine and glycine 
on cumulative food intake (A) and body weight gain (B). 
Rats were orally gavaged with (i) water, (ii) 4000µmol/kg L-cysteine or (iii) 4000µmol/kg glycine 
three times over the course of the dark phase for five days. (A) Cumulative food intake; (B) Body 
weight throughout the study. Data are expressed as mean ± S.E.M. * = p < 0.05 vs. water; *** = p < 
0.001 vs. water; n = 6-9 per group. 
A 
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4.6. Discussion 
The studies described in this chapter suggest that dietary supplementation with L-cysteine may be a 
viable approach for obesity treatment. Intraperitoneal administration of 2000μmol/kg L-arginine, L-
cysteine, glycine or L-lysine did not induce conditioned taste aversion, as there was no significant 
reduction in one-hour Kool-Aid consumption. This suggests that the anorectic effects of L-arginine, L-
cysteine and L-lysine are not secondary to visceral illness or nausea. Animals administered L-cysteine 
did have slightly reduced one-hour Kool-Aid consumption, but this effect was far from statistically 
significant. Whether L-cysteine produces symptoms of visceral illness is therefore unclear and it 
would be prudent to repeat the study with larger n numbers to determine whether the reduction in 
Kool-Aid consumption in the L-cysteine group is biologically relevant. However the effect of L-
cysteine is minor and lower doses of L-cysteine still significantly reduce food intake, making it 
unlikely that the anorectic effects of L-cysteine are purely secondary to nausea. Intraperitoneal 
administration of 127mg/kg LiCl induced a robust conditioned taste aversion as expected (Thiele et 
al., 1997). The mean consumption of Kool Aid in LiCl treated animals was only 0.1g in this group, as 
compared to 16.8g in the saline group, despite a 23 hour period of fluid deprivation. It would also be 
sensible to look at the effects of oral administration of these amino acids, as the eventual aim would 
be to use oral amino acid supplementation to reduce food intake. 
To determine whether chronic administration of specific amino acids might influence energy 
homeostasis over the long term, their effects on food intake and body weight following 
administration in the dark phase (the natural feeding period of the rat) for several days were 
determined. Although rats do not eat ‘meals’ comparable to the feeding patterns of humans, amino 
acids were given three times over the course of the dark phase. However, all previous feeding 
studies had been conducted in fasted animals rather than during the dark phase. I therefore 
conducted an acute feeding study to determine whether L-arginine, L-cysteine and L-lysine 
significantly reduced acute food intake at the onset of the dark phase. I also investigated the effect 
of glycine in this study as it would be used as a negative control for the chronic study. Surprisingly, L-
arginine and L-lysine had no effect on acute food intake. However, L-cysteine retained its potent 
anorectic effect in the dark phase. I therefore decided to investigate the chronic effects of L-
cysteine, comparing them to the effects of water and of glycine as a negative control.  
Chronic oral administration of L-cysteine significantly reduced cumulative food intake over a period 
of 5 days by approximately 10%. Glycine had no effect on cumulative food intake. It is interesting 
that no treatment induced any significant change in body weight gain over the period of 5 days, 
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despite L-cysteine significantly reducing food intake. This could be due to increased water retention 
in the L-cysteine group. If this is the case, it may be that if the study had been continued for a longer 
period of time, the body weights of the groups would have started to diverge as water retention 
reached its maximum. It is also possible that any changes in weight resulting from a difference in 
food intake of only 14g were too small to be detected given the n numbers and the variation in body 
weights between the animals. Alternatively, the reduction in food intake without an accompanying 
reduction in body weight gain might be due to an increase in lean muscle mass at the expense of fat 
mass. Body composition analysis on these animals will reveal whether or not this is the case. The 
studies described in this chapter suggest that L-cysteine has potential as a dietary supplement to 
reduce food intake on a long-term basis, and may ultimately be useful to reduce body weight. 
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Food intake and energy expenditure are tightly regulated by the CNS which responds to peripheral 
signals of hunger and satiety. It has recently become more apparent that nutrient sensing can 
influence appetite and subsequent food intake (Blouet and Schwartz, 2010). 
Amino acids have many functions in metabolism and are critical to life. One particularly important 
function is to serve as the building blocks of proteins. This is important not only because our bodies 
are largely composed of proteins, but also because exogenous protein is one of the three 
macronutrients on which we depend for our energy requirements. There is a large body of evidence 
suggesting that ingestion of protein results in a feeling of satiety which is greater than that induced 
by other macronutrients. As protein is ingested it is broken down into small peptides and into 
individual amino acids. It is therefore possible that it is these individual amino acids that signal 
satiety, rather than the protein itself, with individual amino acid concentrations influencing the 
degree of satiety. 
I have shown that specific amino acids are able to reduce acute food intake in rodents. L-Arginine, L-
cysteine and L-lysine reduced food intake in the rat after both oral and i.p. administration. These 
effects were observed without any adverse effects on animal behaviour. The rats did not develop 
conditioned taste aversion when given the amino acids intraperitoneally, suggesting that the 
reduction in food intake was not secondary to feelings of nausea or visceral illness. L-Cysteine did 
induce a minor, non-significant reduction in intake of the novel flavour. Although the groups were 
randomised according to body weight and fluid intake, the fluid intake in the L-cysteine group was 
non-significantly lower than the other groups at the beginning of the study, which may have had 
some influence on the later components of the study. As discussed in chapter 4, it would be prudent 
to repeat this study with a larger n number to determine whether this reduction is biologically 
significant. However, L-cysteine reduces food intake at doses lower than those given in this study, 
and it therefore seems unlikely that the anorectic effects of L-cysteine are purely secondary to 
nausea. This study should be repeated using oral administration, as this is the route by which the 
amino acids could be utilised to increase satiety in humans. 
There are several mechanisms which might mediate the effects of amino acids on food intake. One 
proposed mechanism is the CNS sensing of amino acids. I looked at c-fos expression in the 
hypothalamus following oral administration of L-arginine, l-cysteine, L-lysine and glycine as a 
negative control. This study did not demonstrate a robust effect of L-arginine, L-cysteine or l-lysine 
on any hypothalamic nuclei. L-cysteine may increase activation in the SON, but the n numbers for 
the matched sections for this nucleus were too few to analyse statistically. This putative effect in the 
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SON could be due to an osmotic effect of amino acids. The SON is a well characterised thirst centre 
in the hypothalamus, and any activation could indicate thirst. It is possible that if the animals were 
thirsty they would drink more and subsequently reduce their acute food intake. However, the 
behavioural studies did not indicate any increase in drinking behaviour, and it therefore appears 
unlikely that the anorectic effects of L-cysteine are due to an increased fluid intake. In addition, 
neither L-arginine nor L-lysine increased neuronal activation in the SON, so the anorectic effects of 
these amino acids are most likely unrelated to fluid balance. It would, however, be of interest to 
directly measure fluid intake following administration of these amino acids to definitively exclude 
this possibility. 
To further investigate the possibility of central sensing of L-arginine, L-cysteine and L-lysine 
mediating the anorectic effects of these amino acids I administered them directly into the third 
cerebral ventricle. None of the amino acids significantly affected food intake at any of the doses 
tested, and it therefore appears unlikely that the anorectic effects observed following peripheral 
administration are due to hypothalamic sensing mechanisms. 
My in vivo investigations strongly suggest that L-arginine, L-cysteine and L-lysine modulate the 
release of gut hormones, although L-cysteine appears to have different effects to L-arginine and L-
lysine. In addition, these effects are different following oral and i.p. administration. Oral 
administration of L-arginine and L-lysine increase the release of GLP-1 and PYY. This was investigated 
both 30 and 60 minutes post-administration. Thirty minutes post-administration, L-lysine 
significantly increases plasma GLP-1, whilst L-arginine significantly increases plasma PYY. L-arginine 
increases GLP-1 and L-lysine increases PYY but these effects are not significant. When this 
experiment is repeated looking at plasma levels of gut hormones 60 minutes post-administration, 
both L-arginine and L-lysine significantly increase plasma GLP-1 to a similar magnitude as in the 30 
minute study. In this experiment, L-lysine also significantly increased plasma PYY, whilst L-arginine 
had no significant effect on PYY. The levels of plasma PYY reached by L-arginine administration in 
this study are not dissimilar to those achieved following L-arginine administration in the 30 minute 
study, but the water treated controls have a higher level of plasma PYY. It may be that this set of 
animals had higher baseline levels of PYY than the animals in the 30 minute study, which could mask 
any increase caused by administration of L-arginine. The fact that L-lysine is much more potent at 
stimulating PYY release at this time point whilst L-arginine is more potent at the 30 minute time 
point might reflect, for example, differences in transport across the gut lumen. Both L-arginine and 
L-lysine utilise the b0/+ amino acid transport system for transport across the gut lumen apical 
membrane (Broer, 2008). It could be that the b0/+ amino acid transport system transports L-arginine 
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more efficiently. In contrast to the oral administration experiments, i.p. administration of these 
amino acids does not alter plasma levels of GLP-1 or PYY. The effects of L-arginine and L-lysine on gut 
hormone stimulation are therefore likely to be due to mechanisms within the gut lumen. It would be 
interesting to pharmacologically inhibit the GLP-1R and the Y2 receptor to determine whether oral 
administration of L-arginine and L-lysine would still be able to induce an anorectic effect. If blockade 
of the GLP-1R and/or Y2 ameliorated the anorectic effects of L-arginine and L-lysine, it would suggest 
that the sole mechanism underlying the anorectic effect of these hormones was increased secretion 
of anorectic gut hormones. However, i.p. administration of these amino acids still reduces acute 
food intake, so there must be an alternative mechanism by which these anorectic effects occur. 
As L-arginine and L-lysine appeared to have potent effects on GLP-1 release in vivo, their effects 
were studied in an in vitro model. I used the NCI-H716 L-cell model which secretes GLP-1. Incubation 
with L-arginine or L-lysine significantly increased secretion of GLP-1 from these cells, in accord with 
the in vivo data. 
Neither oral nor i.p. administration of L-cysteine altered plasma levels of GLP-1 or PYY at any of the 
time points measured. However, following i.p. administration of L-cysteine, plasma levels of total 
ghrelin and acyl-ghrelin were significantly reduced compared to saline treated controls. Following 
oral administration, plasma levels of acyl-ghrelin and acyl-ghrelin as a percentage of total ghrelin 
were reduced, but these effects did not achieve statistical significance. The anorectic effect of L-
cysteine may therefore be mediated by different gut hormones to that of L-arginine and L-lysine. It 
would be interesting to determine whether L-cysteine would reduce food intake in a ghrelin-null 
mouse model. If L-cysteine did not reduce food intake in this model, it would suggest that the 
anorectic effects of L-cysteine are mediated by ghrelin signalling. 
An alternative mechanism by which protein is thought to mediate satiety is vagal signalling. The 
vagus nerve terminates in the NTS of the brainstem, which then relays the signal to the 
hypothalamus. Oral administration of L-cysteine significantly increased neuronal activation in the 
NTS compared to water treated controls. This suggests that the vagus nerve could be involved in 
mediating the anorectic effects of L-cysteine. L-Cysteine administration reduces plasma levels of 
ghrelin and it has been shown that following vagotomy, ghrelin has no orexigenic effect in rodents 
(Williams et al., 2003), though other studies have not found this to be the case (Arnold et al., 2006). 
It is therefore possible that L-cysteine is modulating ghrelin secretion which subsequently alters NTS 
neuronal activity.  The ghrelin receptor is expressed in the brainstem (Zigman et al., 2006) and 
peripheral administration of ghrelin induces c-fos expression in the NTS and AP of the brainstem 
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(Nakazato et al., 2001). It is therefore also possible that the reduction in ghrelin levels following 
administration of L-cysteine affects neuronal activity in the brainstem. However, given that L-
cysteine reduces ghrelin levels, it might be expected to reduce neuronal activation in the NTS if this 
was a ghrelin-dependent effect. Determining whether L-cysteine could induce an anorectic response 
in vagotomised rats would indicate the importance of vagal signalling in L-cysteine-induced satiety. 
One further mechanism by which protein is proposed to induce satiety is through gluconeogenesis. 
Although I did not comprehensively investigate whether amino acids could induce satiety by 
modulating glucose metabolism, I did investigate the effects of amino acid administration on insulin 
release. Oral administration of L-cysteine and i.p. administration of L-lysine significantly increased 
plasma insulin levels. Administration of L-arginine via either route did not appear to affect plasma 
insulin, in contrast to published in vitro data (Thams and Capito, 1999). It is unclear whether these 
amino acids directly modulate glucose metabolism. However, L-cysteine and L-lysine do alter insulin 
secretion and it is possible that this might, in part, mediate some of the anorectic effects of these 
amino acids. Further investigations into the effects of these amino acids on glucose homeostasis 
would be of interest. 
Although one or more of these mechanisms might mediate the anorectic effects of amino acids 
observed in this thesis, the way in which they are sensed in order to induce these effects is still 
unknown. The recently discovered family of L-amino acid sensing receptors have been shown to be 
present in areas of the body relevant to food intake regulation (Wellendorph et al., 2010). These 
amino acid receptors are responsive to the L-enantiomer of each amino acid only, not the D-
enantiomer. To determine whether one or more of these receptors might be responsible for 
mediating the anorectic effects of L-arginine, L-cysteine and L-lysine, I carried out a study to 
investigate whether the anorectic effects of these amino acids were limited to the L-enantiomer. If it 
were the case that the D-enantiomer did not reduce food intake, it would support the anorectic 
effect of the L-enantiomers was being mediated by one or more of these promiscuous L-amino acid 
receptors. I carried out studies giving the L- and D-enantiomers of these amino acids both orally and 
intraperitoneally. Neither oral nor i.p. administration of D-cysteine induced an acute reduction in 
food intake. This suggests that the anorectic effects of L-cysteine might be mediated by either the 
GPRC6A, T1R1/T1R3 or CaR. 
In contrast to this study, oral and i.p. administration of D-arginine and D-lysine reduced acute food 
intake to a comparable degree to their L-enantiomers. The potential reasons behind these results 
were discussed in chapter 2. It is possible that the effects of L-arginine and L-lysine are not mediated 
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by any of the promiscuous L-amino acid receptors but by an, as yet, unidentified receptor. Further 
investigation of basic amino acid transport mechanisms might reveal potential routes by which L-
arginine and L-lysine activate anorectic pathways. It is also possible that the effects of the L- and D-
enantiomers are mediated by different receptors but achieve the same result. The T1R2/T1R3 sweet 
taste receptor is responsive to D-amino acids and so it is possible that this receptor mediates the 
anorectic effects of D-arginine and D-lysine, whilst either the GPRC6A, T1R1/T1R3 or CaR mediates 
the anorectic effects of the L- enantiomers.  
Correlation of food intake with in vitro receptor activation suggests that the T1R1/T1R3 receptor 
might be involved in mediating the anorectic effects of the amino acids investigated. The limitations 
to using this correlation to draw conclusions regarding the receptors that might be responsible were 
discussed in chapter 2. In order to definitively determine which, if any, of the promiscuous 7TM L-
amino acid receptors are mediating the anorectic effects of L-arginine, L-cysteine and L-lysine, it 
would be necessary to pharmacologically or genetically block the effects of a specific receptor and 
determine whether the anorectic effects of the amino acids are abolished. Pharmacological 
antagonists of CaR and T1R1/T1R3 are available, but due to species differences in receptor 
pharmacology, they are mainly only effective at the human orthologues, although one CaR 
antagonist has been found to induce parathyroid hormone secretion in rats (Nemeth et al., 2001). 
These antagonists would be of use, however, in determining whether one of the promiscuous L-
amino acid receptors mediates the amino acid-induced secretion of GLP-1 from NCI-H716 cells. If 
blockade of CaR or T1R1/T1R3 with one of these antagonists prevented L-arginine and L-lysine 
increasing secretion of GLP-1, it would be evidence that these receptors mediate at least that aspect 
of their effects. 
Several genetically altered mice which would be of utility in determining the role of the promiscuous 
amino acids receptors are commercially available. As all the feeding studies discussed so far were 
carried out in rats, I conducted feeding studies in mice to confirm the anorectic effects of L-arginine, 
L-cysteine and L-lysine in the mouse. As discussed in chapter 3, the majority of the results of these 
experiments were consistent with the effects in rats. However, oral administration of L-arginine 
failed to significantly reduce acute food intake in mice. This could be because the receptor that 
mediates the anorectic effects of L-arginine does not lie within the GI lumen. Alternatively, the 
mouse orthologue of the receptor which mediates the effects of L-arginine within the GI lumen in 
rats might not be activated as potently by L-arginine as the rat orthologue. This lack of effect does at 
least suggest that there are specific mechanisms that mediate the effect of L-arginine on food intake, 
rather than the reduction in food intake being entirely secondary to, for example, alterations in 
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stomach pH. GPRC6A and CaR knockout mice are available, as well as mice lacking the T1R1 or T1R3 
monomers. If L-arginine, L-cysteine or L-lysine failed to induce an anorectic response in these 
animals, it would suggest a key role for that receptor in mediating their anorectic effects. However, 
the CaR knockout mouse has a number of metabolic derangements which could potentially mask an 
effect on food intake. An α-gustducin knockout mouse is also available. Alpha-gustducin is involved 
in the downstream signalling of the T1R1/T1R3 and if the amino acids failed to reduce food intake in 
these mice, it would suggest physiological involvement of the T1R1/T1R3 in mediating the anorectic 
effects. Knockout models could also determine whether the T1R2/T1R3 dimer was involved in 
mediating the anorectic effect of D-arginine and D-lysine. If they failed to reduce food intake in a 
T1R2 knockout mouse, it would suggest involvement of sweet taste signalling in mediating these 
anorectic effects.  
Knockout mice may have developmental compensation for the loss of a gene, and results must 
therefore be treated with caution. All of these receptors are suspected to dimerise with each other 
and with as yet unidentified receptors (Kim et al., 2003, Delay et al., 2006, Wellendorph et al., 2005). 
Thus, even if L-arginine, L-cysteine and L-lysine retained their anorectic effects in knockout models, it 
would not necessarily confirm that the receptors were not involved in mediating the anorectic 
effects, as other subunits may dimerise with other receptors to salvage signalling ability. 
Chronic oral administration of L-cysteine significantly reduced cumulative food intake. Dietary 
supplementation with L-cysteine may therefore prove useful in reducing food intake in obese 
populations. It would be useful to determine whether chronic administration of L-cysteine could 
ameliorate a diet-induced obese phenotype by increasing satiety and reducing food intake. The 
literature suggests that a high protein diet improves body composition compared to an equicaloric 
diet which is high in carbohydrate (Johnston et al., 2004, Layman et al., 2003). It would therefore be 
interesting to determine whether chronic administration of amino acids improves body composition. 
Body composition analysis of the animals in study 4.5.3. will determine whether they have reduced 
body fat or increased muscle mass. The literature, however, suggests that the improvements in body 
composition are only seen when compared to equicaloric diets. In study 4.5.3. the animals treated 
with L-cysteine had a reduced cumulative food intake, demonstrating the satiating effects of L-
cysteine. It would, however, make the direct effects on body composition difficult to determine, as 
the groups consumed different amounts of food. A similar study in which an additional control group 
is pair-fed to the L-cysteine group would reveal whether L-cysteine has direct effects on body 
composition. 
 
 
 256 
In study 4.5.3. the animals received an oral gavage three times over the course of the dark phase. 
Although this is representative of the feeding pattern of humans, who tend to consume three meals 
over the course of 24 hours, it is not representative of the normal dietary pattern of a laboratory rat, 
which consumes food over the course of the dark phase with a less discrete meal pattern. It would 
therefore be interesting to determine whether supplementation of the animal chow with an 
equivalent dose of each amino acid would have the same effect. 
The doses of amino acids administered to rodents in these studies are likely higher than would be 
consumed in ad libitum feeding. It would be interesting to measure the amino acid levels reached 
following ad libitum feeding on a high protein diet after an overnight fast and to determine the 
amino acid dose which would mimic these levels. If the amino acids could reduce food intake at 
these doses, it would suggest that the anorectic effects reflect a physiological rather than a 
pharmacological effect. 
The studies described in this thesis have suggested that L-cysteine may have a specific role in 
reducing food intake. Cysteine is found in most high protein foods, including meat, cheese and eggs, 
and thus may be a good indicator of dietary protein intake. It is therefore possible that sufficient 
ingestion of L-cysteine physiologically inhibits subsequent food intake. 
The ultimate aim of these animal experiments is to identify potential therapies for the treatment of 
obesity in humans. Determining whether these amino acids reduce acute food intake in human 
volunteers will be necessary in order to confirm a viable therapeutic option. Determining which 
promiscuous L-amino acid receptor, if any, is mediating the anorectic effects of these amino acids 
would be of great interest. It would be the first evidence that amino acids regulate food intake by a 
receptor-mediated mechanism, and would implicate these receptors in protein-induced satiety. It 
would also be of therapeutic interest, as small molecule agonists of these receptors could prove to 
be useful drugs for the treatment of obesity. In an environment where energy dense, highly 
palatable, foods are readily available, it is important to develop dietary modifications which can 
increase the satiating value of a given food, in order to reduce food intake and body weight. 
Targeting specific amino acid sensing mechanisms may prove useful in the future treatment of 
obesity. 
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Appendix I – The proteinogenic amino acids, their commonly used abbreviations, side chain 
biochemistry, classification and structure. 
Amino acid 
3 letter 
abbreviation 
1 letter 
abbreviation 
Side chain polarity Side chain charge Classification Structure 
Alanine Ala A Non-polar Neutral Non-polar 
 
Arginine Arg R Polar Positive Basic 
 
Asparagine Asn N Polar Neutral Polar 
 
Aspartic acid Asp D Polar Negative Acidic 
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Amino acid 
3 letter 
abbreviation 
1 letter 
abbreviation 
Side chain polarity Side chain charge Classification Structure 
Cysteine Cys C Non-polar Neutral Non-polar 
 
Glutamic acid Glu E Polar Negative Acidic 
 
Glutamine Gln Q Polar Neutral Polar 
 
Glycine Gly G Non-polar Neutral Non-polar 
 
Histidine His H Polar 
Positive(10%) 
Neutral(90%) 
Basic 
 
Isoleucine Ile I Non-polar Neutral Non-polar 
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Amino acid 
3 letter 
abbreviation 
1 letter 
abbreviation 
Side chain polarity Side chain charge Classification Structure 
Leucine Leu L Non-polar Neutral Non-polar 
 
Lysine Lys K Polar Positive Basic 
 
Methionine Met M Non-polar Neutral Non-polar 
 
Phenylalanine Phe F Non-polar Neutral Non-polar 
 
Proline Pro P Non-polar Neutral Non-polar 
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Amino acid 
3 letter 
abbreviation 
1 letter 
abbreviation 
Side chain polarity Side chain charge Classification Structure 
Serine Ser S Polar Neutral Polar 
 
Threonine Thr T Polar Neutral Polar 
 
Tryptophan Trp W Non polar Neutral Non-polar 
 
Tyrosine Tyr Y Polar Neutral Polar 
 
Valine Val V Non-polar Neutral Non-polar 
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Appendix II – Volumes required for radioimmunoassay 
NSB, non-specific binding; XS, excess antibody. 
Table 1: Volumes of assay components and samples added to the GLP-1 RIA.  
 Standard (µl) Sample   (µl) Antibody (µl) Label      (µl) Buffer     (µl) 
NSB - - - 100 600 
1/2 x Label - - 100 50 550 
2x Label - - 100 200 400 
Zero - - 100 100 500 
Standard 1-100 - 100 100 400-500 
Sample - 100 100 100 400 
XS - - 600 100 - 
Table 2: Volumes of assay components and samples added to the PYY RIA.  
 Standard (µl) Sample   (µl) Antibody (µl) Label      (µl) Buffer     (µl) 
NSB - - - 100 600 
1/2 x Label - - 100 50 550 
2x Label - - 100 200 400 
Zero - - 100 100 500 
Standard 1-100 - 100 100 400-500 
Sample - 200 100 100 300 
XS - - 600 100 - 
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Table 3: Volumes of assay components and samples added to the total ghrelin RIA.  
 Standard (µl) Sample   (µl) Antibody (µl) Label      (µl) Buffer     (µl) 
NSB - - - 100 600 
1/2 x Label - - 100 50 550 
2x Label - - 100 200 400 
Zero - - 100 100 500 
Standard 1-100 - 100 100 400-500 
Sample - 25 100 100 475 
XS - - 600 100 - 
Table 4: Volumes of assay components and samples added to the insulin RIA.  
 Standard (µl) Sample   (µl) Antibody (µl) Label      (µl) Buffer     (µl) 
NSB - - - 100 600 
1/2 x Label - - 100 50 550 
2x Label - - 100 200 400 
Zero - - 100 100 500 
Standard 1-100 - 100 100 400-500 
Sample - 100 100 100 400 
XS - - 600 100 - 
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Appendix III - Solutions 
Antifreeze 
Add 30% (v/v) ethylene glycol and 20% (v/v) glycerol to 0.01M PBS. 
 
Dextran coated charcoal 
2.4g charcoal and 0.24g dextran were added to 100ml phosphate buffer with gelatine and 
mixed for 20 minutes at 4ºC. 
 
Phosphate buffer 
48g Na2HPO4.2H20, 4.14g KH2PO4, 18.61g C10H14H2O8Na2.2H2O, 2.5g NaN3 were dissolved 
in 5l of cooled boiled water, pH was measured to confirm as 7.4 and adjusted accordingly, 
this was stored at 4°C. 
 
Phosphate buffer with gelatine 
Was produced as above, with 12.5g gelatine dissolved in boiled water before it was cooled 
and other components added. 
 
1M phosphate buffered saline (PBS) 
Dissolve 87g NaCl, 14.1g Na2HPO4 and 2.72g of KH2PO4 in 1l GDW. 
 
0.01M phosphate buffered saline (PBS) 
Carry out a 1:100 dilution of 1M PBS as prepared above. 
 
40% Sucrose solution 
 400g of sucrose was dissolved in GDW up to a volume of 1l. 
 
0.1M Tris/HCl solution (pH 7.6) 
Dissolve 12.1g Trizma base in 1l GDW. Adjust to pH 7.6 with HCl. 
 
Veronal Buffer 
 2.575g sodium barbitone and 0.075g sodium azide were dissolved in 250ml water. 
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Appendix IV – Suppliers 
Abbott Laboratories Ltd, (Kent, U.K.) 
Associated Dental Products Ltd. (Kemdent Works, Swindon, Wiltshire, U.K.) 
ATCC (LGC Standards, Teddington, Middlesex, U.K.) 
BDH (Poole, Dorset, U.K.) 
Charles River (Margate, Kent, U.K.) 
Dako UK Ltd. (Ely, Cambridgeshire, U.K.) 
David Kopf Instruments (supplied by Clark Electromedical Instruments, Reading, Berkshire, U.K.) 
Generon (Maidenhead, Berkshire, U.K.) 
GIBCO BRL (Life Technologies, Paisley, Renfrewshire, U.K.) 
GraphPad software Inc. (San Diego, California, U.S.A.) 
Hamilton syringe (Hamilton Company, Reno, Nevada, U.S.A.) 
Harlan (Bicester, Oxon, U.K.) 
Harvard Apparatus Ltd. (Edenbridge, Kent, U.K.) 
Invitrogen (Paisley, Renfrewshire, U.K.) 
Kool Aid (Northfield, Illinois, USA) 
Merck Chemicals Ltd. (Nottingham, Nottinghamshire, U.K.) 
Plastics One Inc. (Roanoke, Virginia, U.S.A.) 
Schering-Plough Ltd. (Welwyn Garden City, Hertfordshire, U.K.) 
Seton Healthcare (Oldham, Lancashire, U.K.) 
Shandon Southern Products Ltd. (Runcorn, Cheshire, U.K.) 
Sigma Aldrich (Poole, Dorset, U.K.) 
Special Diet Services Ltd. (Witham, Essex, U.K.) 
SPI bio bertin (Bertin Pharma, Montigny le Bretonneux, France) 
Statacorp (College Station, Texas, U.S.A.) 
Thermo Electron Corporation (San Jose, California, U.S.A.) 
VWR International Ltd. (Poole, Dorset, U.K.) 
Vector Laboratories (Orton Southgate, Peterborough, U.K.) 
Waters Corporation (Milford, Connecticut, U.S.A.) 
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